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Role of Vascular Endothelial Growth Factor Signaling in Brown Adipocyte 
Survival, Proliferation and Function 
ABSTRACT 
 Both white and brown adipose tissues exhibit extensive vascularity. Increased 
angiogenesis in brown adipose tissue (BAT) is crucial for brown fat activation and 
thermogenesis in animals during cold acclimation. BAT can be similarly activated by food 
intake to generate heat through cellular respiration, in a process known as diet induced 
thermogenesis.  Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that 
regulates both pathological and physiological angiogenesis and can stimulate cell 
proliferation, migration, survival and vessel permeability.  However, VEGF has also been 
shown to affect an increasing number of non-vascular cells such as skeletal muscle and 
kidney podocytes. The expression and function of VEGF in white and brown adipocytes are 
not fully understood. We have previously shown that the expression of VEGF is 
concomitantly regulated with skeletal muscle differentiation.  Here we show that VEGF is 
expressed in BAT and all major white adipose depots in mice. VEGF expression was 
increased during white and brown adipocyte differentiation and was regulated in cultured 
brown adipocytes by the PPARγ agonist troglitazone and by PGC1α in BAT in vivo. 
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Systemic VEGF neutralization led to brown adipocyte apoptosis in vivo, loss of 
mitochondrial cristae and increased mitophagy and was associated with increased 
inflammation and fibrosis. VEGFR2 was expressed in both brown preadipocytes and 
adipocytes. Blockade of VEGF signaling using anti-VEGFR2 antibody DC101 increased brown 
adipocyte apoptosis in vitro. VEGF also functioned as a mitogen and survival factor for 
brown preadipocytes. VEGF 164 and VEGF 188, isoforms that can bind heparan sulfate 
proteoglycans, comprise >98% of total VEGF in BAT, subcutaneous and perigonadal fat 
depots. Embryos that lacked VEGF 164 and 188 displayed abnormal BAT development with 
fewer brown adipocytes, lower levels of mitochondrial uncoupling protein 1 and Cox IV.  
These results indicate a direct role for VEGF signaling in brown adipocytes and 
preadipocytes and suggest the importance of heparan sulfate binding VEGF isoforms in BAT 
development. Elucidation of the role of VEGF signaling in adipocytes is vital to 
understanding adipose tissue expansion and activation and may reveal novel therapeutic 
targets for the activation of brown fat in humans.  
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Chapter 1                                     
INTRODUCTION 
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Adipose Tissue 
Adipose tissue in mammals is categorized to two types, white and brown, according 
to their distinct physiological roles. White adipose tissue (WAT) serves as a storage depot 
for excess calories and functions as an endocrine organ to integrate various homeostatic 
processes. Brown adipose tissue (BAT) is a major thermogenic organ that generates heat 
under regulation of the sympathetic nervous system.  
White Adipose Tissue 
WAT was long thought to be a passive storage depot for excess calories, with few 
other functions. The steep rise in obesity and associated comorbidities, such as type 2 
diabetes and cardiovascular disorders, over the past 30 years has fueled scientific research 
in this area.   
Development and Distribution 
Although most multicellular organisms have cells that store excess energy, 
adipocytes evolved to meet this need at the time of vertebrate radiation. Mammals, birds, 
reptiles, amphibians and many fish have cells that are readily identifiable as adipocytes, 
although their anatomical locations vary considerably across species.  Most mammals have 
WAT dispersed throughout the body in two major types of depots – subcutaneous (SC) and 
intraabdominal (or visceral). In mouse, the inguinal fat is the major SC depot, whereas the 
visceral depots are in the retroperitoneal, periovarian (in females) and epididymal (in males) 
regions. In humans, the major intraabdominal depots of 
Mesenteric 
Epididymal 
Inguinal 
Cervical 
Perirenal and 
retroperitoneal 
Mediastinum 
Interscapular 
Gluteal 
Figure 1.1. Brown and white adipose depots. (A) In humans,  WAT is 
distributed throughout the body with subcutaneous and intra-abdominal 
depots representing the main compartments. BAT is abundant at birth (inset) 
and present in adulthood to a lesser extent. (B)Typical distribution of white and 
brown adipose in a lean mouse at 20C. WAT and BAT depots are present 
throughout life in rodents, but varies depending on weight and environmental 
temperature. Scale bar represents 2 cm. (A) adapted from Gestal et al. 2007, 
(B) adapted from The Adipose Organ, plate 1, Editrice Kurtis Ltd., 1999 
BAT in 
infants 
A 
B 
3 
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WAT are around the omentum, intestines and perirenal areas, whereas SC depots are in the 
buttocks, thighs and abdomen. In addition, WAT can be found in many other areas, 
including in the retro-orbital space, on the face and extremities, and within the bone 
marrow (Gesta et al. 2007). The distribution of WAT varies considerably, not only across 
species but also between individuals of the same species. In humans, obesity in which fat 
deposition is localized in the SC depot (pear shaped obesity) is correlated with a lower risk 
of associated metabolic disorders while deposition in the intraabdominal depot (apple 
shaped obesity) correlates with a higher risk. How excess calories are directed to one depot 
versus the other is not understood. Gene expression profiling has revealed significant 
differences between different adipose depots in both rodents (Gesta et al. 2006) and 
humans (Vidal 2001; Vohl et al. 2004) (Figure 1.1). 
WAT, similar to muscle and bone, is thought to have a mesodermal origin. 
Development of WAT begins at midgestation (in humans) or shortly after birth (in rodents) 
and gradually increases in size throughout life. Adipose tissue develops in close spatial and 
temporal association with the vasculature, and in a presumptive fat depot arteriolar 
differentiation precedes the appearance of preadipocytes. It was recognized very early on, 
that the development of adipocytes in close proximity to blood vessels indicated that an 
established vascular supply is necessary for adipose tissue development (Clark & Clark 
1940); although, sometimes, adipose development is concurrent with arteriolar 
differentiation, depending on the depot (Hausman & Thomas 1986). In adults, fat depots 
consist of mature adipocytes and adipocyte precursors (as well as stromal and vascular 
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cells). Expansion of adipose tissue occurs through an increase in size of existing adipocytes 
as well as the recruitment of preadipocytes.   
Structure 
White adipocytes are 50 – 100 µm in diameter in humans and can be significantly 
larger in obese subjects. A single lipid droplet occupies more than 90% of the cell volume, 
the remaining consisting of a narrow rim of cytoplasm, a nucleus shunted to the side and 
few elongated mitochondria (Figure 1.2). Each lipid droplet is coated with perilipin, which 
protects the lipid from hydrolysis by lipases (lipolysis) under basal conditions but is 
necessary for stimulated lipolysis (Figure 1.3). WAT is extensively vascularized; virtually 
every adipocyte is in close proximity to at least one capillary (Gersh & Still 1945)  (Figure 
1.4). The microvasculature of adipose tissue, unlike muscle, retina and several other organs, 
does not have a particular orientation but is organized in a loose mesh within the 
connective tissue that surrounds adipocytes (Crandall et al. 1997).  WAT depots vary in 
terms of cellular and tissue organization as well as vascular structure. For instance, in 
mouse the epididymal fat pad is more lobular compared to the SC depot, whereas the 
inguinal depot has brown preadipocytes interspersed amidst white adipocytes, which 
acquire brown-like characteristics upon sympathetic stimulation.  
Function  
WAT primarily functions as the storage site for excess calories, which are deposited 
as triglycerides within the droplet of each adipocyte. However, when glucose is limiting,  
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Figure 1.4. Microvasculature and stromal cells of WAT. Scanning electron 
micrograph (SEM) of white adipose tissue (A) Periovarian WAT depot of adult 
rat demonstrating large adipocytes associated with connective tissue. Scale bar 
represents 50 µm. (B) SEM of a capillary surrounding a white adipocyte 
demonstrates the association between adipocytes and the vasculature. Scale 
bar represents 10 µm. Reprinted with permission from The Adipose Organ, 
plates 25 (A) and 10 (B), Editrice Kurtis Ltd., 1999 
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neurohormonal stimulation induces lipases to release triglycerides from the lipid droplets 
into the circulation for use by other tissues as fuel.   
WAT is the largest endocrine organ in mammals. Adipocytes synthesize and release 
peptide hormones, known as adipokines, that coordinate and integrate a wide array of 
homeostatic processes such as control of blood pressure, bone mass, thyroid and 
reproductive function and even the immune response (Trayhurn 2005). Notable among 
these adipokines are leptin, adiponectin, visfatin, resistin and omentin. Adipose tissue (but 
not necessarily adipocytes themselves) also secretes several cytokines, including tumor 
necrosis factor (TNF)-α, interleukins 1 and 6. Some of these secreted factors, such as 
adiponectin and visfatin, have a positive effect on overall insulin sensitivity, whereas others, 
like TNFα, reduce insulin sensitivity.  Interestingly, even though obese subjects have more 
adipose tissue, their circulating adiponectin levels are lower compared to lean subjects 
(Yatagai et al. 2003).  
Adipose tissue expansion and obesity 
Fat depots grow by an increase in size of resident adipocytes through storage of 
more lipids as well as by recruitment of new adipocytes. This expansion is accompanied by 
remodeling of the vasculature and associated connective tissue.  However, in most 
instances of diet-induced weight gain, WAT expansion occurs through hypertrophy of 
existing adipocytes, accompanied by insufficient vascular remodeling.  As a result, adipocyte 
size is increased and capillary density is decreased, resulting in reduced perfusion and local 
10 
 
tissue hypoxia. In WAT, hypoxia is associated with an increased expression of inflammatory 
genes and decreased expression of adiponectin (Ye et al. 2007).  
Adiponectin is a key insulin-sensitizing adipokine and one of the central mediators of 
insulin resistance. A modest increase in the level of adiponectin in ob/ob mice led to 
improvement across all metabolic parameters associated with obesity, from insulin 
resistance to β-cell dysfunction, although the mice remained obese (Kim et al. 2007). In 
addition, it was recently shown in vivo and in vitro that adiponectin transcription by PPARγ 
was dysregulated by cdk5, a cyclin dependent kinase that is activated by pro-inflammatory 
cytokines (Choi et al. 2010). In addition, increased expression of inflammatory cytokines 
such as monocyte chemotactic protein-1 by local hypoxia and endoplasmic reticular stress 
lead to recruitment of macrophages to adipose tissue, which secreted additional 
inflammatory cytokines such as TNFα and interleukin 1. Inflammatory cytokines contribute 
to insulin resistance by suppressing insulin action on peripheral tissue. Thus, these two 
processes, reduced circulating adiponectin and increased localized inflammation in the 
adipose tissue, contribute to development of obesity-associated insulin resistance and 
progression to type 2 diabetes.  
However, not all who are obese develop type 2 diabetes or cardiovascular disorders.  
For some individuals, referred to as “metabolically healthy obese”, weight gain takes place 
through “healthy adipose tissue expansion” and is not accompanied by pathological 
consequences. Healthy adipose tissue expansion consists of enlargement of a fat pad 
through recruitment of new adipocytes, increased angiogenesis and appropriate vascular  
remodeling; there is no associated hypoxia, and minimal fibrosis and inflammation (Sun et 
11 
 
al. 2012).  Thus, although there is increase in fat mass, it is not accompanied by insulin 
resistance and metabolic dysfunction. Recent studies, described later in this chapter, have 
aimed to facilitate healthy adipose tissue expansion in murine models of diet-induced 
obesity  by promoting angiogenesis during the early phase of fat mass expansion (Sun et al. 
2012).  
Brown Adipose Tissue  
Unlike WAT, BAT does not function as a storage depot for triglycerides, instead 
metabolizes them to generate heat when necessary.  Thus, BAT is the major site for 
adaptive non-shivering thermogenesis (NST) in mammals. NST is the process of increased 
heat production, over basal metabolic levels, which is not a result of muscle activity and is 
mediated by the sympathetic nervous system ((SNS). BAT regulates thermogenesis during 
environmental stresses, such as reduced temperatures, to maintain body temperature and 
protect the organism from hypothermia (Smith 1964).  BAT also secretes fatty acids (FA) and 
factors such as leptin (although at a much lower level than WAT), adiponectin, 
triiodothyronine (T3), that are thought to play endocrine roles (Cannon & Nedergaard 
2004). Recent data suggest that BAT activity regulates vascular lipoprotein homeostasis by 
enhancing lipid clearance from plasma during short term cold exposure (Bartelt et al. 2011).  
Distribution of brown adipose tissue 
First described in 1551, BAT was long known to be present in small rodents, 
hibernating animals and newborn mammals, including human infants; essentially mammals 
that are not able to generate heat by shivering (muscular movement) and whose high 
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surface to volume ratio results in increased energy loss as heat (Smith & Horwitz 1969).  In 
rodents, BAT is present in the interscapular, axillary and perinephric depots, of which the 
interscapular depot (often referred to as iBAT) is the largest and most commonly studied. 
It was believed that BAT in humans atrophied with age and was completely absent in 
adults. However, in the last decade several landmark studies provided convincing evidence 
for the presence of metabolically active BAT depots in adult humans (for a review see 
Cypess & Kahn 2010).  BAT in adult humans was originally identified in cancer patients being 
examined by positron emission tomography (PET) – computed tomography (CT) scanning to 
trace the uptake of 18F-fluoro-2-deoxyglucose (18F-FDG) by metabolically active tissue such 
as cancer metastases. In addition to sites of metastasis, this imaging revealed additional 
areas of strong 18F-FDG uptake, particularly in the thoracic region, which were 
symmetrically distributed and hence unlikely to be tumors (Nedergaard et al. 2007); these 
sites were later identified as BAT depots. Currently, it is widely accepted that a significant 
fraction of adult humans possess BAT, although a consensus is yet to be reached regarding 
numbers. Because of the limitations of the 18F-FDG above method in detecting BAT, 
estimates of the prevalence of BAT in the adult population have varied greatly across 
different reports from 7.5 to 25% and even 80% of patients examined (Cypess et al. 2009).  
The two most commonly detected BAT depots in adult humans are located in the 
supraclavicular and neck regions. In addition, a symmetrical pattern of BAT is seen along the 
spinal cord as a paravertebral depot, in the para-aortic area of the mediastinum and around 
the apex of the heart, as well as the perirenal depots, all generally demonstrating weaker 
18F-FDG uptake than those in the thoracic region (Figure 1.5).  While this distribution 
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pattern is similar, but not identical, to BAT distribution in rodents, it closely corresponds 
with the distribution of BAT in human infants (Aherne & Hull 1966). Besides the above 
conventional BAT depots, brown adipocyte precursors are dispersed in certain WAT depots 
of both humans and rodents. These precursors can be induced to differentiate into mature 
brown adipocytes by catecholamines or by the expression of peroxisome proliferator-
activated receptor coactivator 1α (PGC1α) (Tiraby et al. 2003). These induced brown 
adipocytes are referred to as “brite” (brown + white) adipocytes. 
Development  
BAT evolved significantly later than WAT, in parallel with endothermal vertebrates - 
birds and mammals - and their need to regulate body temperature through NST (Gesta et al. 
2007). BAT forms much earlier during development than WAT and reaches its maximum 
mass shortly after birth. In mouse, BAT structures are first observed in the interscapular 
region around embryonic day 15 (E15); fat deposition in the form of single lipid droplets 
begins soon after.  Prior to birth there is rapid expansion of fat mass, which continues 
postnatally accompanied by cell proliferation, a rise in triglyceride content in the form of 
multilocular droplets, an increase in mitochondria number as well as in activity of the 
mitochondrial respiratory enzymes, such as glycerol-3-phosphate dehydrogenase, succinate 
dehydrogenase and cytochrome C and differentiation of mitochondria ultrastructure. At 
birth, there is a temporary depletion of triglycerides, suggesting that BAT might be 
thermogenically active at birth. Postnatal expansion of BAT continues for several days until 
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the tissue is at its peak of differentiation and functional activity between postnatal day 6 
and 15.  In fact, norepinephrine (NE) injected into fetal rats perinatally increases enzyme 
activity significantly, indicating that brown adipose is responsive to NE even at a very early 
stage. Cortisone injections, on the other hand, reduced mitochondrial enzymatic activity, 
although BAT mass increased, possibly due to increased lipid accumulation (Skala & Hahn 
1974).  Around postnatal day 21, a second phase commences marked by involution of BAT 
and reduction of enzymatic activities, which likely coincides with decreasing demand for 
NST as this can be prevented by exposing the animals to cold or NE (Barnard 1969; Zhou et 
al. 2003; Skala & Hahn 1974; Hirning et al. 1989).  
In humans, immature brown adipocytes can be detected as early as in the 29th week 
of gestation. The development of the tissue appears to follow that observed in mouse with 
rapid expansion of cell volume and mitochondrial biogenesis.  Similarly, following birth, cells 
continue to grow, accompanied by a decrease in lipid content. Human infants have an 
estimated 30 g of BAT, about 1% their body weight (Aherne & Hull 1966; Hull 1976). In spite 
of the widespread decline in BAT through the first decade of life, most adults retain some 
functionally active BAT. 
Along with muscle, cartilage, bone and white adipose, BAT has a mesodermal origin, 
but brown adipocytes at different anatomical locations have distinct lineages. In the 
interscapular and perirenal depots of mice, brown adipocytes are derived from a myf5-
expressing progenitor that shares a common myoblastic lineage (Timmons et al. 2007), 
whereas brown adipocyte precursors interspersed within WAT depots and muscle are 
derived from myf5-negative cells that share a common non-myogenic lineage with white 
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adipocytes and have features different from brown adipocytes in the interscapular depot, 
including greater sensitivity to β3-adrenergic stimulation and cold exposure (Timmons et al. 
2007; Seale et al. 2008). When induced by the latter, they differentiate to multilocular 
uncoupling protein (UCP)-1+ thermogenically active cells referred to as “brite” adipocytes 
described above.  
Structure 
There are significant differences between BAT and WAT structure at the tissue and 
cellular level. BAT consists of brown adipocytes interspersed with stromal cells and 
connective tissue in a rich vascular network (Figure 1.6). The blood vessels and individual 
brown adipocytes are directly innervated by the SNS, which regulates its key function, 
adaptive thermogenesis, through the release of NE (Figure 1.7).  
Brown adipocytes are smaller than white adipocytes (38 – 45 µm vs. 50 – 100 µm) 
and are multilocular, containing several small lipid droplets (Figure 1.3). The cytosol is 
densely packed with numerous mitochondria (Figure 1.8), the site of thermogenesis, making 
them the most important organelles in the cell. The number and ultrastructure of the 
mitochondria vary depending on the level of thermogenic activity in BAT.  Table 1 lists the 
major structural features of white and brown adipocytes.  
Function  
The major function of BAT is adaptive NST, which is regulated by the SNS through 
the release of catecholamines, primarily NE.  BAT performs NST under two principal 
conditions: during cold acclimation to maintain body temperature and during diet-induced 
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thermogenesis (DIT). The notion that BAT participated in cold-induced NST was made 
several decades ago and was based on morphological changes observed in BAT  when 
animals were exposed to cold (Smith & Horwitz 1969).  Subsequent studies in rodents 
demonstrated the regulation of the process by the SNS, the role of mitochondria, and 
identified key molecular players in this process, including PGC1α, UCP1 and β-adrenergic 
receptors (Enerbäck et al. 1997; Puigserver et al. 1998). The recent identification of BAT in 
adult humans and measurements of glucose and FA- turnover in BAT using a tracer (Ouellet 
et al. 2012), also demonstrated that BAT functions as a cold-induced effector of NST in 
humans.  
BAT produces heat following food intake, a response known as DIT.  DIT, however, 
does not refer to the heat generated during food digestion. Instead, it refers to the 
induction of BAT thermogenic activity by catecholamines following increased food 
consumption over a prolonged period of time. The concept of metabolic efficiency is central 
to this discussion. Metabolic efficiency refers to the amount of energy stored per unit of 
energy ingested; high metabolic efficiency indicates that a larger fraction of energy is stored 
whereas low efficiency means that a larger fraction of the ingested energy is “lost” as ATP 
or heat. DIT by BAT results in lowered metabolic efficiency since a portion of the ingested 
calories is consumed in thermogenesis, instead of being stored as lipids and glycogen in 
WAT depots.  Thus, by lowering metabolic efficiency, BAT can play a key role in protection 
from diet-induced obesity (DIO).  Accordingly, ablation of BAT reduces energy expenditure 
and increases obesity in response to high-fat diets (Ghorbani et al. 1997; Guerra et al. 1998; 
Lowell et al. 1993).  
Warm Normal 
Cervical 
Supraclavicular 
Paravertebral 
Mediastinum 
Suprarenal 
A 
B 
Figure 1.5. Detection and distribution of BAT in adult humans (A) Cold-induced brown 
adipose tissue activation in adult man. The same patient was investigated by FDG-PET twice 
a few days apart. Left: Patient was kept under warm conditions before injection and until 
imaging. The only uptake visible is that into the brain, heart, kidneys, and bladder. Right: the 
patient had been examined under routine conditions, i.e., in comparatively cold conditions. 
The characteristic symmetrical pattern of uptake into the supraclavicular, neck, paravertebral 
areas, etc., i.e., into brown adipose tissue, is now visible. (B) Sites of FDG uptake 
corresponding to brown adipose tissue in adult humans. The black areas are those that are 
most frequently described; the gray areas are not always found, even in humans positive in 
the black areas. Reprinted from Am J Physiol Endocrinol Metab, 293:444-452,2007. 
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Table 1 – Comparison of white and brown adipose tissue  
Characteristic White adipose tissue Brown adipose tissue 
Color Cream or ivory Brown 
Adipocyte size (diameter) 50 – 100 µm 30-50 µm 
Fat Storage Unilocular lipid droplet Multilocular lipid droplet 
Mitochondria Few Numerous 
Nucleus Peripheral Central 
Unique marker Leptin UCP1 
Primary function Energy storage + endocrine  
 
Energy expenditure by non-
shivering thermogenesis 
 
Prevalence in humans Present in all adults Abundant in infant, present 
in some adults 
Development Throughout life Perinatal 
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Figure 1.7. Innervation of brown adipose tissue. (A) Shown here are the nerves (5 total) 
from the right intercostal region reaching the ventral portion of adult rat interscapular BAT. 
The BAT has been pinched and folded back to reveal the nerves. (B) TEM of interscapular BAT 
showing cross section of a nerve ending (dotted red line) in between three brown 
aidpocytes. LD – lipid droplets; scale bar represents 500 nm. (A) was reprinted with 
permission from The Adipose Organ, plate 13, Editrice Kurtis Ltd., 1999 
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Figure 1.8. Mitochondria in brown and white adipocytes (A) TEM demonstrating the 
mitochondrial content of white (left) and brown adipocyte (right). Whereas a white 
adipocyte has a few mitochondria, the cytoplasm of a brown adipocyte is densely packed 
with mitochondria, which are critical for their function. White adipocyte mitochondria are 
elongated with a few, often incomplete cristae. Brown adipocyte mitochondria are larger, 
uniform and packed with numerous cristae (red arrows) (B) High magnification SEM of a 
typical brown adipocyte mitochondria demonstrating the transverse cristae. Scale bars are 
indicated. (A) adapted from Gestal et al. 2007, (B) adapted from The Adipose Organ, plate 5, 
Editrice Kurtis Ltd., 1999 
A 
B 
White adipocyte Brown adipocyte 
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DIT was first proposed more than thirty years ago based on experiments in which 
rats fed a “cafeteria diet” (composed of foods high in fats and sugars) gained less weight 
than expected from caloric intake and showed increased BAT activity (Rothwell & Stock 
1979). With subsequent generation of transgenic mouse models, two lines of evidence 
pointed to a role for brown adipose-mediated DIT as a metabolic mechanism resulting in 
protection from obesity. One series of studies demonstrated that genetically obese animals 
had inefficient NST and atrophied BAT, implying that metabolic efficiency was increased as a 
result of inadequate BAT function. The other line of evidence made use of transgenic mouse 
models of key NST regulators demonstrating that the animals that were sensitive to cold 
were also quick to develop DIO, whereas those that exhibited increased thermogenesis 
were resistant to DIO (for a review see Lin & Li 2004).  Notably, ablation of BAT (using a 
diphtheria toxin transgene targeted specifically to BAT) exhibited cold sensitivity and 
became obese (Lowell et al. 1993) Taken together, these results indicated the dual function 
of NST in temperature regulation and in the maintenance of body weight. 
In adult humans, the contribution of BAT to metabolism is controversial, but it has 
been estimated that 50 g of maximally active BAT could account for up to 20% of the body’s 
daily caloric expenditure (Rothwell & Stock 1983).  Whether BAT is utilized for DIT in 
humans following “cafeteria diet” has not been investigated, in part due to the lack of 
appropriate non-invasive techniques to measure BAT activity under non-fasting conditions. 
However, a retrospective study that analyzed 18F-FDG PET–CT images of 1972 adult patients 
found BAT activity to be inversely correlated with body mass index, age and blood glucose 
level, suggesting that reduced BAT activity likely contributes to a subset of age-related 
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obesity (Cypess et al. 2009).  In addition to its capacity for NST, it was recently shown that 
activation of BAT via short-term cold exposure led to efficient channeling of FA into BAT 
through a metabolic program that increases uptake of TG-rich lipoproteins.  As a result, lipid 
clearance from plasma became more efficient, implying that BAT might be an important 
regulator of blood lipid levels (Bartelt et al. 2011). 
BAT structure is ideally adapted to its major function, NST, at both the tissue and 
cellular levels. At the tissue level, innervations by sympathetic nerve endings allows 
catecholamines released during SNS stimulation, by cold or food intake, to bind to β3 
adrenergic receptors on the adipocytes and activate thermogenesis.  During this process a 
dense capillary network enables rapid exchange of oxygen and carbon dioxide as well as 
efficient dissipation of the generated heat and its distribution throughout the body. 
Moreover, cold acclimation results in increased vascularity in BAT through angiogenic 
remodeling, increased blood flow and vaso-dilatation (Korac et al. 2008). For instance, cold 
induced a 12-fold increase in glucose uptake by BAT and was  accompanied by doubling of 
perfusion (Orava et al. 2011).  At the cellular level, the enormous capacity for 
thermogenesis derives from the large number of mitochondria in each adipocyte, each of 
which generates heat by the activity of the UCP1 protein, a key component of 
thermogenesis. Thus, the number and volume of mitochondria, and the number of cristae 
increase with thermogenic activity in mature brown adipocytes and are also indicative of 
the cell’s thermogenic activity.   
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Regulation of thermogenic activity in BAT 
The process of thermogenesis takes place in the mitochondria.  PGC1α is a master 
regulator of mitochondrial biogenesis and oxidative metabolism in most cell types, including 
brown fat and skeletal muscle. Genetic ablation of PGC1α results in reduced capacity for 
cold-induced thermogenesis in vivo while ectopic expression of PGC1α in WAT induced 
expression of multiple target mitochondrial and thermogenic genes including UCP1. PGC1α 
thus is a crucial regulator of adaptive thermogenesis (Puigserver et al. 1998; Puigserver 
2003). 
In most eukaryotic cells, the mitochondria are the sites of aerobic respiration i.e., 
the Krebs cycle and the electron transport chain.  Through the electron transport chain,  
which takes place in the inner mitochondrial membrane, a series of transmembrane enzyme 
complexes generate an electrochemical gradient by extrusion of protons (H+ ions) into the 
intermembrane space, and the gradient is converted to chemical energy in the form of ATP, 
by the membrane bound ATP-synthase. However, brown adipocytes express UCP1, a unique 
proton transporter localized to the inner mitochondrial membrane. When activated, UCP1 
pumps protons from the intermembrane space into the mitochondrial matrix, bypassing the 
ATP-synthase and effectively uncoupling the electron transport chain, thereby allowing the 
electrochemical energy to dissipate as heat (Farmer 2008). UCP1 is activated by free FA and 
is inhibited by purine nucleotides.  
Stimulation of the SNS leads to release of NE by nerve endings in BAT. NE then binds 
to the β3 adrenoreceptors on the plasma membrane of brown adipocytes and activates 
adenylyl cyclase, accelerating the conversion of ATP to the second messenger cAMP. cAMP 
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activates protein kinase A, which in turn, phosphorylates and activates hormone sensitive 
lipase as well as the transcription factor cAMP response element-binding protein (CREB).  
Phosphorylated hormone sensitive lipase translocates to lipid droplets, where it hydrolyzes 
the stored triglyceride into FA and glycerol. The release of FA has two purposes: fuel for 
thermogenesis and as activators of UCP1. In parallel, CREB leads to the activation of PGC1α, 
which increases UCP1 transcription.   
BAT and the pandemic of obesity 
Approximately 33% of the global population is obese and another 33% is 
overweight. Obesity results from caloric intake that exceeds energy expenditure over a 
prolonged period of time. Most of the excess calories are stored in WAT. Thus, approaches 
that decrease metabolic efficiency, such as aerobic exercise, are beneficial in avoiding 
weight gain. Accordingly, DIT in BAT can counteract the obese phenotype (Seale & Lazar 
2009) (Figure 1.9).  It is important to note that because basal metabolism in BAT, which 
does not require adrenergic stimulation, is not thermogenic, any pharmaceutical approach 
to increase the total amount of BAT must also include a method to ensure that the tissue is 
adequately stimulated, such as by providing adrenergic stimulation. The discovery of 
adipose-specific β3-adrenoceptors in both mice and humans raised hope that β3-selective 
agonists could stimulate energy expenditure without producing adverse side effects. Such 
compounds were effective for the treatment of obesity in rodents but performed poorly in 
limited clinical trials and suffered from lack of selectivity, low efficacy and poor 
bioavailability (Lin & Li 2004). On other fronts, polymorphisms in the UCP1 gene with 
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linkage to obesity are being investigated. In addition, a recent study reports the existence of  
a muscle-derived hormone, irisin, which is induced by exercise and causes ‘browning’ of 
WAT and thermogenesis, without cold or high fat died (HFD) in both mice and humans. 
Induction of such an agent could be a therapeutic approach to increase BAT thermogenesis  
A greater understanding of the molecular regulators of BAT activity and the basis for 
its presence in some humans but not in others is required to manipulate the huge 
thermogenic capacity of this tissue. Important questions that remain include the following:   
Are there genes in addition to UCP1 that perform the uncoupling function? How can the 
thermogenic capacity of BAT be fully utilized? What is the function of the vasculature 
besides gas/nutrient exchange and heat dissipation? Would increasing vascular remodeling 
enhance efficiency of NST in BAT? 
  
Figure 1.9. Role of WAT and BAT in energy homeostasis. Weight gain and 
obesity are caused by chronic periods of positive energy balance. Energy intake 
comes from food consumption, whereas is “burnt” through exercise and basic 
metabolic processes. Studies suggest that BAT activity could impact daily 
energy expenditure and can thus counteract weight gain if brown adipocytes 
can be activated by food intake-stimulated release of norepinephrine and “use 
up”  energy to generate heat. Individual variability in the amount or function of 
this tissue may impact body weight. In addition, therapeutic 
expansion/activation of this tissue may prove to be an effective therapy for 
obesity. Reprinted with permission from Diabetes, 58:1482-1484,2009. 
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Angiogenesis 
Angiogenesis is defined as the formation of blood vessels from pre-existing vessels 
and is responsible for the formation of a majority of capillaries both in the embryo and in 
the adult. During development, angiogenesis commences before the 20 somite stage (E9.5 
in mouse) and mediates the dramatic expansion of the vascular plexus, initially formed by 
vasculogenesis, the de novo differentiation of endothelial cells. Most organs acquire their 
vasculature through a combination of angiogenesis and vasculogenesis. A majority of 
embryonic blood vessels as well as the vascularization of organs derived from the 
ectoderm-mesoderm, such as the brain and the kidney, take place via angiogenesis. 
Angiogenesis is responsible for vessel growth in the adult under normal physiological 
conditions such as in wound healing, phases of the female reproductive cycle and 
pregnancy, in skeletal muscle following bouts of exercise, in WAT during adipose tissue 
expansion, in BAT during adaptive thermogenesis, as well as in pathological conditions such 
as tumor growth and metastasis and ocular neovascularization. 
Much of the research on the mechanisms of angiogenesis was spurred by Judah 
Folkman’s observations in the early 1970’s that a tumor did not grow beyond a critical mass 
(of 2-3 mm3) without vascularization and the proposal that blocking tumor angiogenesis 
might be a valid approach to controlling tumor growth (Folkman et al. 1971; Folkman 1971). 
Fibroblast growth factors (FGF)-1 and 2 and vascular permeability factor/vascular 
endothelial growth factor (VPF/VEGF)-A were the first tumor derived angiogenic factors 
purified. Subsequently, many pro- and anti-angiogenic factors have been identified 
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including additional members of the VEGF family of growth factors, the fibroblast growth 
factors, semaphorins, the Notch signaling pathway, platelet derived growth factors and the 
angiopoietins. Ultimately, the balance between pro and anti-angiogenic factors in the tissue 
determines the growth or quiescence of the vasculature. 
Angiogenesis occurs primarily through a process of sprouting from pre-existing 
vessels, usually venules. Vascular sprouts are led by specialized endothelial “tip cells” that 
respond to angiogenic stimuli and are connected to endothelial stalk cells that function in 
tube formation. The progression of angiogenesis is initiated by local destruction of the 
basement membrane and the dissociation of pericytes from the capillary, followed by 
migration of tip cells toward an angiogenic stimulus. Proliferation and alignment of 
endothelial cells follows and an endothelial cell tube forms, establishing a lumen. Pericyte 
and/or smooth muscle cell association and basement membrane deposition mediate vessel 
stabilization (for a review, see Patel-Hett & D’Amore 2011). 
Adipose Tissue Angiogenesis  
It has been long known that adipose tissue is extensively vascularized. In fact, as 
early as in 1945, a study comparing the vascularity (defined as the ratio of total surface of 
capillaries to the total volume of tissue supplied) of rat adipose tissue and skeletal muscle 
demonstrated that WAT exhibited a greater degree of vascularity than muscle (Gersh & Still 
1945). BAT is even more richly vascularized that WAT. For optimal thermogenic activity, BAT 
requires a dense microvasculature to ensure a sufficient rate of perfusion, rapid exchange 
of oxygen and substrates and efficient distribution of the heat generated.  
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Link between angiogenesis and adipose function 
The close spatial and temporal association between adipogenesis and 
vascularization requires an intimate cross talk between adipocytes, preadipocytes and 
endothelial cells. The macro- and micro-vasculature functions as  gatekeeper for access of 
blood borne constituents such as gas, nutrients, hormones and growth factors to adipocytes 
(Sun et al. 2011; Hausman & Richardson 2004).  The vasculature is critical for effective 
removal of FA released by adipocytes during fasting when the body shifts from using 
glucose to stored lipids as the primary energy source. Adipose tissue exhibits potent 
angiogenic capacity;  adipose tissue implanted into the avascular rabbit cornea induced 
robust neovascularization, whereas  implants of skeletal muscle and liver did not (Silverman 
et al. 1988).  Moreover, tube-like capillaries sprout from explants of adipose tissue from 
human and mouse embedded in Matrigel (Gealekman et al. 2008). Conditioned media from 
differentiated 3T3 adipocytes induced angiogenesis in the chick chorioallantoic membrane 
angiogenesis assay (Castellot et al. 1982). In fact, long before its angiogenic properties were 
elucidated, adipose tissue was used by surgeons for wound healing and revascularization of 
the intestines, the myocardium (McAllister et al. 1951; Vineberg et al. 1965) and the 
bronchus in human lung transplantation (Silverman et al. 1988). Vascular expansion takes 
place in BAT during cold acclimation or DIT and  angiogenesis is necessary to support the 
thermogenic activity during this phase. The vasculature of BAT differs from WAT in its 
response to NE, resulting in a doubling of blood flow in BAT (Orava et al. 2011).  
WAT displays potent angiogenic activity in vivo and ex vivo,  yet several studies have 
reported a decrease in blood flow and vascular density with obesity, resulting in local 
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hypoxia (for review, see Goossens 2008). Although HIF1α induction has been documented 
in WAT of obese patients (Cancello et al. 2005), it appears that hypoxic WAT is incapable of 
inducing angiogenesis to levels sufficient to compensate for the reduced blood flow 
observed during the WAT expansion associated with obesity.   
Heterogeneity of the adipose vasculature 
There is significant heterogeneity among the vasculatures of distinct adipose depots 
in terms of vessel morphology, capillary density and angiogenic potential.  Capillary density 
varies among  different parts of a depot as well as across different adipose depots (Gersh & 
Still 1945; Hausman & Richardson 2004). The pattern of vascularization of a depot is 
established very early during fat development and is predictive of the ultimate degree of 
vascularity in that depot (Crandall et al. 1997). Endothelial cells isolated from different 
adipose depots also differ in their proliferative capacity (Lau et al. 1996; Lau et al. 1990). 
The angiogenic activity of adipose varies by depot and possibly by species as well. For 
instance, there are reports of omental and SC fat implants inducing similar degrees of 
neovascularization (Silverman et al. 1988) whereas in another study a choloroform-
methanol extract of omental, but not SC, depot induced neovascularization in  the rabbit 
corneal pocket angiogenesis assay (Goldsmith et al. 1984). Humans SC fat had a greater 
angiogenic capacity compared to visceral fat in matrigel-embedded adipose tissue explants. 
In addition, the capillary density and angiogenic activity of SC, but not visceral, fat 
decreased with morbid obesity and was negatively correlated with insulin sensitivity 
(Gealekman et al. 2011). 
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Adipose lineage 
 While it is clear that adipose tissue expansion relies on blood vessel formation, the 
origin of these new vascular cells is unclear. In addition to adipocytes and vascular 
endothelial cells, adipose tissue contains other cell types such as adipose stromal cells and 
mesenchymal stem cells. The contribution of adipocyte stromal cells and mesenchymal 
stem cells to neovascularization is currently being investigated and some reports suggest 
that endothelial cells of the adipose may be derived from subpopulations of cells with 
distinct origins depending on the depot, contributing to their heterogeneity, differential 
gene expression profiles and different responses to treatment. Additionally, a recent study 
suggests an endothelial origin for murine and human adipocytes. In this study capillary 
sprouts from adipose tissue explants were shown to express preadipocyte markers and 
upon PPARγ activation lost their endothelial characteristics and displayed adipocyte 
features (Khanh-Van Tran et al. 2012).  
Angiogenic factors and cross talk between the adipose and vascular cells  
At least three cell types in adipose tissue produce angiogenic factors – adipocytes, 
adipose stromal cells and inflammatory cells. Together, these cells secrete a repertoire of 
pro- and anti-angiogenic factors, including VEGF-A, FGF-2, leptin, hepatocyte growth factor, 
insulin like growth factor, TNFα, transforming growth factor β (TGFβ), placental growth 
factor (PlGF), plasminogen activator inhibitor-1 (PAI-1), VEGF-C, visfatin, resistin, tissue 
factor, neuropeptide Y, heparin-binding epidermal growth factor, matrix metalloproteases 2 
and 9, and granulocyte macrophage colony stimulating factor. While most of these 
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molecules have been shown to increase angiogenesis, some such as TGF-β and plasminogen 
activator inhibitor (PAI)-1, can have a pro- or an anti- angiogenic effect depending on their 
concentration and the tissue context. Additionally, inflammatory cells recruited to growing 
adipose tissue also secrete high levels of a number of factors such as TNF-α, VEGF, 
interleukins 1, 6 and 8. Adipose tissue also produces anti-angiogenic factors such as 
endostatin, thrombospondin-1 and soluble VEGFR2 and these are detected at high levels in 
overweight and obese patients (for a review, see Yihai Cao 2007).  
VEGF, a potent angiogenic factor, is expressed at high levels by both BAT and WAT 
and accounts for most of the angiogenic activity in adipose tissue (Zhang et al. 1997; 
Fukumura et al. 2003).  The role of VEGF in adipose tissue angiogenesis is covered in greater 
depth later in this chapter. 
The adipokine visfatin is elevated in the serum of obese subjects and patients with 
type 2 diabetes. Visfatin induces endothelial cell proliferation and angiogenesis by 
increasing the expression of VEGF and VEGFR2 as well as MMP -2 and -9 via the PI3K/Akt 
and MAPK1/2 pathways (Adya et al. 2008). In addition, visfatin has a cardioprotective effect 
during myocardial infarction and plays a protective role in non-alcoholic fatty liver disease 
(Rosen & Spiegelman 2006). 
The hormone leptin produced by adipocytes regulates food intake and energy 
homeostasis and it dysfunction leads to severe obesity, diabetes and infertility. Leptin also 
stimulates angiogenesis by binding to the leptin receptor in endothelial cells and induces 
tube formation in vitro and corneal neovascularization. In addition to its direct angiogenic 
activity, leptin stimulates angiogenesis synergistically with both FGF-2 and VEGF, and 
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endothelial fenestrations and vascular permeability with VEGF, although the exact 
mechanism of this synergistic interaction is not known  (Cao et al. 2001).   
PAI-1 has been shown to regulate endothelial cell migration in vitro. During 
embryonic adipose development, PAI-1 is secreted along with αvβ3 integrin by human 
preadipocytes and endothelial cells thus providing a mechanism for the formation of the 
organs as preadipocytes can migrate with the endothelial cells during angiogenesis (Crandall 
et al. 2000).  PAI-1 can both positively and negatively regulate angiogenesis depending on 
dosage (Devy et al. 2002).  
There are several additional examples of paracrine communication between 
endothelial cells and adipocytes. Media conditioned by endothelial cells promotes 
preadipocyte proliferation and extracellular matrix components secreted by endothelial 
cells stimulate preadipocyte differentiation in vitro. VEGF-B, which is highly expressed by 
BAT and skeletal muscle, signals through VEGFR1 and Nrp1 on the endothelium to regulate 
transcription of vascular FA transport proteins, which control FA uptake by the endothelium 
and thus its availability to the vascularized BAT or muscle (Hagberg et al. 2010). PPARγ 
agonist rosiglitazone increases formation of angiogenic sprouts from adipose tissue explants 
but not from aortic explants, and this is mediated via upregulation of angiopoietin-like 
factor 4  and VEGF in adipocytes (Gealekman et al. 2008). Similarly, results of a randomized 
clinical trial reported that adipose tissue from patient biopsies cultured on Matrigel had 
increased capillary density and enhanced angiogenic sprout formation following treatment 
with rosiglitazone (Gealekman et al. 2012) .  
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Tweaking the vasculature  
In light of the demonstrated angiogenic capacity of adipose tissue, the close 
spatiotemporal coordination of adipogenesis and angiogenesis, and the multiple examples 
of paracrine interactions between adipocytes and endothelial cells, it is not surprising that a 
majority of obesity-associated disorders are coupled with vascular dysfunction. Pathological 
obesity is generally associated with a failure of vascular remodeling to keep pace with the 
expanding adipose tissue (Sun et al. 2011). This raises the prospect of regulating the 
expansion of adipose tissue by manipulating its vasculature as a novel therapeutic approach 
to obesity and associated metabolic comorbidities, especially type II diabetes.  Numerous 
studies have investigated this possibility including:  (i) application of broad spectrum anti-
angiogenic peptides, such as endostatin  and angiostatin (O’Reilly et al. 1994; O’Reilly et al. 
1997);  (ii) use of the small molecule TNP-470, which inhibits endothelial cell proliferation in 
vitro  and angiogenesis in vivo (Morita et al. 1994; Wang et al. 2000); (iii) targeted induction 
of apoptosis in the vasculature of white adipose tissue using a pro-apoptotic homing 
peptide;  and, (4) administration of anti-VEGF or anti-VEGF receptor antibodies to murine 
models of HFD-induced and genetic obesity using the LepR deficient ob/ob mice (Tam et al. 
2009; Sun et al. 2012; Elias et al. 2012;  Lu et al. 2012).  In each case, administration of these 
anti-angiogenic agents resulted in a dose dependent and reversible reduction in weight and 
adipose tissue without significantly affecting food intake (Rupnick et al. 2002). Interestingly, 
administration of TNP-470 also demonstrated additional signs of improved metabolic health 
such as reduced serum low density lipoprotein levels and increased insulin sensitivity, signs 
of a treatment that would be important in preventing the development of type II diabetes in 
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obese subjects (Bråkenhielm et al. 2004). Induction of apoptosis in the vasculature of WAT 
in obese mice by targeting prohibitin, a specific marker of the adipose vasculature, resulted 
in ablation of the adipose and reduced body weight along with normalization of metabolism 
through increased insulin sensitivity and glucose tolerance (Kolonin et al. 2004). As 
prohibitin is also found in human WAT vasculature, this opens up the possibility of 
prohibitin as a therapeutic target that might lead to the destruction of WAT leaving the BAT 
and other organs unaffected.  
Studies of anti-VEGF treatment in ob/ob mice, which are obese and have preexisting 
adipose tissue dysfunction, demonstrated that VEGF blockade led to improved metabolism 
through reduced weight gain, reduced adipocyte size, increased insulin sensitivity and 
decreased inflammatory factors. But anti-VEGF treatment during the early stages of HFD-
induced adipose tissue expansion resulted in poor metabolic health, no weight change and 
reduced glucose tolerance (Sun et al. 2012; Tam et al. 2009). On the other hand, VEGF 
overexpression during early stages of HFD improved metabolic health by increasing insulin 
sensitivity, energy expenditure and lipid clearance while reducing hepatic steatosis (Elias et 
al. 2012). VEGF overexpression also resulted in “browning” of WAT and increased 
thermogenesis, which likely contributed to the increased energy expenditure observed in 
these mice. Notably, these studies demonstrate that the consequences of modulating 
angiogenesis on obesity and metabolic health are context-dependent: pro-angiogenic 
activity during early stages of adipose tissue expansion is beneficial, associated with 
protective effects on metabolism, whereas in the context of preexisting adipose tissue 
dysfunction anti-angiogenesic therapy was required to improve metabolic conditions.  
37 
 
Vascular Endothelial Growth Factor  
VEGF-A (hereafter referred to as VEGF) was first purified in 1983 from the ascites 
fluid of guinea pig tumor on the basis of its potent ability to increase vascular permeability 
and known as vascular permeability factor (Senger et al. 1983) and soon after, from the 
conditioned media of folliculostellate cells as an endothelial cell specific mitogen (Ferrara & 
Henzel 1989). VEGF was subsequently determined to be a key regulator of angiogenesis.  
Family   
The VEGF family, of which VEGF-A is the founding member, is comprised of a 
number of secreted cysteine-knot glycoproteins including VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
VEGF-E and PlGF. VEGF-B has been shown to play a central role in cardiac angiogenesis and 
was recently demonstrated to control endothelial FA uptake (Hagberg et al. 2010). VEGF-C 
and VEGF-D promote lymphatic vessel development whereas PlGF has been studied 
primarily in pathological conditions where it is thought to stimulate angiogenesis in 
coordination with VEGF-A. The VEGF family also consists of lesser known members such as 
VEGF-E, which was identified in certain viruses, the snake-venom derived VEGF-F and 
endocrine gland (EG)-VEGF, which acts only on endocrine gland endothelial cells. The VEGF 
family members are biologically active as homodimers although naturally occurring 
heterodimers of VEGF-A and PlGF have been reported. 
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Structure 
Alternative splicing of the human VEGF gene produces eight isoforms, with the most 
abundant and well-studied isoforms being VEGF 121, 165 and 189 (120, 164 and 188 in 
mouse and rat). The isoforms differ in their ability to bind heparan sulfate and neuropilin-1 
(for a review see Patel-Hett & D’Amore, 2011). Charged domains in VEGF164 and VEGF188 
mediate their binding to heparan sulfate proteoglycans on the cell surface and in the 
extracellular matrix, where they may be sequestered and function locally. VEGF120 lacks 
these charged domains, so is freely diffusible and able to function at sites distant from the 
secreting cell.  The distribution of VEGF isoforms varies among tissues, suggesting that 
different isoforms may play distinct roles in vascular development and in the adult (Ng et al. 
2001) (Figure 1.10). This notion was substantiated by the distinct phenotypes of mice that 
were engineered to express single isoforms of VEGF (Carmeliet et al. 1999; Stalmans et al. 
2002). 
VEGF receptors 
VEGF binds to the tyrosine kinase receptors VEGFR1 (also called Flt-1) and VEGFR2 
(also known as Flk-1 or KDR in humans). VEGFR1 and VEGFR2 are 44% homologous at the 
amino acid level and each contains three functional domains – seven IgG like repeats in the 
extracellular domain, a single trans-membrane region and a cytoplasmic tyrosine kinase 
domain. Following VEGF binding, mediated by the second and third IgG repeats, the   
VEGF120 
VEGF164 
VEGF188 
proteoglycans 
heparin 
binding site 
A 
B 
Figure 1.10. VEGF isoforms and their localization. (A) VEGF isoforms with their exons along 
with important properties of each exon. Binding to VEGFR2 and VEGFR1 is mediated by 
exons 1 through 5, Nrp1 binding by exon 7 and heparan sulfate binding by exons 6 and 7. As 
VEFG120 lacks both the above exons, it does not bind to heparan sulfate, while VEGF188, 
possessing both exons 6 and 7, tightly binds heparan sulfate, and VEFG164 binds heparan 
sulfate but to a lesser extent compared to VEGF188. (B)  Differences in diffusibility of VEGF 
isoforms due to their differential ability to bind heparan sulfate proteoglycans. As VEGF120 
does not bind heparan sulfate, it is readily diffusible and can function at a site distant from 
its site of production. VEGF188 strongly binds heparan sulfate, which is present in the cell 
membrane and extracellular matrix, and is thus contained within the juxtracrine vicinity of 
the secreting cell. VEGF164 binds heparan sulfate as well, but not as strongly as VEGF188 
and thus can function locally as well as at a distance, and is the most abundant isoform. 
Image courtesy of P. D’Amore, unpublished. 
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receptors homo- or heterodimerize, which leads to activation of their kinase activity, 
autophosphorylation of multiple tyrosine residues and initiation of downstream signaling. 
While both receptors have high affinity for VEGF, VEGFR2 has ten-fold stronger tyrosine 
kinase activity compared to VEGFR1.   
VEGFR2, thus, is the primary signaling receptor for VEGF, initiating several signaling 
cascades including phosphatidyl inositol 3-kinase, mitogen activated protein kinase, protein 
kinase C, AKT and phospholipase C pathways, leading to increases in endothelial 
proliferation, migration, MMP expression, survival and cell permeability. The critical role of 
this receptor is reflected in the fact that homozygous knockout of VEGFR2 leads to 
embryonic lethality at E8.5–9.5 due to defects in the development of hematopoietic and 
endothelial cells and the absence of yolk sac vasculature (Shalaby et al. 1995). Initially 
thought to be specific for endothelial cells, subsequent studies have reported expression of 
VEGFR2 in multiple non-endothelial cell types such as myocytes and kidney podocytes 
(Bryan et al. 2008; Guan et al. 2006). 
With its high affinity for VEGF but weak tyrosine kinase activity, it is believed that 
VEFGR-1 functions as a “decoy” receptor, sequestering VEGF, thereby modulating signaling 
through VEGFR2 (Clauss 1998). In support of this, mice deficient for VEGFR-1 are embryonic 
lethal around E8.5 due to overgrowth of endothelial cells and impaired blood vessel 
formation (for a review see Nieves et al. 2009). In addition to the full-length membrane-
bound form, VEGFR1 also exists as an alternatively spliced, soluble form (sVEFGR1 or sFlt1).  
sFlt1 binds VEGF with higher affinity than VEGFR2 and is implicated as a negative regulator 
of angiogenesis. The complexity of VEGFR-1 biology is underscored by the fact that even 
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though it is not thought to signal in endothelium, it has been shown to function in several 
non-endothelial cell types, including breast cancer cells and macrophages and monocytes. 
VEGF receptors also reportedly heterodimerize with neuropilin-1 and 2. While neuropilins 
enhance VEGFR-2 mediated signaling, it is unclear whether they are capable of independent 
signaling.  
Expression  
Using a mouse in which LacZ had been knocked into the VEGF locus, VEGF 
expression was shown to commence before gastrulation  and was detectable at all stages of 
vascular development in the embryo (Miquerol et al. 1999). The cellular distribution and the 
extent of VEGF expression indicate its pleiotropic role in development. High levels of 
expression appeared to be associated with vasculogenesis and permeability, whereas lower 
levels were associated with angiogenesis and cell migration. In addition, VEGF was 
demonstrated to be expressed in a subtype of endothelial cells present in the endocardium 
(Miquerol et al. 1999).  In the brain and the kidney, organs which are vascularized by 
angiogenesis, VEGF expression was detected by in situ hybridization around E16-17. 
Moreover, a tight spatial coordination was observed between the expression patterns of 
VEGF and VEGFR-2 and while VEGF was expressed by a wide variety of embryonic cells, 
VEFGR-2 expression was confined to the endothelium.  In the adult, VEGF is expressed in a 
cell-specific manner in nearly all vascularized adult tissues including select endothelium, and 
VEGFR2 is constitutively phosphorylated across several tissues in vivo. The pattern of VEGF 
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expression is unique in each organ; in white and brown adipose tissue VEGF is produced by 
adipocytes, adipose stromal cells and inflammatory cells.  
Function in endothelial cells 
 Tumor cells as well as epithelial and mesenchymal cells during development and in 
the adult secrete VEGF and it expression is further induced by hypoxia and other stimuli. 
Upon binding to VEGF receptors on the nearby endothelium, VEGF initiates angiogenesis 
and stimulates recruitment of newly formed blood vessels to the source tissue. VEGF 
promotes angiogenesis by inducing endothelial cell proliferation, migration, survival, 
extracellular matrix degradation, formation of fenestration and cell permeability. This 
process occurs extensively during embryonic angiogenesis and during physiological and 
pathological angiogenesis in the adult.  During development, VEGF is essential for both 
vasculogenesis and angiogenesis. Vascular development is dependent on tight regulation of 
VEGF as deletion of a single VEGF allele in mice results in early embryonic lethality (by E9.5) 
due to severe vascular defects (Carmeliet et al. 1996; Ferrara et al. 1996), whereas slight 
overexpression of VEGF similarly results in embryonic lethality around E12.5 (Miquerol et al. 
2000). 
Early studies of VEGF neutralization in mouse tumor models (Kuo et al. 2001) 
revealed no obvious side effects, suggesting that VEGF is not required in the adult and 
making it an attractive target for the treatment of a variety of diseases. As a result, many  
agents have been designed to target either VEGF or its receptors. Though beneficial effects 
have been observed, particularly for use in the treatment of ocular angiogenesis, the 
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development of significant side effects suggest that VEGF is important in the maintenance 
of adult vasculature and non-vascular tissues. Indeed, several studies have demonstrated 
that one important role of VEGF in the adult is in the induction and maintenance of 
fenestrated capillaries, as blockage of VEGF signaling resulted in capillary regression in 
several organs including choroid plexus, thyroid, pancreatic islets and epididymal fat 
(Kamba et al. 2006), and loss of alveolar, tracheal, and peritubular capillary endothelium.  
Function in non-endothelial cell types  
Although VEGF was initially thought to target only endothelial cells, numerous 
studies have identified roles for VEGF on a wide range of non-endothelial cell types. VEGF is 
essential for the maintenance of choroid plexus structure and integrity, including 
ependymal cell function (Maharaj et al. 2008).  VEGF also  promotes Müller cell survival 
through autocrine signaling, has a paracrine neuroprotective effect on photoreceptors 
(Saint-Geniez et al. 2008),  functions in an autocrine loop to promote the survival of kidney 
podocytes (Guan et al. 2006), as well as the maintenance of the retinal pigmented 
epithelium (Ford et al., 2011)  skeletal muscle (Bryan et al. 2008), bone differentiation 
(Mayer et al, 2005)  and in the structural and functional maintenance of arterial neuro-
effector junctions.  
VEGF in white and brown adipose 
While adipocytes secrete a number of angiogenic factors, it has been demonstrated  
that VEGF mediates most of the angiogenesis in adipose tissue in both white and brown 
adipose tissue (Zhang et al. 1997; Fukumura et al. 2003). Conditioned media from 
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endothelial cells grown in the presence of VEGF promoted adipocyte differentiation in vitro 
more robustly compared to conditioned media without VEGF or with both VEGF and VEGF-
neutralizing antibodies. This indicates that  VEGF secreted by adipocytes functions in a 
paracrine manner by signaling through VEGFR2 on endothelial cells, which in turn secrete 
adipokines that promote adipogenesis in vivo and in vitro and its blockage prevented both 
adipose tissue neovascularization and adipogenesis (Fukumura et al. 2003)  VEGF is also 
required for angiogenic plasticity of expanding WAT in murine models of HFD-induced 
obesity. From recent studies (described earlier in this chapter) it appears that the effect of 
VEGF in adipose tissue expansion and overall metabolic health may be context dependent: 
in the early stages of HFD increased VEGF expression facilitates healthy adipose tissue 
expansion and confers protection from metabolic insults, whereas in the context of pre-
existing adipose tissue dysfunction blockage of VEGF signaling leads to improved insulin 
sensitivity and metabolic health (Sun et al., 2012).  
Multiple reports have demonstrated that brown adipocytes express VEGF in vivo and 
in vitro and VEGF expression is lower in the BAT of genetically obese rats (Tonello et al. 
1999; Asano et al. 1997).  VEGF  expression increases in primary rat preadipocytes 
differentiated to brown adipocytes, whereas there was a slight decrease in the expression 
of VEGF-B and C (Asano et al. 2001).  VEGF expression in BAT increases upon adrenergic 
stimulation resulting from cold exposure or injection of β-adrenergic receptor agonists. 
This VEGF expression is independent of the hypoxia that results from intense oxygen 
consumption during thermogenesis mediated by UCP1 as UCP1-null animals also displayed 
increased VEGF expression and angiogenesis following cold exposure. VEGF transcription in 
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brown adipocytes induced by NE is mediated by NE is mediated by cAMP and protein kinase 
A (PKA) (Fredriksson et al. 2000; Fredriksson et al. 2005; Xue et al. 2009). Further, a recent 
study has shown that exercise induced  transcription of VEGF in skeletal muscle is mediated 
by PGC1α and is independent of HIF1α (Arany et al. 2008).  Thus, it is possible that PGC1α 
also regulates hypoxia -independent VEGF expression in BAT. 
Interest in its potential for weight control has led to significant work on the effect of 
VEGF neutralization in WAT, but very little is known on the role of VEGF in brown adipose.  
While there are several reports of VEGF expression in BAT and its role in promoting 
angiogenesis during cold acclimation, detailed analysis of the dynamics of this expression 
are not known. There are also no reports of expression of VEGF receptors in brown 
adipocytes, which forestalls investigation on the role of VEGF, if any, on brown adipocytes 
themselves, in addition to its role on the BAT endothelium. Adipose tissue is very plastic 
throughout adult life, yet adipose-derived tumors are rare, suggesting that both adipose 
tissue and its microvasculature are tightly regulated. Thus my aim was to study the 
dynamics of VEGF as well as VEGF receptor expression in white and brown adipocytes, 
hypothesizing that both are tightly coordinated during adipogenesis. I also hypothesized 
that VEGF must play a functional role in either white or brown adipocytes, depending on 
the  VEGF receptor expression and activation in these cells, in addition to supporting 
adipose angiogenesis.  
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Chapter 2                                   
EXPRESSION OF VEGF AND VEGF 
RECEPTORS IN WHITE AND BROWN 
ADIPOSE 
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Introduction 
While there are multiple reports of VEGF production in white and brown adipocytes, 
detailed analysis of the dynamics of this expression during phases of adipocyte 
differentiation is lacking.  VEGF expression has been shown to increase with differentiation 
of multiple cell types such as kidney podocytes, osteoblast differentiation and myocyte 
differentiation (Bryan et al. 2008; Guan et al. 2006; Mayer et al. 2005). In light of the fact 
that adipose tissue is a very plastic organ that undergoes adaptive tissue growth, like 
skeletal muscle, I hypothesized that VEGF expression increases during brown and white 
adipocyte differentiation. I also hypothesized that VEGF receptor expression on brown 
and/or white adipocytes would be indicative of a direct functional role of VEGF signaling in 
these cells. Therefore, in this chapter I have explored the expression of VEGF and VEGF 
receptors in white and brown adipocytes.  
Results 
VEGF and its receptors are expressed in BAT and all major WAT depots  
The expression of VEGF and its receptors in brown adipose tissue (BAT) and white 
adipose tissue (WAT) were analyzed by RT-PCR in interscapular BAT as well as subcutaneous 
(SC) WAT from the inguinal region and visceral WAT from mesenteric, perigonadal (PG)   
and retroperitoneal depots of adult male mice (Figure 2.1). VEGF mRNA was detected in all 
BAT and WAT depots, with the highest expression in BAT, followed by SC and PG depots; all 
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expressed each of the three major VEGF isoforms. Mesenteric and retroperitoneal depots 
expressed lower levels of VEGF, mostly as the 164 isoform.  VEGFR2 was expressed robustly 
in BAT, followed by PG and SC. Low expression was detected in the mesenteric depot 
whereas there was no detectable VEGFR2 in the retroperitoneal depot. VEGFR1 expression 
was similar to that of VEGFR2.  
VEGF expression increases during 3T3L1 differentiation  
To investigate the temporal relationship between VEGF expression and white 
adipocyte differentiation I examined the expression of VEGF in the 3T3L1 system,  an 
established and well characterized model of in vitro white adipocyte differentiation (Green 
& Kehinde 1975). 3T3L1 preadipocytes were grown to confluence in Dulbecco’s modified 
Eagle’s medium (DMEM). Forty-eight hours after the cells reached confluence, adipocyte 
differentiation as induced by replacing the growth medium with DMEM containing insulin, 
dexamethasone, IBMX and fetal bovine serum (FBS) (Figure 2.2). Distinct morphological 
changes were observed as the 3T3L1 cells underwent differentiation; the cells changed in 
shape from a fibroblast-like appearance to spherical, lipid-containing cells.  Intracellular lipid 
droplets were visible by light microscopy by the fifth or sixth day of differentiation, and 
increased in number and size. By day twelve of differentiation, more than 95% of cells had 
one or more large droplets (Figure 2.3A). The droplets were confirmed histochemically as 
lipid containing by staining with Oil Red O, which stains triglycerides and lipids (Figure 2.3B, 
left), and by the immunofluorescence (IF) with antibody to perilipin, an adipocyte marker 
that  coats and protect lipid droplets from hydrolysis (Figure 2.3B, right).  
Figure 2.1. VEGF and VEGF receptor levels in adipose depots.  mRNA 
expression of VEGF and receptors, VEGFR2 and VEGFR1, in BAT and 
subcutaneous, mesenteric, epididymal and retroperitoneal WAT depots of 
adult male mouse were measured by RT-PCR.  
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Figure 2.2. Schematic representation of 3T3L1 and brown preadipocyte 
differentiation. Undifferentiated preadipocytes were cultured for 48 hours 
beyond confluence in the growth media. On day 0, the media was replaced 
with adipose differentiation media, comprised of growth media supplemented 
with insulin, dexamethasone and isobutylmethylxanthine. After 48 hours, the 
differentiation media was replaced with differentiation maintenance media 
containing insulin. Cells were maintained in the maintenance media until fully 
differentiated judged by their morphology and accumulating lipid droplets 
(10-12 days for white adipocytes and 7-9 for brown adipocytes), replacing 
media every other day. 
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RNA was isolated from the cells at different time points during differentiation and 
analyzed by qRT-PCR for markers of adipocyte differentiation. Expression levels of the 
transcription factor PPAR, which is essential for adipocyte differentiation, increased nearly 
eight-fold by day four compared to the beginning of differentiation (day zero) and rose 
steadily to a 15-fold increase by day twelve (Figure 2.4A, left). The expression of aP2, an 
adipocyte-specific fatty acid binding protein and well-characterized marker of adipocyte 
differentiation, increased 20-fold from day zero levels by day four and remained elevated 
through the 12 days examined (Figure. 2.4A, right). Analysis of VEGF mRNA levels in the 
differentiating 3T3L1 cells showed a five to seven - fold increase between days eight and 12 
relative to levels at day zero (Figure 2.4B).  Absolute quantification of VEGF isoforms using 
isoform-specific primers indicated that the level of each isoform increased with 
differentiation, with VEGF 164 the most abundant isoform at 50% of the total VEGF, VEGF 
188 about 35% and VEGF 120 accounting for 15% of the total VEGF in mature differentiated 
3T3L1 adipocytes (Figure 2.4C). This result demonstrates that VEGF expression increases 
concomitantly with adipose differentiation and is consistent with the notion that VEGF 
expression is coordinately regulated as part of the process of white adipocyte 
differentiation.   
There was greater than 10-fold decrease in VEGFR2 levels by day four of 
differentiation and the levels remained low throughout differentiation (Figure 2.5A, left).  
There was no significant change in VEGFR1 expression during differentiation (Figure 2.5A, 
right). This was in contrast to mature primary adipocytes isolated from both inguinal and 
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epididymal fat pads of adult mice, and demonstrated to be mature adipocytes by 
expression of aP2, which showed robust expression of both VEFGR2 and VEGFR1 (Figure 
2.5B).  In an attempt to reconcile the difference, I examined isolated primary adipocytes for 
potential contamination by endothelial cells, which express VEGFR2 and should have 
separated with the stromal-vascular fraction during the isolation process.   
Immunofluorescence localization of the adipocyte marker perilipin and the endothelial cell 
marker endomucin (Kuhn et al. 2002), revealed unilocular white adipocytes with strong 
perilipin localization as single cells or in clumps of two-three cells. However, in a fraction of 
these clumps, several endomucin-positive endothelial cells were also observed (Figure 
2.5C). Analysis of VEGFR2-LacZ mouse did not reveal VEGFR2 expression in white 
adipocytes, whereas endothelial VEGFR2 expression was observed in lungs. IHC localization 
of VEGFR2 did not detect any VEGFR2 on either SC or PG WAT depots (data not shown). 
These data indicated that VEGFR2, the primary VEGF signaling receptor, was not present in 
detectable levels in white adipocytes.  
VEGF expression increases during brown adipocyte differentiation 
To study VEGF expression during brown adipocyte differentiation I utilized an 
immortalized murine brown preadipocyte cell line, derived from neonatal brown adipocyte 
precursors, that has been shown to differentiate into brown adipocytes in vitro (Fasshauer 
et al, 2000).  Brown preadipocytes were grown to confluence in DMEM and induced to 
differentiate as described for the 3T3L1 cells above (Figure 2.2).  Intracellular lipid droplets  
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Figure 2.3. Morphological and functional changes during 3T3L1 differentiation. 
(A) Change in cell morphology from a fibroblast like appearance to cuboidal shape 
with accumulation of lipid during differentiation (B) Uptake of Oil Red O by 
triglycerides (bottom panel, left) and expression of perilipin (bottom panel, right) 
in differentiated adipocytes.  Nuclei visualized by DAPI. Scale bar represents 50 
µm. 
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Figure 2.4. Increase in VEGF expression during 3T3L1 differentiation (A) 
Expression of adipocyte markers PPARγ (left) and aP2 (right).  (B) VEGF 
expression increases during adipocyte differentiation along with adipocyte 
marker expression, quantified using quantitative PCR (qPCR) (C) Absolute 
quantification of VEGF isoforms during differentiation using qPCR with isoform 
specific primers. p*<0.05, p**<0.01, p***<0.001. 
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Figure 2.5. VEGFR2 expression in white adipocytes in vivo and in vitro (A) VEGFR2 expression 
decreases during 3T3L1 differentiation while VEGFR1 expression is not significantly changed, 
quantified using qPCR (B) VEGF receptor expression in white adipocytes isolated from 
subcutaneous and perigonadal WAT of two groups of wild type male mice (C) IF was performed 
on isolated adipocytes with the adipocyte marker, perilipin, and endothelial marker, endomucin, 
to determine whether there was contamination by stromal-vascular fraction. Representative 
images indicate that adipocytes isolated had some contamination with vascular endothelial cells. 
Nuclei visualized by DAPI . p***<0.001. 
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were visible as early as day three of differentiation and by day six, more than 95% of cells 
had multiple lipid droplets, morphologically resembling their in vivo counterparts (Figure 
2.6A). The differentiation of brown adipocytes is accompanied by increased mitochondrial 
biogenesis. Accordingly, mitochondria in differentiated brown adipocytes were visualized 
using CMTM Rosamine MitoTracker, a mitochondria-specific vital dye, and lipid droplets 
were visualized by IF staining for perilipin (Figure 2.6B). RNA isolated from the cells at 
different time points during differentiation was analyzed by qRT-PCR for markers of 
adipocyte differentiation. Levels of PGC1, a key regulator of brown adipocyte 
differentiation and of mitochondrial biogenesis, increased as early as day three of 
differentiation and the elevated levels were maintained throughout differentiation (Figure 
2.7A, left). The expression of UCP1,  a protein essential for brown adipocyte thermogenesis, 
was increased 50-fold by day six and 170-fold by day eight (Figure 2.7A, center).  The 
expression of β3 adrenoreceptor, which is more abundant in brown adipocytes compared 
to the β1 and β2 isoforms and is important for activation of BAT by the sympathetic nervous 
system, was increased  30-fold by day three and 100-fold by day eight (Figure 2.7A, right). 
Analysis of VEGF mRNA expression by qPCR at various time points during differentiation 
demonstrated that brown preadipocytes expressed VEGF and that VEGF levels were 
increased by 2.5- to 3-fold over the course of differentiation (Figure 2.7B). Of the three 
VEGF isoforms, VEGF164 was the most abundant isoform whereas low levels of VEGF188 
and 120 were also detected. VEGF164 constituted 90% of total VEGF at day zero and rose to 
98% of total VEGF by day eight. While levels of VEGF120 also increased during the course of 
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differentiation, it decreased from approximately 10% of the total at day zero to about 1% at 
day eight. VEGFR2 was expressed by both brown preadipocytes as well as differentiated 
brown adipocytes, with the level of expression being slightly lower in the more 
differentiated cells. VEGFR1 was also expressed in brown preadipocytes and differentiated 
brown adipocytes. Additionally, Nrp1 was expressed by both undifferentiated cells and 
differentiated brown adipocytes (Figure 2.7D).  As was observed for white adipocytes, these 
data suggest that VEGF expression may be coordinately regulated with the process of 
brown adipocyte differentiation. Moreover, the expression of VEGF receptors in both 
preadipocytes and differentiated brown adipocytes raises the possibility of an autocrine 
role for VEGF in these cell types.  
VEGF expression increases in brown adipocytes following adrenergic 
stimulation  
To test whether VEGF expression in BAT increases as a result of acute adrenergic 
stimulation adult mice were injected with the adrenergic receptor agonist CL 316243 (CL), 
which is specific for the β3 receptor isoform. BAT RNA was isolated from the mice at 2, 6 
and 24 hours post injection.  I first analyzed by qRT-PCR for known effectors of adrenergic 
stimulation in BAT.  UCP1 mRNA levels doubled rapidly compared to control within two 
hours of injection and remained elevated at twenty four hours.  PGC1α mRNA expression 
increased rapidly following CL injection, rising to 18-fold over control mice 2 hours after 
injection, and returned to baseline  levels by twenty four hours post-injection (Figure 2.8A, 
left). The upregulation of VEGF expression by adrenergic stimulation followed a similar 
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pattern to that of PGC1α, peaking at 1.7-fold over control at 2 hours and showed a slight 
but consistent decrease by 24 hours post injection (Figure 2.8B). VEGF 164 and 188 were 
the most abundant isoforms, constituting 60% and 40% of total VEGF mRNA, respectively, 
while little or no VEGF 120 was detected. Following CL injection, proportion of VEGF 164 
increased slightly from 60% to 75% of total VEGF whereas the level of VEGF 188 isoform 
decreased accordingly (Figure 2.8C). 
To investigate whether the increase in VEGF expression measured in BAT following 
adrenergic stimulation was a direct effect on the brown adipocytes, brown adipocytes 
differentiated in vitro were treated with norepinephrine (NE) for 1 hour.  As expected, the 
levels of PGC1α and UCP1 mRNA increased eight- and fourteen-fold, respectively, compared 
to untreated control cells (Figure 2.9A). Similar to the observations in vivo, there was a 
nearly 3-fold increase in the expression of VEGF mRNA within 1 hour of treatment 
compared to untreated cells (Figure 2.9B). These results indicate that quiescent 
(unstimulated) BAT expresses VEGF, which is elevated following adrenergic stimulation. The 
in vitro data shows that the increased VEGF expression in BAT following adrenergic 
stimulation is derived, at least in part, from brown adipocytes indicating that elevated VEGF 
expression was a direct effect of NE/β adrenergic agonists on brown adipocytes.  
  
A 
B 
Day 9 
perilipin CMTM Ros merge 
Day 8 Day 4 Day 0 
Figure 2.6. Morphological and functional changes during brown adipocyte 
differentiation (A) Change in cell morphology from a fibroblast to a 
multilocular appearance during differentiation (B) Lipid droplets are identified 
using perilipin (left), mitochondria is visualized using CMTM Rosamine 
MitoTracker on live cells, depicting large amount of mitochondria (middle), 
merge (right). Nuclei visualized by DAPI . Scale bar represents 50 µm. 
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Figure 2.7. Increase in VEGF expression during brown adipocyte differentiation. (A) 
Expression of adipocyte markers PGC1α(left), UCP1(center) and β3 adrenergic receptors 
(right), quantified using qPCR. (B) Increase in VEGF expression during brown adipocyte 
differentiation in parallel to brown adipocyte markers shown in (A). (C) Absolute 
quantification of VEGF isoforms during differentiation using isoform specific primers and 
qPCR. (D) VEGF receptor expression during brown adipocyte determined by RT-PCR indicate 
strong VEGFR2 expression in both preadipocytes and differentiated  adipocytes. p*<0.05, 
p**<0.01, p***<0.001. 
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Figure 2.8. VEGF expression increases in BAT in vivo following adrenergic stimulation by 
the β3 receptor agonist CL 316,243. Mice were injected intraperitoneally with CL 316,243 
and tissue was harvested at various time points from 2 hours to 24 hours post injection. (A) 
Increase in PGC1α (left) and UCP1 (right) expression, determined by qPCR, indicate 
activation of brown adipocytes. (B) VEGF expression is elevated during adrenergic 
stimulation and parallels PGC1α expression (C) Quantification of the percentage of VEGF 
isoforms contributing to total VEGF at various time points after adrenergic stimulation using 
absolute quantification with isoform specific primers. p**<0.01, p***<0.001. 
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Figure 2.9. VEGF expression increases in cultured brown adipocytes following treatment 
with norepinephrine. Brown adipocytes on day eight of differentiation were serum starved 
for three hours and treated with 10 µM norepinephrine for 1 hour. (A) Robust increase in 
PGC1α (left) and UCP1 (right) expression indicate activation of brown adipocytes. (B) VEGF 
expression, determined by qPCR, is elevated during adrenergic stimulation and parallels 
PGC1α expression (C) Quantification of the percentage of VEGF isoforms contributing to 
total VEGF in unstimulated and stimulated brown adipocytes using absolute quantification 
with isoform specific primers. p*<0.05, p***<0.001. 
62 
63 
 
Discussion 
VEGF expression was detected in BAT and in all major WAT depots. The level of 
VEGF expression in BAT was higher than in any of the WAT depots, consistent with the 
densely vascularized nature of the tissue. Earlier reports of VEGF expression in BAT show a 
level of expression that was comparable to other highly vascularized tissue such as kidney, 
lungs and the heart (Asano et al. 1997; Tonello et al. 1999). In agreement with a prior report 
(Zhang et al. 1997),  levels of VEGF among WAT depots, were higher in SC than PG.  
Numerous studies have reported that VEGF secretion by adipose tissue increases with the 
amount of adipose tissue and that plasma VEGF levels are positively correlated with body 
weight in both humans and mice (Gómez-Ambrosi et al. 2010; Miyazawa-Hoshimoto et al. 
2005). One series of studies reported that VEGF secretion by primary adipocytes was only 
one-tenth that from adipose tissue explants maintained in media for 48 hours (Fain & 
Madan 2005; Fain et al. 2004).  Though these observations may suggest that adipocyte-
derived VEGF accounts about 10% of total adipose tissue VEGF in humans, these studies are 
also complicated by the fact that establishing cells in culture leads to significant changes in 
gene expression, which may impact these results. Further, the explants may be hypoxic 
which would result in a higher production of VEGF compared to the adipocytes in culture.  
My results indicated that VEGF mRNA expression increases during 3T3L1 
differentiation, a finding that is in agreement with earlier observations made in another 
adipogenic cell line, 3T3-F442A. In 3T3-F442A cells induced to differentiate into adipocytes 
increased VEGF was detected as early as day four of differentiation (Claffey et al. 1992), 
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whereas using 3T3L1 cells as a model, we observed increased VEGF expression around day 
eight of differentiation; results that are in concurrence with an earlier study that used these 
cells (Miyazawa-Hoshimoto et al. 2005). This difference in time course of expression could 
be attributed to the cell lines or to the sensitivity of techniques used to quantify VEGF.  Our 
laboratory and others have demonstrated that VEGF expression increases in concert with 
differentiation in several systems including differentiating skeletal muscle (using C2C12 
cells) (Bryan et al. 2008; Claffey et al. 1992), podocytes (Guan et al. 2006), osteoblasts ( Liu 
et al. 2012; Mayer et al. 2005) and retinal pigmented epithelium (Ford et al. 2011), 
suggesting that VEGF expression is under the control of the same factors that regulate 
differentiation and therefore a part of the differentiation process itself.  
I also demonstrate that all isoforms of VEGF are expressed during white adipocyte 
differentiation with VEGF164 and VEGF188, the heparan sulfate binding isoforms, 
comprising 90% of the total VEGF. Although the precise distribution of VEGF isoforms in 
white adipose had not been previously determined, one study did report that the mitogenic 
activity of adipocyte conditioned media on endothelial cells was maximal in the heparin 
sulfate binding fraction, supporting my observations that the heparan sulfate binding VEGF 
isoforms make up the majority of adipocyte VEGF (Zhang et al. 1997). 
I did not detect VEGFR2 in white adipocytes in vivo or in vitro, an observation that  is 
in agreement with previous findings using 3T3F442A preadipocytes which reported the 
absence of a direct effect of VEGF on adipocytes (Fukumura et al. 2003). On the other hand,  
VEGF secreted by adipocytes has been shown to be functionally active on endothelial cells; 
conditioned media from primary white adipocytes and differentiated 3T3L1 adipocytes 
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induced human umbilical vein endothelial cells proliferation (Zhang et al. 1997) and tube 
formation (Miyazawa-Hoshimoto et al. 2005) in vitro, which was blocked by anti-VEGF 
antibody. Additionally, in a model of SC fat pad created by transplantation of 3T3F442A cells 
into SCID mice, inhibition of VEGFR2 was shown to block not only angiogenesis and vessel 
remodeling in the implanted fat pad but also differentiation of the 3T3F442A cells into 
adipocytes. Whereas the addition of VEGF to preadipocytes in culture did not have any 
effect on their proliferation, survival or differentiation, conditioned media from endothelial 
cells cultured in the presence of VEGF increased preadipocyte proliferation and 
differentiation, effects that were largely abrogated by anti-VEGFR2 (Fukumura et al. 2003). 
Adipocyte-derived VEGF, therefore, plays a paracrine role to support both angiogenesis and 
adipogenesis.  Serum VEGF levels are also elevated with increasing adiposity. Obese 
subjects have higher serum VEGF levels, which is lowered after bariatric surgery (García de 
la Torre et al. 2008). Thus it is possible that VEGF may play an endocrine role in vessel 
maintenance, and it remains to be determined whether the alteration of VEGF levels with 
obesity and related comorbidities like type 2 diabetes exacerbate angiogenesis in distant 
sites such as observed in proliferative diabetic retinopathy (Petrovic et al. 2008).  
VEGF expression was also increased in concert with brown adipocyte differentiation.  
While it has been reported that VEGF is expressed in whole BAT tissue (Asano et al. 1997) as 
well as in brown preadipocytes and adipocytes (Tonello et al. 1999; Asano et al. 2001), there 
had been no quantitative measure of the change in VEGF or VEGF receptor expression 
during the course of brown adipose differentiation. My observation that VEGF levels 
increased in parallel with key modulators of brown adipocyte function such as PGC1α, UCP1 
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and β3 adrenoreceptors suggest that VEGF expression may be coordinately regulated as 
part of the process of differentiation.  Elevated VEGF expression was similarly observed 
during myocyte and podocyte differentiation and was shown to be blocked when the 
process of skeletal muscle differentiation was prevented by use of a dominant negative 
MyoD (Bryan et al. 2008).  
As VEGF has three major isoforms and we and others have demonstrated that the 
isoforms have differential expression in various tissues, I wanted to study the expression of 
VEGF isoforms during brown adipocyte differentiation. Preadipocytes expressed low levels 
of VEGF120, which further decreased to less than 1% in fully differentiated brown 
adipocytes. This observation is in agreement with my data on VEGF expression in adult BAT, 
where very low levels of VEGF120 were detected. As the VEGF isoforms differ in the 
presence or absence of charged domains that can mediate binding to heparan sulfate 
proteoglycans on the cell surface and extracellular matrix, they vary in their ability to 
diffuse. The relatively low levels of VEGF120 in BAT detected by us and others (Asano et al. 
1997) suggest a dispensable role for the 120 isoform or functional redundancy with the 
other heparan sulfate binding isoforms.   However, there was virtually no detectable VEGF 
188 in cultured adipocytes, an observation that has been previously reported (Tonello et al. 
1999) and appears to be a limitation of the in vitro culture system, which otherwise 
represents a good model of brown adipocyte differentiation as indicated by the robust 
expression of UCP1 and other brown adipocyte markers.   
My results demonstrate the expression of the two major VEGF receptors, VEGFR2 
and VEGFR1, as well as the co-receptor Nrp1, in preadipocytes as well as adipocytes. One of 
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the notable differences between white and brown adipocyte differentiation is in the level of 
VEGFR2 expression. VEGFR2 expression decreased significantly during white adipocyte 
differentiation and was not detectable in differentiated adipocytes. On the other hand, 
VEGFR2 was expressed at significant levels in both brown preadipocytes and in 
differentiated adipocytes. As VEGFR2 is the primary receptor for VEGF signaling, this 
observation is very interesting and suggests that VEGF may have a direct effect on brown 
adipocytes, which express VEGFR2, but not in white adipocytes.  
Cold exposure stimulates release of NE by the sympathetic nervous system; its 
binding to adrenergic receptors in brown adipocytes results in adrenergic stimulation of 
BAT. In addition to exposure to cold temperatures, this phenomenon can be experimentally 
simulated by administration of NE or β3 adrenergic receptor agonists such as CL 316,243 in 
vivo or in vitro.  As noted earlier, adrenergic stimulation is followed by cAMP mediated 
activation of PKA and an increase in PGC1α levels, which leads to mitochondrial biogenesis 
and increased expression of UCP1. As expected, treatment of cultured brown adipocytes 
with NE led to a robust increase in PGC1α and UCP1 and injection of mice with CL 316,243 
produced a significant increase in PGC1α mRNA and a two-fold increase in UCP1 mRNA. The 
increase in UCP1 activity following adrenergic stimulation is regulated at both 
transcriptional as well as posttranslational levels; in the latter case fatty acids activate UCP1 
by binding to its C terminal. Thus, the observed increase in UCP1 mRNA expression 
represents only a portion of the total increase in UCP1 activity.  Cold exposure also results in 
BAT hyperplasia, an example of adaptive tissue growth, and is characterized by increased 
proliferation of brown adipocyte precursors and endothelial cells. Similar adaptive 
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responses are seen in muscle following endurance training and bouts of exercise where 
VEGF expression has been shown to increase.  
VEGF expression similarly increases during adrenergic stimulation of BAT in vivo and 
in vitro. My findings agree with earlier reports of 2 to 3-fold increase in VEGF expression 
within a few hours of cold exposure or injection with β agonists (Asano et al. 2001; 
Fredriksson et al. 2005; Tonello et al. 1999). Absolute quantification of VEGF isoforms after 
CL injection in vivo revealed that VEGF isoforms 164 and 188 comprised 99.8% of total VEGF 
(Asano et al. 1997). An earlier report examining adrenergic stimulation in rats reported that 
VEGF120 levels increased from 11% to 30%. While the difference in levels of VEGF120 
measured between my work and the earlier report are most likely attributed to sensitivity 
of measurement techniques (I used quantitative PCR and the prior report employed semi-
quantitative PCR), both agree that the heparan sulfate binding isoform VEGF164 
predominates.   This is consistent with the fact that the increased VEGF during adrenergic 
stimulation would function both at a distance, on endothelial cells to promote angiogenesis, 
as well as locally, on adipocytes.  
My investigation of the expression of VEGF and its receptors in white and brown 
adipose tissue demonstrate VEGF expression by white and brown adipocytes. VEGF 
expression increased during differentiation of white and brown adipocytes. My novel 
finding that VEGF receptors, VEGFR2, VEGFR1, as well as co-receptor Nrp1, are expressed in 
brown preadipocytes and adipocytes, raises the interesting possibility of an autocrine role 
of VEGF signaling in brown adipocytes and preadipocytes. 
  
69 
 
 
 
 
 
Chapter 3                                               
ROLE OF VEGF SIGNALING IN BROWN 
ADIPOCYTES  
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Introduction 
While it has been demonstrated that VEGF is expressed in BAT, preadipocytes and 
adipocytes, the sole function of VEGF was assumed to be as an angiogenic factor and 
potential actions outside of this have not been explored. Co-expression of VEGF and 
VEGFR2 has been observed in several cell types including podocytes (Guan et al. 2006), 
skeletal  muscle (Bryan et al. 2008) and the retinal pigmented epithelium (Ford et al. 2011); 
in each of these cells VEGF signaling was also demonstrated to play a role. My observation 
that VEGF and VEGFR2 are present in brown adipocytes therefore, led me to hypothesize 
that VEGF signaling may play a functional role in brown adipocytes in addition to supporting 
angiogenic remodeling. In this chapter I have explored the role of VEGF signaling in brown 
preadipocytes and adipocytes in vitro and in vivo.  I investigated if VEGF is important for 
brown preadipocyte survival and proliferation using in vitro assays and brown adipocyte 
survival and function in vitro and in vivo.  
Results 
VEGF is a mitogen for brown preadipocytes and acts asa survival factor 
through the PI3K-Akt pathway 
The expression of VEGF, VEGFR2 and co-receptor Nrp1 in brown preadipocytes 
suggests that VEGF may function in an autocrine manner in these cells. To investigate a role 
for VEGF-VEGFR2 signaling in brown preadipocytes, VEGFR2 activation was assessed by 
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examining the phosphorylation of known tyrosine residues in unstimulated brown 
preadipocytes in regular culture conditions. Western blot analysis of lysates of 
preadipocytes revealed phosphorylation of VEGFR2 at tyrosine 951, indicating VEGF 
signaling through VEGFR2 (Figure 3.1).  
Brown preadipocytes have been shown to be sensitive to serum starvation (growth 
factor withdrawal). To determine if VEGF signaling was playing a role in brown preadipocyte 
survival, cells were maintained in regular media but without serum, in the presence or 
absence of VEGF or the VEGFR2 neutralizing antibody DC101.  After 12 hours of serum 
starvation, about a third of the cells were seen to be detached by light microscopy; this 
increased to greater than 80% by 24 hours.  The levels of apoptosis marker protein from 
whole cell lysates of the above samples were analyzed by western Blotting.  Cleavage of the 
inactive proenzyme caspase 3 to its smaller (17-19 kD and 12 kD), proteolytically active 
forms is considered a marker of apoptosis, as the cleaved fragments are critical executioner 
of apoptosis(Fernandes-Alnemri et al. 1994; Nicholson et al. 1995).  As expected, nutrient-
deprivation resulted in robust activation of caspase 3, demonstrated by the presence of the 
cleaved 17-19kD fragments.  Culture of the cells with nutrient deprivation but in the 
presence of VEGF resulted in 70% reduction in caspase 3 cleavage and activation, indicative 
of reduced apoptosis. The addition of DC101 along with VEGF, thereby blocking VEGF 
signaling, resulted in 80% increase in caspase 3 cleavage levels and apoptosis compared to 
cells in VEGF alone. Additionally, the pattern of VEGFR2 phosphorylation was inversely 
correlated with caspase 3 activation, providing further evidence that VEGFR2 signaling was 
necessary for the observed protective effect.  
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  The phosphatidylinositol 3-kinase (PI3K) -Akt pathway has been demonstrated to 
confer protection from apoptosis in multiple cells and is also reported to be downstream of 
the VEGF–VEGFR2 signaling cascade.  To examine the signaling pathways involved in VEGF-
conferred protection of brown preadipocytes from apoptosis, I examined Akt activation in 
the above samples.  As expected, Akt was phosphorylated in control cells that were grown 
in normal growth media and did not show any apoptosis.  In contrast, nutrient deprivation 
resulted in a nearly complete loss of Akt phosphorylation along with loss of VEGFR2 
phosphorylation, indicating that Akt signaling was downstream of VEGF-VEGFR2 signaling in 
brown preadipocytes.  The presence of VEGF resulted in robust Akt phosphorylation 
compared to levels in control samples, and the addition of DC101 reduced this 
phosphorylation by 80% (Figure 3.1).   
To determine the role of VEGF signaling in preadipocytes, we assessed the effect of 
VEGF on preadipocyte proliferation.  Preadipocytes were cultured in low serum in the 
presence or absence of 10ng/ml VEGF and counted daily.  The growth of brown 
preadipocytes with VEGF led to a stimulation of cell proliferation when compared to 
untreated cells, with an increase in cell number of 70% at 48 hours (Figure 3.2).  
Blockage of VEGF signaling sensitizes brown adipocytes to apoptosis  
The association between VEGF expression and adipocyte differentiation as well as 
the expression of VEGF receptors in differentiated brown adipocytes demonstrated earlier, 
suggest that VEGF may play a role in mature brown adipocytes. In light of my observation 
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that VEGF acted as a survival factor for brown preadipocytes, I hypothesized that VEGF 
might serve a similar function for brown adipocytes.  
While nutrient deprivation does not lead  to death of  mature brown adipocytes, TNFα in 
combination with low (10 µg/ml) dose of cycloheximide (CHX) has been shown to induce 
apoptosis in brown adipocytes, with a maximal effect between 4 to 6 hours, without 
cytotoxicity due to CHX alone (Boucher et al. 2010; Miranda et al. 2010; Nisoli et al. 1997). 
To study the effect of VEGF signaling on brown adipocyte survival, brown adipocytes 
differentiated in vitro were treated with 10 nM TNFα and 10 µg/ml CHX for 6 hours in the 
presence or absence of VEGFR2 neutralizing antibody, DC101.  Quantification of cells 
revealed that whereas TNFα/CHX alone resulted in a 7% reduction in the number of cells 
compared to untreated brown adipocytes, treatment with DC101 in addition to TNFα/CHX 
resulted in a 15% reduction in the number of brown adipocytes compared to those treated 
only with TNFα/CHX (Figure 3.3A).  This level of cell death is significant as adipocytes are 
known to be relatively resistant to apoptosis. For an additional measure of survival, the 
percentage of cells with caspase 3 activation was measured. FACS analysis revealed a 5-fold 
increase in the number of adipocytes with cleaved caspase 3 in TNFα/CHX –treated cells 
grown with DC101 compared to cells grown with TNF/CHX (Figure 3.3B), indicating that 
blockade of VEGF signaling sensitizes brown adipocytes to apoptosis.  
  
Figure 3.1. VEGF activates PI3K/Akt pathway and mediates brown 
preadipocyte survival. Serum-starved brown preadipocytes cultured in 
25ng/ml VEGF for 12h were protected from apoptosis, judged by the reduced 
expression of cleaved (activated) caspase 3, which was lost upon the addition 
of VEGFR2 blocking antibody 15µg/ml DC101. Phosphorylation of VEGFR2 at 
Y951 was detected to check for active VEGF signaling and phosphorylation of 
Akt at S453 was done to check for PI3K/Akt activation.  
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Figure 3.2. VEGF increases brown preadipocyte proliferation. Increase in 
number of brown preadipocytes grown in 1% FBS in the presence of 10 ng/ml 
VEGF compared to 1% FBS alone. p**<0.01, p*<0.05.  
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Figure 3.3. Blockage of VEGF signaling sensitizes brown adipocytes to 
apoptosis. Differentiated brown adipocytes at day 7 were treated with 10nM 
TNFα and 10µg/ml CHX for 6 hours to induce apoptosis, in the presence or 
absence of VEGF-blocking antibody DC101 (15 µg/ml). (A) Cell numbers 
revealed treatment with DC101 in addition to TNFα/CHX led to reduced 
survival and fewer brown adipocytes compared to TNFα/CHX alone; p**<0.01 
(B) Apoptotic adipocytes detected using FACS analysis for cleaved (activated) 
caspase 3 also revealed an increased apoptosis in the presence of DC101; p = 
0.067.  
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VEGF neutralization reduces BAT vascular density  
Given my observation indicating a role of VEGF in brown adipocytes and 
preadipocytes in vitro, I next investigated a possible function for VEGF in the adult BAT.  To 
block VEGF signaling in vivo mice were injected intravenously with an adenovirus expressing 
sFlt1 (Ad-sFlt1) or an empty adenovirus (Ad-null). Previous work from our group has shown 
that this is an effective model for systemic VEGF neutralization, and that a circulating sFlt1 
level of at least 200 ng/ml is required for effective VEGF neutralization and that these levels 
can be maintained for up to 28 days (Maharaj et al. 2008; Ford et al. 2011 and unpublished 
data). Thus, mice were injected with adenovirus via the tail vein, serum was collected five 
days after injection to measure  circulating sFlt1 levels and tissue was harvested from the 
mice seven days post injection (Figure 3.4).  
To examine BAT capillary density of mice with systemic VEGF neutralization, BAT 
sections were probed with antisera against the endothelial-specific glycoprotein, 
endomucin, which is expressed by the endothelium of capillaries and veins but not arteries 
(Kuhn et al. 2002; dela Paz & Patricia a D’Amore 2009). Seven days following injection of the 
adenovirus, there was a marked reduction in microvessel density in the Ad-sFlt1 injected 
mice compared to Ad-null injected mice (Figure 3.5A). Whole tissue lysates from BAT of 
both groups were examined for the levels of endomucin (as a surrogate for vascular 
density) by Western blotting and revealed a 50% decline in endomucin levels in the BAT of 
Ad-sFlt 1 injected mice (Figure 3.5B), indicating that  VEGF neutralization led to a reduction 
in the microvascular density of brown adipose tissue.   
7.5 x 10^10 PFU Ad-sFlt1 
or Ad-null (negative control)  
Day 0 : Adult (8wk) male C57Bl/6J mice injected with sFlt1 or null virus 
Day7: Fat pads were harvested  
from mice with > 200 ηg/ml circulating sFlt1 
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Figure 3.4. Schematic representation of Ad-sFlt1 tail-vein injections for 
systemic VEGF neutralization.  8 week old male C57Bl/6J mice were injected 
with sFlt1 or null adenovirus via the tail vein. Serum levels of sFlt1 were 
measured by ELISA 5 days post injection. Mice expressing at least 200 ng/ml of 
circulating sFlt1 were included in the study.  Circulating sFlt1 levels can be 
maintained up to 28 days post injection. 7 days post injection mice were 
sacrificed and fat pads harvested for protein, histology and ultrastructure 
analysis using TEM. For TEM mice were first perfused with appropriate fixative.  
Day5: Serum collected by submandibular 
bleeding, circulating sFlt1 levels measured by 
ELISA 
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Figure 3.5. VEGF neutralization reduces BAT vascular density.  (A) Capillary 
density of sFlt1 and control BAT sections were examined by IF with endomucin, 
which marks the microvasculature. Nuclei were labeled with DAPI. There were 
fewer capillaries (white arrowheads) in the sFlt1-injected BAT compared to null. 
Scale bar represents 50 µm (B) Total endomucin protein levels in whole tissue 
lysates from BAT detected by Western Blotting (top) and quantification of 
endomucin levels normalized to β tubulin was done as a surrogate for vascular 
density; p*<0.05 
Endomucin = capillary endothelium 
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Figure 3.6. VEGF neutralization is associated with fibrosis of BAT. Collagen 
deposition in BAT of sFlt1 and control mice detected by Masson’s trichrome 
staining. Increased collagen (yellow arrowheads), indicative of fibrosis, was 
observed around veins and arteries as well as between brown adipocytes in the 
sFlt1-expressing mice. Collagen was detected as thin sheets in the control mice 
as well, but not at levels that are outside of normal. Scale bar represents 50 µm. 
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Figure 3.7. VEGF neutralization is associated with inflammation of BAT. IHC 
localization of F4/80 revealed infiltrating macrophages (black arrowheads) in 
the BAT of ad-sFlt1 injected mice but none in ad-null mice. F4/80 positive cells 
were detected attaching to the vessel walls of sFlt1 mice (red arrowheads), 
suggesting local inflammation, while no attachment was detected in null mice.  
Dotted black line – endothelial lining, L – lumen, scale bar represents 50 µm. 
 
81 
82 
 
VEGF neutralization is associated with fibrosis and inflammation of BAT in 
vivo 
Reduced microvessels often result in tissue hypoxia, which can, in turn, lead to 
fibrosis and local inflammation (Halberg et al. 2009). Collagen I, the predominant collagen in 
adipose tissue (Napolitano 1963), was detected by Masson’s trichrome staining (TRI), which 
stains muscle red, nuclei dark purple and collagen bright blue. Collagen appeared as thick 
blue depositions around adipocytes and blood vessels in the sFlt1-expressing mice 
compared to the thin collagen sheets in the wild type mice, which is normal (Figure 3.6).  
IHC localization of F4/80 revealed the presence of a large number of macrophages in 
the BAT of sFlt1-expressing mice, whereas no macrophages were observed in the BAT of 
control mice (Figure 3.7). The features of immune cell infiltration, including adhesion and 
extravasation of the F4/80 positive cells, were observed in the sFlt1-injected BAT and 
suggest that VEGF neutralization resulted in local inflammation in BAT.  
VEGF neutralization leads to brown adipocyte apoptosis in vivo 
Since blockage of VEGF signaling resulted in increased apoptosis in vitro, I wanted to 
investigate the effect of VEGF neutralization on brown adipocyte survival in vivo. Apoptosis 
was first assessed by IHC localization of activated (cleaved) caspase 3 in BAT.  Many cells 
stained positively for cleaved caspase 3 in the BAT of sFlt1-expressing mice compared to 
only a few positive cells in null mice (Figure 3.8). High magnification revealed that these 
cells, occurring in clusters or singly, were adipocytes with activated caspase 3 accumulation 
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in the cytosol surrounding lipid droplets (Figure 3.8, bottom panel); a few endothelial cells 
with activated caspase 3 were also observed.  
To confirm apoptosis by another approach and to quantify apoptotic cells, Terminal 
Transferase dUTP Nick End Labeling (TUNEL) assay was performed (Figure 3.9A). TUNEL 
staining similarly revealed a large number of apoptotic (TUNEL +) cells in the BAT of sFlt1-
expressing mice compared to null.  To distinguish the adipocytes from the vascular cells, 
BAT sections were co-stained with endomucin to identify the endothelium (Figure 3.9B). 
There was a six to seven-fold increase in the number of apoptotic adipocytes in the BAT of 
sFlt1-expressing mice compared to control BAT. The BAT of mice that had been injected 
with Ad-null had ten or fewer apoptotic cells per section (Figure 3.9C). These data indicate 
that VEGF acts as a survival factor for brown adipocytes in vivo. 
Effect of VEGF neutralization on brown adipocyte morphology and 
mitochondrioma in vivo 
Lipid droplets 
Whereas brown adipocytes from the control mice had numerous small lipid droplets 
that is typical of BAT histology, brown adipocyte of sFlt1-expressing mice exhibited much 
larger lipid droplets (Figure 3.10), a phenotype that is indicative of increased lipid content 
and unusual in normal brown adipocytes of lean mice . This morphological difference was 
readily observed during histological analysis by H&E and Masson’s trichrome staining as 
well as during ultrastructural analysis with TEM. This was surprising as the BAT mass was 
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reduced after VEGF neutralization and thus was not a direct outcome of adipocyte 
hypertrophy (data not shown). 
Mitochondria 
As mitochondria are central to the function of brown adipose, I wanted to assess the 
effect of VEGF neutralization on mitochondrial ultrastructure. Ultrastructural analysis of 
BAT taken from control mice seven days post injection revealed that each adipocyte 
contained numerous mitochondria. However, the number of mitochondria was reduced by 
about 30% in brown adipocytes of ad-sFlt1 injected mice compared to control (Figure 
3.11A).  Control mice contained mitochondria that were uniform in shape and size, 
displayed dense, tightly packed cristae that spanned the width of each mitochondrion. In 
contrast, mitochondria in brown adipocytes from sFlt1-expressing mice often lacked cristae 
or had cristae that were incomplete, irregular in arrangement and/or did not span the 
mitochondrion (Figure 3.11B).  Incomplete or absent cristae are associated with 
mitochondrial degeneration and inactivity. The mitochondrial anomalies, along with the 
presence of large lipid droplets in brown adipocytes of sFlt1-expressing mice, suggest that 
VEGF neutralization may lead to reduced brown adipocyte function.  
Electron microscopic examination of the brown adipocytes of sFlt1-expressing mice 
also revealed autophagosome engulfing double-membraned organelles reminiscent of 
mitochondria, structures that were not observed in null mice (Figure 3.12A). The individual 
mitophagic vesicles appeared either electron dense or light, likely reflecting the stage of 
autophagic degradation. The light chain (LC)-3 proteins, LC3-I and II, are widely used as 
markers of autophagy  (Kabeya et al. 2000). During autophagy, LC3-I is converted to LC3-II, 
Figure 3.8. VEGF neutralization leads to brown adipocyte apoptosis in vivo. 
Apoptosis detected by IHC localization of activated (cleaved) caspase 3. Top panel: 
Adipoyctes with activated caspase 3 (black arrowhead) are rare in the BAT of control 
mice; low magnification (left), high magnification (right). Middle and lower panels: 
Apoptotic cells, with cleaved caspase 3 in the cytosol surrounding lipid droplets, 
occur frequently in clumps or singly near vessels in the BAT of sFlt1 expressing mice. 
L-lumen, LD-lipid driplet, scale bar represents 50 µm. 
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Figure 3.9. Quantification of apoptosis in BAT after VEGF neutralization. (A) 
TUNEL staining of BAT sections demonstrating that BAT of mice injected with 
ad-sFlt1 have more TUNEL+ cells (white arrowheads) compared to null. Scale 
bar represents 100µm. (B)TUNEL+ adipocytes (white arrowheads) versus 
endothelial cells (red arrowheads) were identified by co-staining with 
endomucin and only TUNEL+ adipocytes were counted for quantification. (C) 
Quantification of TUNEL+ cells in each section reveals more than a six fold 
increase in apoptosis in sFlt1 BAT. L-lumen, LD-lipid driplet, scale bar represents 
50 µm; p*<0.05 
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Figure 3.10. VEGF neutralization results in alteration in brown adipocyte lipid 
droplets. Brown adipocyte histology analyzed by Masson’s trichrome stain 
demonstrating multiple small lipid droplets in each cell typical of brown 
adipocyte morphology (left), whereas ad-sFlt1 injected mice had significantly 
larger lipid droplets (yellow arrowhead) not usually observed in lean mice. 
Scale bar represents 50 µm 
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which become associated with autophagic vesicles (Tanida et al. 2004) and therefore 
indicates autophagy.  Thus, to further characterize the observed mitochondrial autophagy, I 
assessed LC3B levels in BAT using IHC. A light brown pattern of puncta was distributed 
diffusely throughout the cytosol of individual cells in both null and sFlt1-expressing mice, 
reflecting a basal level of autophagy. However, in the sFlt 1-expressing mice many 
adipocytes exhibited denser dark brown puncta within the cytoplasm, suggestive of a higher 
abundance of autophagosomes (Figure 3.12B). This staining pattern was rarely observed in 
null mice, an observation that is consistent with our TEM analysis that did not reveal 
mitophagy in any BAT from control mice. Increased mitophagy is associated with reduced 
lipolysis in WAT (Singh et al. 2009) and reduced thermogenesis in BAT (Milosevic & 
Ukropina 2008). These observations of altered mitochondrial structure in BAT associated 
with VEGF neutralization supports a role for VEGF in the maintenance of brown adipocyte 
survival/integrity.  
The effects of VEGF on brown adipocytes and preadipocytes observed in vivo and in 
vitro are summarized in Table 2. 
 
  
Figure 3.11. VEGF neutralization results in reduced mitochondria and disrupted 
ultrastructure. (A) Average number of mitochondria per field indicates a significant 
decrease in the total number of mitochondria in ad-sFlt1 injected mice. (B) (Left) 
Electron micrograph of brown adipocyte showing abundant mitochondria, lipid 
droplets (LD) and a nearby vessel (L) in control mice. Mitochondria were typical of 
functional brown adipocytes, numerous and densely packed with complete double 
membrane cristae (white arrowhead). (Right) Fewer mitochondria present in sFlt1 
brown adipocytes; a majority of mitochondria showed obvious signs of degeneration 
such as incomplete cristae, involuting cristae etc (red arrowhead) and several lacked 
cristae entirely (yellow asterisks); high magnification depicted in bottom panel.  L – 
lumen, LD - lipid droplet, scale bar represents 500 nm ; p=0.00007 
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Figure 3.11 (continued) 
Figure 3.12. VEGF neutralization results in brown adipocyte mitophagy. (A) Electron 
micrograph of brown adipocyte from ad-sFlt1 injected mice showing autophagy of 
mitochondria (red arrowhead). Left: Advanced stage of autophagy in which the 
autophagosome has already fused with a lysosome and material has degraded 
resulting in a lower density compared to the surrounding tissue. The double 
membranous structure present in the autophagolysosome is indicative of a 
mitochondria. Right: An early stage of mitophagy in which the intact mitochondria is 
being engulfed by an autophagosome. Note that the engulfed mitochondria appears 
healthy with complete cristae indicating that mitophagy in sFlt1-expressing mice is 
not a clearance pathway for abnormal mitochondria but a separate mechanism for 
reduction in overall mitochondria. Scale bar represents 500nm. (B) IHC localization of 
the autophagic marker LC3B. Puncta indicate autophagosomes with which the LC3B 
form II is associated. There are increased puncta in sFlt1 BAT compared to null mice. 
N – nucleus, LD - lipid droplet, scale bar represents 50 µm. 
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Figure 3.12 (continued) 
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Table 2 – Summary of effects of VEGF on brown adipocytes in vitro and in vivo  
Function In vitro In vivo 
Preadipocyte proliferation VEGF increases Not studied 
Preadipocyte apoptosis VEGF decreases Not studied 
Adipocyte apoptosis DC101 increases apoptosis sFlt1 increases apoptosis 
Adipocyte differentiation No significant effect Not studied 
Lipid droplet morphology Not studied sFlt1 increases lipid droplet size 
Number of mitochondria Not studied sFlt1 decreases 
Mitochondria morphology Not studied Abnormal with sFlt1 
Mitochondria autophagy Not studied sFlt1 increases  
BAT fibrosis - sFlt1 increases 
BAT inflammation - sFlt1 increases 
 
Section in pink indicates features associated with brown to white transdifferentiation. Section in green 
indicates probable effect of hypoxia resulting from capillary dropout.  
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Discussion 
There are now numerous reports that the action of VEGF is not confined to the 
vasculature. A variety of non-endothelial cells express VEGFR2, the primary VEGF signaling 
receptor, and VEGF has been shown to act on these cells to mediate proliferation, 
differentiation and/or survival.  Multiple lines of evidence, such as the presence of both 
VEGF and VEGF receptors in brown adipocytes, the dynamics of VEGF expression during 
brown adipocyte differentiation and cold acclimation of BAT, led me to hypothesize that 
VEGF signaling plays a role in brown adipocytes.  
The increased metabolic capacity of cold acclimated-BAT results not only from 
elevated thermogenic activity in individual adipocytes but also a greater number of 
adipocytes. Hyperphagia or cold adaptation in BAT is accompanied by robust hyperplasia as 
a result of proliferation of both preadipocytes and endothelial cells. In fact, 3H -thymidine 
labeling revealed a 70-fold increase in the number of proliferating cells in rats exposed to 
cold for two days compared to those at normal temperature (Bukowiecki et al. 1982). 
Whereas vascular remodeling takes a few days to a few weeks, we and others have 
observed that VEGF levels increase rapidly after cold exposure or adrenergic stimulation 
and return to initial (pretreated) levels 24 hours after treatment.  This disconnection 
between time frame of increases in VEGF levels and that of vascular remodeling suggests 
that VEGF may regulate proliferation in brown preadipocytes. Furthermore, it was recently 
demonstrated that approximately ten percent of adipocytes are renewed annually 
throughout adult life, irrespective of body mass index (Spalding et al. 2008).  While the 
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latter study was focused on white adipocytes, this observation nevertheless underscores 
the tight regulation of preadipocyte proliferation, differentiation and apoptosis.  
Apoptosis in brown preadipocytes is regulated by insulin through PI3K/Akt signaling 
(Boucher et al. 2010; Miranda et al. 2010). I have demonstrated that VEGF also signals in 
these cells through VEGFR2 and the PI3K/Akt pathway to confer protection from apoptosis. 
While a role for VEGF in brown preadipocyte apoptosis has not been reported until now, it 
is a survival factor for a number of other cell types such as photoreceptors, podocytes and 
the retinal pigmented epithelium (Saint-Geniez et al. 2008; Ford et al. 2011; Guan et al. 
2006). The data here demonstrate that VEGF acts as a mitogen on brown preadipocytes. As 
preadipocytes express VEGF and also VEGFR2, which we have shown is phosphorylated; it is 
likely that VEGF signals through an autocrine loop in these cells.  
The effect of systemic VEGF neutralization on BAT has been investigated during cold 
acclimation (Xue et al. 2009) where it was shown to block angiogenesis. As there have been 
no reports on the effect of VEGF neutralization on unstimulated BAT or brown adipocytes I 
assessed the role of VEGF through systemic VEGF neutralization achieved by adenovirus 
mediated sFlt1 overexpression. VEGF neutralization reduced microvascular density of BAT, 
measured using the endothelial cell marker endomucin, by 50% in seven days of VEGF 
neutralization. A recent study reported that overweight/obese subjects had 44% lower 
capillary density compared to lean individuals (Pasarica et al. 2009). Thus, the level of 
capillary dropout in BAT (or BAT rarefaction) resulting from sFlt1 overexpression in my 
experiments is within the physiologically relevant range observed in obesity.   
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As adipose tissue is the most plastic organ in the adult; both hyperphagia or cold 
acclimation resulting  in hyperplasia of BAT as well as WAT expansion during weight gain are 
accompanied by angiogenesis and remodeling of the adipose tissue vasculature. To adapt to 
the function and characteristics of adipose tissue, therefore, it is imperative that the 
microvasculature of adipose tissue be particularly plastic. In a study reporting the plasticity 
and VEGF dependency of adult vascular beds, thyroid and pancreatic  islet vasculature were 
found to be the most plastic  with about 70% reduced capillary density  after 14 days of 
VEGF neutralization using ad-sFlt1 (Kamba et al. 2006), whereas microvasculature of the 
brain and retina are not affected in that time (Saint-Geniez et al. 2008). In comparison, our 
observation of a 45% reduction in microvascular density (judged by endomucin protein 
levels) after only seven days of VEGF neutralization, therefore, underscores the plasticity of 
adipose tissue vasculature and how it is primed for remodeling during adaptive tissue 
growth. Fenestrated capillaries with high levels of VEGFR2 have been found to be more 
plastic, whereas microvascular beds such as the retina and brain that have been shown to 
be more “stable” are characterized by a high pericyte to endothelial cell ratio. Therefore it 
would be interesting to examine the pericyte distribution and fenestrations in the BAT 
vasculature.  High levels of VEGF expressed by BAT and the significant capillary dropout in 
BAT noted after seven days of VEGF neutralization is also consistent with the concept that 
high local levels of VEGF in a tissue reflect a strong dependence on VEGF compared to the 
vasculature in regions with lower VEGF levels (Saint-Geniez et al. 2008; Kamba et al. 2006).  
As oxygen diffuses from the capillary bed, its partial pressure falls from 
approximately 100 mm Hg as it leaves the vessel to almost zero within as little as 100 µm 
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(Folkman et al. 2000). Reduced capillary density therefore results in local hypoxia. Hypoxia 
has been documented in the adipose tissue of obese humans and mice. Recent studies have 
demonstrated that fibrosis and inflammation are part of the response of adipose tissue to 
hypoxia (Pasarica et al. 2009; Halberg et al. 2009; Sun et al. 2012).  The molecular response 
to hypoxia was modeled in a transgenic mouse that overexpressed HIF1α in adipose at 
levels found in the WAT of genetically obese ob/ob mice (Halberg et al. 2009).  These 
transgenic mice had significantly increased collagen deposition in SC WAT compared to 
control mice.  The levels of other extracellular matrix components such as collagens I, III and 
VI were also increased. Moreover, the adipose of the HIF1α-overexpressing mice was 
significantly more inflamed than that of the controls as evidenced by the presence of 
infiltrating macrophages.  A recent study also reported that partial pressure of oxygen was 
lower in the adipose of overweight/obese humans compared to lean subjects and low 
partial pressure of oxygen was correlated with increased expression of inflammatory 
cytokines such as CD68 and macrophage inflammatory protein 1α  (Pasarica et al. 2009).  
In my experiments, systemic VEGF neutralization was associated with both the 
above hypoxia-mediated pathological outcomes, fibrosis and inflammation.  Ad-sFlt1 
injected mice had increased fibrosis, detected by Masson’s trichrome staining of collagen 
fibers. This observation complements recent reports that adipose-specific overexpression of 
VEGF led to a reduction of fibrosis in adipose tissue of mice fed high fat diets (Sun et al. 
2012 ) and  is consistent with in vitro studies that demonstrated hypoxia induced expression 
of collagen I, fibronectin and TIMP1, in various mesenchymal cell lines.  Similarly, there was 
increased local inflammation, judged by the presence of F4/80 positive cells present in BAT 
99 
 
and attaching to the endothelium wall of ad-sFlt1 injected mice. This finding is in agreement 
with an earlier report from our group demonstrating that VEGF (or TGFβ) neutralization 
resulted in a significant increase in the number of leukocytes rolling along the mesenteric 
endothelium.  That study also showed elevated expression of surface adhesion molecules 
that mediated increased leukocyte adhesion, indicating an essential role for VEGF (and 
TGFβ) in maintaining the endothelium in a non-activated state (Walshe et al. 2009). The 
data here complement a recent report which showed that increased adipose expression of 
VEGF lessened inflammation associated with high fat died, measured by reduced expression 
of inflammatory cytokines such as TNFα and IL6 compared to control mice (Sun et al. 2012). 
Whether the inflammatory infiltrate is induced by adipocyte death or in response to 
chemokines secreted by BAT is unclear.   
Local hypoxia is one of the earliest characteristics of adipose tissue expansion and 
leads to a cascade of obesity-associated adipose tissue dysfunctions, such as fibrosis and 
inflammation. Inflammation is a key link between obesity and pathogenesis of type 2 
diabetes. In my experiments VEGF neutralization leads to fibrosis and inflammation in BAT, 
which resemble those observed in dysfunctional adipose tissue associated with obesity. 
These findings raise the possibility that reduced local VEGF expression and inadequate 
vascular remodeling may lie upstream of fibrosis and inflammation in adipose tissue. 
Systemic VEGF neutralization resulted in brown adipocyte apoptosis, indicating that 
VEGF is important for mature brown adipocyte survival in vivo. As brown adipocytes express 
both VEGF as well as its receptors, VEGFR1 and VEGFR2, this finding also suggests an 
autocrine role for VEGF in brown adipocytes in vivo.  This notion is supported by 
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observations in vitro. Cultured brown adipocytes, in which apoptosis was induced by 
treatment with TNFα and CHX, showed a higher level of cell death when VEGF signaling was 
blocked with DC101. This is physiologically relevant because circulating TNFα is significantly 
higher in obese animals, is known to induce apoptosis in brown adipocytes and my data 
suggest that the cytotoxic effects of TNFα may be aggravated in the absence of VEGF. 
Significantly more apoptosis was noted with systemic VEGF neutralization than in brown 
adipocytes treated with DC101 in vitro. These differences may be due to variation in 
duration of VEGF withdrawal, which was a few days in vivo compared to six hours in vitro. 
Additionally, as sFlt1 neutralizes the VEGF ligand, signaling through VEGFR2 and VEGFR1 are 
both blocked. Since both VEGFR2 and VEGFR1 are expressed in brown adipocytes, it is 
possible that there is compensatory VEGF signaling through VEGFR1. However, further 
experiments are needed to test this hypothesis. Further, sFlt1 also binds placental-derived 
growth factor and while there are no reports of placental growth factor expression in brown 
adipocytes, this possibility cannot be completely ruled out.  Yet another explanation is that 
increased apoptosis is a secondary effect of VEGF neutralization on brown adipocytes, in 
response to the capillary regression resulting from VEFG neutralization. However, given my 
results on cultured brown adipocyte it seems unlikely that the increased brown adipocyte 
apoptosis in vivo is entirely a secondary effect, but may explain the difference between the 
degrees of apoptosis observed in vitro compared to in vivo. VEGF has been demonstrated to 
be protective for other highly specialized cell types such as photoreceptors, the retinal 
pigmented epithelium,  Mϋller cells and podocytes .  
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Mitochondria are critical to brown adipocyte function, and a high density of 
mitochondria is a hallmark of functional brown adipocytes. The mitochondrial phenotype 
(or mitochondrioma), which is a measure of both mitochondria number and morphology, is 
a reliable indicator of the state of brown adipocyte activity. In active functional brown 
adipocytes, mitochondria are densely packed in the cytoplasm with transverse cristae 
spanning the entire length of the mitochondria (for a review see Cinti 2007). Active brown 
adipocytes are converted to an inactive state through degeneration of mitochondria, which 
are marked by partial or complete loss of cristae, and decrease in the number of 
mitochondria (Cigolini et al. 1986). Transdifferentiation of brown to white adipocytes is also 
accompanied by changes in the mitochondrioma. Systemic VEGF neutralization resulted in 
significant changes in the brown adipocyte mitochondrioma; there were fewer 
mitochondria in each cell compared to controls as well as histological evidence of massive 
mitochondrial degeneration, in the form of complete or partial loss of cristae and 
mitochondrial autophagy.  
Autophagy, a lysosomal degradative pathway that mediates the removal and 
breakdown of cellular components, is critical to the maintenance of cellular homeostasis 
and for supplying the cell with metabolic substrates in times of nutrient deprivation (Czaja 
2010). There are at least three distinct autophagic pathways: macroautophagy, 
microautophagy and chaperone-mediated autophagy. Macroautophagy is a multistep 
process through which portions of cytoplasm and/or organelles are sequestered in double 
or multi-membrane structures, known as an autophagosomes, and delivered to the 
lysosome for degradation. Fusion of the autophagosome with the lysosome, leads to the 
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formation of an autophagolysosome or autophagic vacuole. Although macroautophagy is 
generally considered a nonselective lysosomal process, there are instances in which 
organelles, such as mitochondria, appear to be preferentially sequestered, a process termed 
mitophagy (for a review see Kundu & Thompson 2005). Autophagy-related 7 (Atg7), which is 
critical for macroautophagy, is an ubiquitin E1-like enzyme that is involved in the formation 
of the autophagosome  (Ichimura et al. 2000; Kabeya et al. 2004; Wu et al. 2006) and in the 
conversion of LC3 form I to the autophagy specific form II (Kabeya et al. 2000).  
The profound changes in mitochondria along with the large lipid droplets seen in 
BAT from mice with systemic VEGF neutralization have at least two probable explanations. 
First, VEGF neutralization may result in transdifferentiation of brown adipocytes to white 
adipocytes, as seen in obesity. Two recent reports have demonstrated the effects of 
increased VEGF expression on WAT in mice engineered to overexpress VEGF specifically in 
adipose. Adipose specific VEGF expression resulted in WAT depots acquiring brown 
adipocyte-like properties, also known as “browning”, including elevated levels of UCP1 and 
PGC1α compared to control mice (Sun et al. 2012).  In addition, VEGF overexpression led to 
increased BAT mass and elevated UCP1 and PGC1α protein levels in BAT. An increase in 
body temperature in these mice compared to control mice was indicative of increased BAT 
activity (Elias et al. 2012). My results are consistent with these observations and suggest 
that the absence of VEGF leads to the opposite i.e. loss of brown adipocyte characteristics.  
Recent work has demonstrated that autophagy may play a role in adipocyte 
differentiation (Singh et al. 2009a).  Mice lacking the key macroautophagy regulator, Atg7, 
exhibited reduced white adipose and increased brown adipose. The reduced WAT depots 
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had morphologic and molecular features of brown adipocytes, including elevated levels of 
UCP1 and PGC1α. These findings indicated that the lack of autophagy favored the 
transdifferentiation of brown adipocytes from white adipocytes. While the mechanism of 
transdifferentiation remains to be determined, it has been hypothesized that autophagy, via 
the removal of the large numbers of mitochondria in brown adipocytes, may drive a critical 
remodeling function that mediates conversion of brown adipocytes to white adipocytes 
(Dong & Czaja 2011). My findings support this hypothesis as significant mitophagy is 
observed in brown adipocytes of ad-sFlt1 injected mice, along with fewer mitochondria and 
large lipid droplets, features atypical of brown adipocytes and suggestive of an early phase 
of brown to white transdifferentiation.  
A second explanation for the changes in mitochondria seen in BAT with VEGF 
neutralization may be that reduction in capillary density presumably results in a nutrient 
poor environment for brown adipocytes which can trigger mitophagy. Mitophagy enables 
energy conservation by reducing overall number of mitochondria, the major fuel consumers 
of the cell, and by recycling their components. Mitochondrial degeneration also reduces the 
number of functional mitochondria and lowers the overall fuel requirements of the cell. 
Without active mitochondria to utilize triglycerides as fuel, they are stored in large lipid 
droplets in the brown adipocyte as it transitions from an active to an inactive state. To test 
this hypothesis, metabolic activity, such as rate of triglyceride oxidation and mitochondrial 
function of brown adipocytes from sFlt1 and control mice must be compared. In addition, to 
determine if VEGF neutralization is associated with transdifferentiation of brown adipocytes 
to white adipocytes or whether the brown adipocytes simply become inactive, levels of 
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leptin, expression of which is much higher in white adipocytes than brown adipocytes, 
should be compared in the BAT of  sFlt1–expressing  and control mice. 
The role of brown adipose-derived VEGF is manifold and complex. VEGF promotes 
survival and proliferation signaling in brown adipocytes and acts on endothelial cells to 
stimulate angiogenesis as well as vascular cell survival. VEGF may have yet unidentified 
roles in brown adipocyte function that are key to normal BAT activity and the blockage of 
VEGF signaling could  contribute to the pathogenesis of metabolic disorders. Given that 
many therapies for diseases employ VEGF neutralization; these agents should be used with 
caution as long term use may lead to unexpected and undesired side effects.  
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Chapter 4                                      
ISOFORM-SPECIFIC ROLE OF VEGF IN BAT 
DEVELOPMENT 
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Introduction 
The VEGF gene is alternatively spliced and polycationic regions encoded by exons 6 
and 7 mediate binding to heparan sulfate proteoglycan, which determines their 
extracellular localization. The VEGF120 isoform, which does not include exons 6 and 7, does 
not bind heparan sulfate proteoglycans and is freely diffusible; VEGF188, which contains 
both exons 6 and 7, binds strongly to heparan sulfate and remains largely cell- and matrix-
associated; and, VEGF164, which includes only exon 7, displays intermediate properties. The 
pattern of VEGF isoform expression varies among tissues both during development and in 
the adult (Ng et al., 2001).  Mice expressing single VEGF isoforms, generated by deletion of 
splice sites or by replacement of genomic DNA (Carmeliet et al. 1999; Stalmans et al. 2002), 
demonstrated that the VEGF isoforms played distinct roles during development and in the 
adult both in vascular and non-vascular cells. Thus, I sought to investigate the distribution 
and role of the VEGF isoforms in adipose tissue. 
Results 
VEGF isoform expression in fat depots  
To characterize the profile of VEGF isoform expression in BAT and WAT, qPCR was 
performed using isoform-specific VEGF primers. Absolute quantification of VEGF isoforms in 
white and brown fat depots revealed that together VEGF164 and 188 comprised >99% of 
total VEGF whereas VEGF120 accounted for <0.5% of total VEGF in both BAT and SC. In  
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Figure 4.1. VEGF164 and 188 are the predominant isoforms in adipose 
tissue, which expresses very little VEGF120. The absolute amount of each 
isoform of VEGF was determined by quantitative PCR using isoform specific 
primers and serial dilutions of a known amount of standard. The total VEGF 
mRNA was the sum of the three isoforms. The percentage of each isoform 
was calculated based on the total VEGF thus obtained.  
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Figure 4.2. VEGF120 isoform specific mouse. This mouse was engineered by 
targeted deletion of exons 6 and 7 of the VEGF gene by homologous 
recombination in all cells, so that transcription of only VEGF120 is possible. 
These mice express the same total amount of VEGF, but only in the 120 isoform 
and present multiple vascular and organ specific abnormalities. (Carmeliet et 
al., 1999) 
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Figure 4.3. Brown adipose tissue in the wild type mouse embryo. BAT 
develops around E15 in the mouse. (A) Embryonic interscapular BAT depots at 
E15.5, visualized by Masson’s trichrome staining, are depicted (top panel). The 
right and left depots are visible (dotted black line) on either side of the 
notochord on the dorsal part of the embryo. Bottom panel: embryonic BAT at 
E16.5, visualized by H&E. The right and left sides are now closer, indicating 
rapid expansion of BAT mass. The appearance at this stage is very similar to 
interscapular BAT of neonatal mice. Scale bar represents 100 µm. (B) Higher 
magnification of interscapular BAT, visualized by H&E, at E15.5. They have 
densely packed cells with cuboidal morphology and tiny lipid droplets 
(arrowheads). Scale bar represents 50 µm. 
 
E15.5 
E16.5 
109 
110 
 
BAT, 45% of the VEGF was VEGF164 and 55% was VEGF188, whereas VEGF in SC was 84% 
VEGF164 and 16% VEGF188 (Figure 4.1).   
Abnormal BAT Morphology in VEGF 120/120 Embryo  
To investigate the role of more locally acting VEGF isoforms, 164 and 188, in adipose 
development, I examined adipose tissue in mice, which were genetically engineered to 
express only the 120 isoform (VEGF120/120), but at a level comparable to total VEGF in wild 
type mice (Figure 4.2). Since VEGF 120/120 mice die during late gestation and WAT forms 
only after birth, my analyses were confined to BAT, which develops in the interscapular 
region around E15.5.  The notochord and dorsal dermal layer separate the left and right 
interscapular BAT depots and there is rapid expansion of BAT mass such that by E16 there is 
significant amount of interscapular BAT (Figure 4.3). As E15.5 was the latest time point at 
which VEGF 120/120 mouse could be obtained, the structure of BAT from VEGF 120/120 
and wild type E15.5 littermates was examined using hematoxylin & eosin and Masson’s 
trichrome staining. There was a significant reduction in the volume of brown adipose tissue 
(dotted white line) in 120/120 embryos compared to their wild type littermates (Figure 
4.4A). Whereas brown adipocytes in wild type mice were arranged in compact clusters, 
brown adipocytes in VEGF 120/120 mice were disorganized and scattered in the 
interscapular region, with large gaps containing some collagen deposition separating much 
smaller clusters of adipocytes (Figure 4.4B). Typical of this stage in development, brown 
adipocytes in wild type mice were cuboidal in shaped and had tiny lipid droplets. In 
contrast, there was no apparent lipid accumulation in the adipocytes of VEGF 120/120 mice  
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Figure 4.4. Reduced BAT and abnormal BAT organization in embryo with only 
VEGF120 (A) Morphology of brown fat in wild type (left) and VEGF 120/120 
(right) embryos at E15.5 revealed by H&E staining shows reduced embryonic 
brown adipocytes in the interscapular depot of 120/120 embryo compared to 
wild type (B) Masson’s Trichrome (higher magnification) reveals disorganized 
tissue structure. Small clusters of embryonic brown adipocytes are surrounded 
by abundant extracellular matrix, with some collagen deposition (arrowhead). 
Scale bar represents 50 µm. 
 
111 
Cox IV = mitochondrial marker 
UCP1 = brown adipocyte marker 
Wild type 120/120 
120/120 Wild type 
Figure 4.5. Abnormal brown adipocyte differentiation and mitochondrial 
content of embryonic BAT with only VEGF120 (A) IHC localization of UCP1, a 
brown adipocyte  marker, showing robust expression in wild type but reduced 
and mosaic expression in 120/120 brown adipocytes. Dotted red lines indicate 
clusters of brown adipocyte cells in 120/120, in which most cells have a low 
expression compared to wild type, with a few cells depicting strong expression 
(blue arrowheads). (B) IHC localization of the mitochondrial marker Cox IV 
depicting strong expression in almost all wild type cells and low expression 
(white arrowheads) in most 120/120 cells, with very few depicting strong 
expression (red arrowheads) . Scale bar represents 50 µm. 
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Abnormal mitochondrial protein expression in VEGF 120/120 Embryo  
To gauge the functional integrity of the brown adipose, I examined the distribution 
of UCP1, which is essential for brown adipocyte thermogenesis, and Cox IV protein, a 
member of the electron transport chain and a well established mitochondrial marker. 
Brown adipocytes in wild type embryos stained strongly for both UCP1 and Cox IV whereas 
in VEGF 120/120 embryo there was  a significant decrease in number of cells expressing 
UCP1 (Figure 4.5A). Cox IV expression was also reduced in the VEGF120/120 brown 
adipocytes relative to that of wild type; in the VEGF120/120 mice there was a high level of 
Cox IV expression (Figure 4.5B red arrowheads) in a few cells and low-to-undetectable levels 
in other cells (white arrowheads). The relative absence of mitochondrial markers indicates 
that the putative brown adipocytes were not properly differentiated. There was no 
difference in apoptosis between the VEGF 120/120 and wild type brown adipocytes at E15.5 
(data not shown) nor was there any measurable difference in cell proliferation, which was 
visualized by IHC with Ki67 and phosphorylated histone H3 antibodies (data not shown).  
These observations suggest that the reduction in brown adipocytes at E15.5 is likely due to 
decreased cell survival or proliferation at an earlier point in development, possibly at the 
stage of adipocyte precursors or adipoblast.  
Discussion 
Nearly all of the VEGF in BAT and WAT depots are isoforms that bind heparan sulfate 
proteoglycans (VEGF164 and VEGF188).  The pattern of VEGF isoform distribution varies 
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widely among vascularized tissues.  For example, VEGF188 is the predominant VEGF isoform 
in the lungs whereas the retinal pigmented epithelium (RPE) expresses virtually no VEGF188 
(Saint-geniez et al. 2009). Based on the distribution of VEGF among a variety of tissues our 
laboratory has observed that the pattern of VEGF isoform expression in a tissue appears to 
be ‘consistent’ with the proximity between the VEGF source and its target(s). For instance, 
in the lung VEGF188 is produced by type II pneumocytes, which are separated from their 
target, the alveolar capillaries, by a very thin basement membrane (Galambos et al., 2003) 
and the lungs of mice lacking the heparan sulfate-binding forms of VEGF (i.e. expressing 
only VEGF 120) reveal extensive microvascular and pulmonary defects.  In the eye, on the 
other hand, the RPE produces VEGF120 and VEGF164, but virtually no VEGF188, presumably 
reflecting the fact that VEGF produced by the RPE must diffuse across, Bruch’s membrane, 
an elastic lamina, to reach the choriocapillaris. Accordingly, mice that express only VEGF188 
display age-dependent degenerative changes in the RPE-choroid complex (Saint-Geniez et 
al. 2009). Similarly, in the brain the choroid plexus epithelium produces predominantly 
VEGF120, which supports not only the underlying fenestrated microvasculature but diffuses 
into the cerebrospinal fluid to act on the VEGFR2-expressing ependymal cells of the 
ventricular lining (Maharaj et al. 2008).  Thus, the predominance of VEGF188 and VEGF164 
in BAT suggests that VEGF plays both an autocrine role to support the integrity and survival 
of brown adipocytes and a paracrine function to promote angiogenesis during development 
and then vascular maintenance in the adult.  
VEGF 120/120 mice express VEGF at the same level as total VEGF in wild type mice 
(Carmeliet  et al. 1999) and die in late gestation due to defects in pulmonary and cardiac 
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angiogenesis. Mice expressing only VEGF120 exhibited defective ocular development 
including microphthalmia, abnormal lens differentiation and hyperplastic hyaloid vessels 
(Saint-Geniez et al. 2009). The diminished volume of BAT and the abnormal organization of 
the brown adipocytes that do develop in 120/120 embryos could be due to a direct effect 
on brown adipocytes or be secondary to defective angiogenesis.  Observations that VEGF 
120/120 mice exhibit abnormal vascularization and angiogenesis in multiple organs such as 
lungs, heart and cartilage (Zelzer et al. 2002) favor the latter hypothesis, particularly 
because angiogenesis precedes adipogenesis in the development of adipose depots 
(Hausman & Richardson 2004). On the other hand, the mitochondrial abnormality detected 
in the 120/120 adipocytes, coupled with my observations of mitochondrial degeneration in 
mature brown adipocytes of mice with systemic VEGF neutralization, suggest that there 
may also be a direct effect of VEGF on embryonic brown adipocytes. The resulting 
phenotype may well be an outcome of a possible direct effect of VEGF on adipocytes as well 
as an indirect effect through abnormal angiogenesis and further analyses of BAT 
development at different time points in 120/120 embryos is needed to better analyze the 
phenomenon.  
Based on my observations that VEGF promotes adipocyte survival it was surprising 
that no apoptosis was detected in the 120/120 embryos at the stage examined. However, 
my finding that VEGF is a mitogen for preadipocytes points to the possibility of reduced 
proliferation and/or survival of brown adipocyte precursors which led to a diminished 
population of adipocyte precursors available to differentiate to. A recent report 
investigating forebrain development reported reduced proliferation of neural precursors in 
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VEGF 120/120 mice and suggested a role for the heparan sulfate binding VEGF isoforms in 
maintenance of the neural precursor population (Darland et al. 2011). In order to test this 
hypothesis, a reliable marker unique to brown adipocyte precursors would be required to 
examine embryos at earlier stages of development. While the existence of such markers is 
not widely reported, there is some evidence to suggest that engrailed1 and c-myc are 
expressed in precursor cells in the interscapular BAT depot.   
My results, along with other reports on phenotypes of mice expressing single VEGF 
isoforms, emphasize the fact that the various VEGF isoforms serve different yet overlapping 
roles. Whereas mice lacking only one allele of VEGF die at E8.5, mice expressing only 
VEGF120 survive until late gestation, indicating that VEGF120 can at least partially 
compensate for the functions of the other isoforms. On the other hand, the specific 
abnormalities exhibited by mice expressing only one VEGF isoform underscore the distinct 
functions of each isoform in individual tissue and cellular contexts.  
  
117 
 
 
 
 
 
Chapter 5                                 
REGULATION OF VEGF EXPRESSION IN 
BROWN ADIPOCYTES 
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Introduction 
In light of my observations that VEGF expression increases concomitantly with 
adipocyte differentiation and VEGF plays a significant role in brown adipocytes, it appears 
likely that VEGF expression and brown adipocyte differentiation are coordinately controlled 
by the same molecular regulators. The transcription factor PPARγ, the master regulator of 
adipogenesis, and its transcriptional cofactor PGC1α are crucial in brown adipocyte 
differentiation and function. I therefore hypothesized that VEGF expression is regulated by 
PPARγ and PGC1α in brown adipocytes.  
Results 
PPARγ agonists increase VEGF expression in brown adipocytes in vitro 
PPARγ expression during brown adipocyte differentiation was examined by qRT-PCR 
(Figure 5.1). By day three of differentiation PPARγ expression was increased nearly 10-fold 
compared to undifferentiated cells, and remained high during the eight day course of 
differentiation. The increased VEGF expression (Figure 2.7) followed the pattern of PPARγ 
expression.  The levels  of hypoxia inducible factor (HIF)1α, a known regulator of VEGF, were 
observed to decrease over the course of differentiation (Figure 5.1) as did the expression 
estrogen related receptor (ERR)α, another recently described regulator of VEGF in skeletal 
muscle (data not shown). To test my hypothesis, differentiated brown adipocytes were 
treated with the PPARγ agonist troglitazone and RNA was collected from samples at various 
119 
 
time points following treatment. Analysis of VEGF mRNA expression revealed a 1.5-fold 
increase in the expression of VEGF within six hours of treatment and a nearly two-fold 
increase after twelve hours of treatment compared to untreated cells; the increase was 
sustained through 24 hours post TZD treatment (Figure 5.2). Expression of aP2, which is a 
known target of PPARγ and was used as a positive control, also increased compared to 
untreated cells, reaching a nearly six-fold increase following 24 hours of TZD treatment.  
VEGF expression in BAT is reduced in the absence of PGC1α  
PGC1α is crucial for BAT thermogenesis and has  been shown to induce VEGF 
expression in skeletal muscle following exercise through the ERRα transcription factor 
(Chinsomboon et al. 2009). Moreover, the pattern of VEGF expression in BAT with CL 
316,243 stimulation temporally mirrored that of PGC1α (Figure 2.8). Thus, to investigate 
whether PGC1α can alter VEGF expression in BAT I examined VEGF mRNA levels in the BAT 
of PGC1α knockout mice. VEGF RNA was significantly reduced in the BAT of adult male 
PGC1α null mouse, with an average VEGF expression of 40% of that in wild type (Figure 5.3). 
Preliminary observations of heterozygous mice showed that VEGF expression was 70% that 
of wild type mice, suggesting a dose dependent regulation of VEGF by PGC1α.  
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Figure 5.1. Transcription factor expression during brown adipocyte 
differentiation. PPARү expression increases during brown adipocyte 
differentiation while HIF1α expression decreases, determined by qPCR. 
p*<0.05, p**<0.01. 
* 
120 
Figure 5.2. Induction of VEGF in brown adipocytes following treatment of 
PPARү agonist troglitazone. Brown adipocytes on day eight of differentiation 
were treated with 1µM troglitazone (TRO) and expression of VEGF measured at 
various time points using qPCR. VEGF expression is induced within six hours of 
treatment and sustained upto 24 hours. aP2 expression is used as a control for 
PPARү transcription activity as a known transcriptional target of PPARү. 
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Figure 5.3. Reduced VEGF expression in BAT of PGC1α knockout mice. VEGF 
expression (right) in the BAT of adult male mice lacking one or both alleles of 
PGC1α examined by qPCR, indicated dose dependant decrease in levels of 
VEGF in the absence of PGC1α (left). p**<0.01, p***<0.001. 
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Discussion 
Diverse VEGF expression is regulated by hormonal and developmental signals. The 
transcription factor HIF1α is a major mediator of hypoxia-induced gene expression changes 
and has been shown to regulate VEGF expression. In fact, hypoxic regulation of VEGF 
expression via HIF1α is the best characterized mechanism of VEGF control, including during 
vascularization of some tissues such as retina (Ferrara et al. 2003). However, this 
mechanism was not likely to play a role in the observed VEGF expression that accompanied 
in vitro brown adipocyte differentiation as the cells in culture are not hypoxic.  Interestingly, 
in spite of the intense focus on the role of HIF1α in the regulation of VEGF,  deletion of the 
hypoxia-response element in the VEGF promoter resulted in a viable mice with only minor 
phenotypes whereas VEGF -/-  and +/-  mice are embryonic lethal.  The dispensable nature 
of HIF1α-mediated VEGF transcription suggests that HIF1 is much less important in the 
regulation of VEGF than previously suspected.  My data suggest PPARγ/PGC1α-mediated 
regulation of VEGF transcription in adipocytes. VEGF expression was increased after 
treatment of differentiated brown adipocytes with TZD and was significantly reduced in the 
BAT of mice lacking PGC1α.  
Several studies have reported the PPARγ-activation mediated regulation of VEGF. In 
vascular smooth muscle cells and murine macrophages both endogenous and synthetic 
PPARγ agonists increase VEGF expression by 1.5- to 2-fold and 2.5- to 3-fold, respectively, 
through transcriptional activation of the VEGF promoter  (Jozkowicz et al. 2000). 
Furthermore, oxidized low density lipoproteins increase VEGF expression through PPARγ 
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activation in a number of human monocyte/macrophage cell lines and in human coronary 
artery endothelial cells (Inoue et al. 2001). On the other hand, both endogenous and 
synthetic PPARγ agonists have been demonstrated to repress VEGF expression in human 
endometrial cells also through its activity on the VEGF promoter (Peeters et al. 2005). 
Rosiglitazone has been shown to repress VEGF expression by 40 – 55% in tumor cell lines 
derived from lung carcinoma and glioblastoma (Panigrahy et al. 2002). Thus, it appears that 
the effect of PPARγ activation on VEGF expression is dependent on the cell type and tissue 
context.  
Work by our group has previously demonstrated that VEGF expression increases 
during myocyte differentiation in vitro and that this increase is regulated by the 
transcription factor MyoD, a key myogenic differentiation factor, which associates with the 
VEGF promoter (Bryan et al. 2008).  It has also been shown that VEGF expression in skeletal 
muscle induced by intense exercise does not involve the canonical hypoxia response 
pathway and HIF1α. Rather, it is mediated by PGC1α through the transcription factor ERRα 
binding to conserved binding sites in the promoter and first intron of the VEGF gene to 
activate VEGF transcription (Chinsomboon et al. 2009). PGC1α increases during brown 
adipocyte differentiation as well as following adrenergic stimulation, and is a key effector of 
the thermogenic response in brown adipocytes (Puigserver 2003; Kajimura et al. 2010). 
VEGF expression in brown adipocytes has also been demonstrated to be independent of 
hypoxia during cold acclimation, and regulated via a β3 adrenoreceptor/cAMP/PKA pathway 
(Fredriksson et al. 2000; Fredriksson et al. 2005; Xue et al. 2009).   
125 
 
Thus, we hypothesized that PGC1α would also regulate VEGF expression in normal 
brown adipocytes and during cold acclimation. Our preliminary results indicating a dose-
dependent association between VEGF expression and PGC1α levels in vivo are consistent 
with this hypothesis. A recent report showing that PGC1α and -β mediate VEGF expression 
in brown adipocytes during hypoxic conditions provides further evidence in support of PGC1 
mediated regulation of VEGF (Pino et al. 2012). While PGC1α is required for VEGF 
expression in BAT, as a cofactor it requires a transcription partner to alter gene expression. 
Based on my preliminary data, I propose a model in which PGC1α and PPARγ regulate VEGF 
expression in brown adipocytes.  
 Future studies will examine whether the absence of PPARγ activation affects VEGF 
expression in brown adipocytes and if VEGF expression is altered by endogenous PPARγ 
activators. Moreover, it would also be of interest to determine whether VEGF increase 
observed during adrenergic stimulation, while independent of hypoxia and HIF1α, is 
regulated by PPARγ.  Since PPARγ agonists are used in the treatment of type 2 diabetes, 
their effects on the expression of VEGF is clinically relevant.  
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Chapter 6 
GENERAL DISCUSSION  
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Discussion 
While several studies have reported the production of VEGF in BAT and brown 
adipocytes and have demonstrated the role of VEGF in adipose tissue angiogenesis, the 
function of VEGF on brown adipocytes themselves has not been explored. A few recent 
studies have provided interesting hints, such as the increased BAT function and “browning “ 
of WAT observed in mice expressing adipose specific transgenic VEGF, to suggest that VEGF 
may play a direct role in brown adipocytes ( Sun et al. 2012; Elias et al. 2012).   
My examination of white and brown fat depots revealed high levels of VEGF 
isoforms and their receptors VEGFR1 and VEGFR2 in most depots with BAT having a higher 
expression of both VEGF and receptors when compared to WAT.  In addition, VEGF 
expression was coordinately regulated with brown adipocyte differentiation as evidenced 
by the concomitant increase in the expression of PPARγ, PGC1α, UCP1 and the adrenergic 
receptor type β3 with VEGF.  Differentiated, but not precursor, brown preadipocytes 
expressed PGC1α and UCP1, the hallmark genes of brown adipocytes, and responded to 
norepinephrine stimulation by increased mitochondrial biogenesis and UCP1 expression. 
The expression of VEGFR2 in undifferentiated preadipocytes and differentiated brown 
adipocytes was a surprising and novel finding. VEGFR2 was phosphorylated in unstimulated 
cultured brown preadipocytes and adipocytes indicating active VEGF signaling in these cell 
types. VEGF expression also appeared to be coordinately regulated with WAT 
differentiation where the increase in VEGF during 3T3L1 differentiation was temporally 
correlated with the expression of PPARγ and with the expression of aP2, a known adipocyte 
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marker.  In contrast to differentiated brown adipocytes, VEGFR2 was not expressed in white 
adipocytes, a finding that is consistent with a previous report (Fukumura et al., 2003). 
My finding of VEGFR2 phosphorylation in cultured brown preadipocytes and 
differentiated adipocytes supports the hypothesis of autocrine or juxtacrine VEGF signaling. 
In support of this notion, the addition of VEGF induced preadipocyte proliferation in vitro 
and VEGF was a survival factor for both preadipocytes and mature adipocytes in vitro. These 
results were corroborated in vivo; systemic neutralization of VEGF resulted in apoptosis of 
brown adipocytes as early as seven days post injection and was associated with 
inflammation and fibrosis, presumably the result of the significant cell death and hypoxia.  
Examination of the ultrastructure of BAT from sFlt1-expressing mice revealed 
abnormal mitochondria with partial or complete loss of cristae, a phenotype that is 
commonly associated with reduced mitochondrial activity and degeneration (Cinti 2007; 
Cigolini et al. 1986). Adipocytes in mice with systemic VEGF neutralization also displayed 
macroautophagy of mitochondria (mitophagy), a phenomenon completely absent in control 
BAT, along with an increase in autophagosomes, judged by the presence of LC3B form II 
puncta. The mitochondrial autophagy in brown adipocytes seen with VEGF neutralization 
was intriguing as it has been proposed that mitophagy regulates brown-white 
transdifferentiation of adipocytes and negatively correlates with brown adipocyte fate 
(Singh et al. 2009b). Inhibition of mitophagy by deletion of the critical autophagy regulator 
Atg7 decreased WAT mass, increased “browning” of white adipocytes, including brown 
specific gene expression, reduced lipid storage, and increased BAT mass (Singh et al. 2009b). 
The BAT from mice expressing sFlt1 exhibited large fusing lipid droplets, a characteristic 
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more typical of white adipocytes, and a trend towards higher triglyceride content was also 
observed even though the BAT mass itself was reduced in sFlt1-expressing mice compared 
to controls.  Our findings complement this report as increased mitophagy is associated with 
loss of brown adipocyte characteristics and features indicative of early stage of brown to 
white transdifferentiation. Another likely explanation is that systemic VEGF neutralization 
results in dysfunctional or inactive brown adipocytes in which the mitochondria are not 
employed in fatty acid oxidation, and thus targeted for autophagy to maintain cellular 
homeostasis and conserve cellular resources. Consistent with our observation of decreased 
brown adipose features, it has recently been demonstrated that adipose tissue-specific 
VEGF expression results in “browning” of white adipose tissue, increased BAT mass and 
function, and protection against high fat diet and insulin resistance (Elias et al. 2012; Sun et 
al. 2012).  
The pattern of VEGF isoform expression varies among tissues both during 
development and in the adult (Ng et al., 2001). Examination of VEGF isoform expression in 
BAT revealed that VEGF188 and VEGF164 each comprised approximately 50% of total VEGF 
with VEGF120 accounting for less than 1%. The splice variants of VEGF have different 
binding affinities to heparan sulfate: VEGF120 lacks heparan sulfate binding sites and is 
freely diffusible, whereas VEGF188 binds strongly to heparan sulfate. VEGF188 largely 
remains matrix- and cell- associated and is thought to act locally whereas VEGF164 has 
intermediate properties. Our laboratory has found that the pattern of VEGF isoform 
expression in various tissues reflects the proximity between the VEGF source and its 
target(s). The predominance of heparan sulfate-binding VEGF isoforms in BAT is consistent 
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with my findings that VEGF functions in brown adipocytes in an autocrine or juxtacrine 
manner. To investigate the role of VEGF188 and VEGF164 in development of BAT, I used 
mice that were engineered to express only VEGF120 (Carmeliet et al. 1999). The absence of 
VEGF188 and 164 led to significant morphological abnormalities in the embryonic brown 
adipocytes, including disorganization and a marked reduction in number relative to 
embryonic wild type brown adipocytes. There was no detectable difference in adipocyte 
proliferation or apoptosis at the time point examined.  Based on my in vitro observations 
that VEGF is a mitogen for preadipocytes, I speculate that the BAT anomalies seen in VEGF 
120/120 mice may be the result of decreased survival or proliferation of brown 
preadipocytes.  
UCP1 expression was markedly reduced in the brown adipocytes of VEGF 120/120 
mice, with most cells displaying little or no expression, a phenotype indicative of incomplete 
differentiation. Mitochondrial content was also significantly reduced, indicating impaired 
mitochondrial biogenesis. This finding in VEGF 120/120 mice was consistent with my 
observation that systemic VEGF neutralization resulted in massive mitochondrial 
degeneration and reduced mitochondrial number and may point to a novel role for VEGF in 
the regulation of adipocyte metabolism.  VEGF has been shown to regulate a variety of 
functions in other cell types. For instance, in murine podocytes VEGF is involved in 
homeostasis of slit diaphragm proteins such as podocin and CD2AP that are required for the 
function of the glomerular filtration barrier (Guan et al. 2006). VEGF promotes myotube 
hypertrophy in vitro and neutralization of VEFG leads to myotube hypotrophy (Bryan et al. 
2008) and  increases bone mineralization during osteogenic differentiation (Mayer et al. 
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2005). Culture of RPE cells with VEGF neutralization results in blunted and reduced 
microvilli, structures which facilitate the critical interaction between RPE and photoreceptor 
outer segments (Ford et al. 2011). Alternatively or additionally, the observed mitochondrial 
degeneration may be an indirect effect resulting from an overall nutrient poor environment 
due to capillary dropout after systemic VEGF neutralization.  
We previously demonstrated that the expression of VEGF is coordinately regulated 
as part of the myogenic differentiation program where it serves not only to induce 
angiogenesis but in an autocrine function in differentiating myocytes. MyoD, the 
transcription factor critical for myogenic differentiation regulated VEGF transcription in 
C2C12 myocytes in vitro (Bryan et al. 2008). Here we show that VEGF expression is 
coordinately increased during normal brown adipocyte differentiation and that its 
expression in brown adipocytes is positively regulated by PPARγ agonists in vitro and PGC1α 
in vivo, both critical for brown adipocyte differentiation and function.  Based on my 
preliminary data I propose a model in which PGC1α mediates VEGF expression in brown 
adipocytes with the transcription factor PPARγ in tandem with the process of brown 
adipocyte differentiation and during cold acclimation.  
The formation of a vasculature is essential for proper organ development and 
function and is tightly regulated by various pro- and anti-angiogenic factors. The resulting 
vascular network is specialized with features, such as fenestrations or tight junctions, to 
meet the needs of the organ it supplies. As for virtually all other tissues, adipogenesis and 
angiogenesis are spatially and temporally coupled (Crandall et al. 1997). In the adult, 
adipose tissue is one of the most plastic organs. Cold acclimation is marked by profound 
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hyperplasia in BAT of preadipocytes and endothelial cells (Bukowiecki et al. 1982). The mass 
of WAT varies greatly with body weight and expanding adult WAT is characterized by 
endothelial cell proliferation (Crandall et al. 1997). It is well known that VEGF is critical for 
adipose tissue angiogenesis. Administration of neutralizing antisera against VEGFR2 to 
obese mice led to significantly lower body weights and improved metabolic function (Sun et 
al. 2012). On the other hand, increased expression of VEGF in adipose tissue improved 
insulin sensitivity and metabolic profile during the early stages of high fat diet-induced 
weight gain, as well as inducing browning of WAT depots and increased BAT mass (Sun et al. 
2012; Elias et al. 2012). This underscores the pivotal role of VEGF in adipose angiogenesis. 
Our work has identified an additional function of VEGF in BAT, its direct beneficial effects on 
brown adipocytes to promote their survival, proliferation and maintenance of brown 
adipocyte mitochondrioma. 
Our work and that of others have demonstrated that VEGF acts in an autocrine 
manner on non-endothelial cell types of multiple adult tissues. In addition to those 
described earlier in this chapter, VEGF promotes survival of Muller cells of the adult retina 
(Saint-Geniez et al. 2008), induces neuronal differentiation of astroglial cells of the adult 
brain (Li et al. 2012), functions in the maintenance of the ependymal cells of the of the 
choroid plexus overlying fenestrated vessels (Maharaj et al. 2008), promotes the survival 
and maintenance of RPE (Ford et al. 2011), increases survival and slit diaphragm protein 
homeostasis in podocytes (Guan et al 2006) and promotes osteoblast differentiation over 
adipocyte differentiation in mesenchymal stem cells through an intracrine signaling 
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pathway involving VEGF receptors (Liu et al. 2012). Our findings add to the growing list of 
pleiotropic effects of VEGF.  
Future studies on the role and regulation of VEGF in brown adipose are likely to 
reveal valuable insights on the scope of its role in brown adipocytes. For instance, it would 
be interesting to study the effect of blockage of VEGF signaling in vivo in brown adipocytes 
only, which can be achieved by adipocyte specific VEGFR2 knockout as it would not affect 
the action of adipocyte-secreted VEGF on the neighboring endothelium. The role of VEGF 
on brown adipocytes during BAT acclimation to cold or hyperphagia would also be relevant, 
in particular because activating BAT is a major goal in combating obesity.   
Closing Thoughts 
I have demonstrated that VEGF and its primary receptor VEGFR2 are expressed in 
brown adipocytes. VEGF signaling plays a significant role in brown adipose function and 
maintenance through its effects on both brown preadipocytes and mature brown 
adipocytes. VEGF functions as a mitogen and a survival factor on preadipocytes rescuing 
them from apoptosis induced by growth factor withdrawal. Further, VEGF has anti-
apoptotic effects on mature brown adipocytes in vivo and in vitro and plays a role in 
maintenance of brown adipocyte mitochondrioma in vivo, in addition to its paracrine role to 
promote angiogenesis in BAT. VEGF has an isoform specific role in BAT development and 
brown adipocyte mitochondrial biogenesis.  VEGF is regulated by both the critical adipose 
transcription factor PPARγ and the transcriptional cofactor, PGC1α. Taken together my 
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findings identify novel functions of the endothelial growth factor VEGF in the context of 
brown adipocytes that are significant from a translational standpoint because brown fat 
activation and angiogenic intervention are each promising therapeutic targets for obesity 
and associated metabolic dysfunction.  
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Chapter 7                                    
MATERIALS AND METHODS   
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Materials 
Antibodies  
Antibodies used for Western blotting included: anti-phospho-Y951-VEGFR2 (1:300; 
#4991), VEGFR2 (1:1000, #2479), cleaved caspase 3 (1:1000, #9661), whole caspase 3 
(1:1000, #9662), phospho-S473-Akt (1:250, #9271), pan-Akt (1:1000, #9272) purchased 
from Cell Signaling Technologies (Danvers, MA, USA). Antiserum against β-tubulin (1:500, 
ab6046 ) was purchased from Abcam (Cambridge, MA, USA). Anti-endomucin (1:1000, sc-
65495) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Secondary 
antibodies used included horseradish peroxidase (HRP)-conjugated anti-rabbit 
immunoglobulin G (IgG) from donkey (1:7500; GE Healthcare, Buckinghamshire, UK). 
Antibodies used for immunohistochemistry to UCP1 (1:500; ab10983), cox IV (1:1000; 
ab16056), F4/80 (1:100; ab6640) were purchased from Abcam, LC3B (1:200, # 2775) and 
cleaved caspase 3 (1:100) from Cell Signaling Technology and perilipin (1:200; P1873) from 
Sigma-Aldrich (St. Louis, MO, USA). Secondary antibodies for immunohistochemistry were 
biotinylated anti-rat IgG (1:400) and anti-rabbit IgG (1:500), both raised in goat (Vector 
Laboratories, Burlingame, CA, USA) and for immunofluorescence  were Alexa Fluor-488 
conjugated anti-rat and Dylight 549-conjugated anti-rabbit IgG (1:300, Invitrogen). 
Methods 
Animal models 
 C57Bl/6J wild type and VEGF 120/120 mice were used. For ad-sFlt1 and CL 316,243 
studies, eight-week old male C57Bl/6J mice were purchased from Jackson Laboratories (Bar 
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Harbor, ME, USA).  VEGF 120/120 mice were generated by targeted deletion of exon 6 and 7 
of the VEGF gene, which encode the 164 and 188 isoforms, as previously described 
(Carmeliet et al., 1999). VEGF 120/120 embryos were generated by breeding C57Bl/6J VEGF 
120/+.  The ages of the embryos were calculated based on plug date, which was defined as 
E0. Timed-pregnant females were euthanized at E15.5. PGC1α -/- mice were generated by 
breeding PGC1α +/- mice on a C57Bl/6J background. All mice were maintained on a regular 
chow diet and kept on a 12-hour light-dark cycle. Adult mice were euthanized by carbon 
dioxide inhalation; embryos older than E13.5 were euthanized by decapitation.  All 
protocols for animal use were reviewed and approved by the Schepens Eye Research 
Institutional Animal Care and Use Committee in accordance with the National Institutes of 
Health guidelines.  
3T3L1 culture and differentiation  
3T3L1 cells were maintained as subconfluent cultures in Dulbecco’s modified Eagle’s 
medium (DMEM containing 4.5g/L of glucose, L-glutamine and sodium pyruvate (Cellgro; 
Manassas, VA, USA) supplemented with 10% FBS (Atlanta Biologicals; Lawrenceville, GA, 
USA), 100U/ml penicillin and 100µg/ml streptomycin (Lonza; Basel, Switzerland) (hereafter 
referred to as growth medium).  To induce differentiation, cells were cultured for 48 hours 
beyond confluence in the growth medium described above. On day 0, the medium was then 
replaced with adipose differentiation medium, which comprised growth media 
supplemented with 10µg/ml insulin, 1µM dexamethasone and 0.5mM 
isobutylmethylxanthine (IBMX), all from Sigma-Aldrich. After 48 hours, the differentiation 
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medium was replaced with adipose maintenance medium, which is growth medium 
supplemented with 5µg/ml insulin. Cells were maintained in the maintenance medium until 
fully differentiated (10-12 days) and medium was replaced every other day (Figure 2.2).  
Brown preadipocyte culture and differentiation  
Brown preadipocytes were generously provided by Dr. C. R. Kahn (Joslin Diabetes 
Center) and were maintained as subconfluent cultures in the growth media described 
above. To induce differentiation, cells were cultured to confluence and allowed to grow in 
the above growth media for an additional forty-eight hours. Growth medium was then 
replaced with fresh brown adipose differentiation medium (day 0) consisting of growth 
media with 20nM insulin, 1µM dexamethasone, 0.5 mM IBMX, 1nM triiodothyronine (T3; 
Sigma) and 0.125mM indomethacin (Sigma). After forty-eight hours, the differentiation 
medium was replaced with adipose maintenance medium made by supplementing DMEM 
growth media with 1nM T3 and 20nM insulin. Cells were maintained in the maintenance 
medium until fully differentiated (usually eight days) and medium was replaced every other 
day (Figure 14).  In the studies using norepinephrine, fully differentiated brown adipocytes ( 
day eight) were incubated in serum-free medium for three hours, followed by treatment 
with 10µM norepinephrine for 1 hour.  For treatment with PPARγ agonists, fully 
differentiated cells (day eight) were treated with 1µM troglitazone (Sigma) in regular 
growth medium for 6, 12, 24 and 48 hours.  
RNA isolation, cDNA synthesis  
139 
 
Total RNA was isolated from adipocytes using RNA Aqueous 4PCR Kit (Life 
Technologies, formerly Ambion; Grand Islands, NY, USA), following the manufacturer’s 
instructions. RNA concentration and integrity were determined using the Nanodrop 2000 
(Thermo Fisher Scientific, Waltham, MA, USA). RNA was treated with DNase to remove 
contaminating DNA as follows: 8-10µg of RNA was treated with 50U of DNase (Life 
Technologies) in a total volume of 50µl of 1x DNase Digestion Buffer for 30 min at 37°C. 
DNase Inactivation Agent was added, followed by incubation at room temperature for 2-3 
min and centrifugation at 10,000 x g for 1.5 min. The resulting DNA-free RNA supernatant 
was used subsequently for reverse transcription (RT) and cDNA synthesis.  RT was 
performed on 1µg RNA using SuperScript III (Life Technologies, formerly Invitrogen) as per 
the manufacturer’s instructions. Briefly, RNA was incubated with random hexamers, 
oligo(dT)12 – 18 and deoxyribonucleotide triphosphates (DNTP) in an aqueous base for 5 min 
at 65°C , and 1 min on ice followed by addition of the first-strand buffer and remaining 
reagents. Then final reaction mixture (20µl) contained 1µg RNA, 50ng of random hexamers, 
200ng of oligo(dT)12 – 18 and 10nmoles of deoxyribonucleotide triphosphates (DNTP), 200U 
SuperScript III, 40U RNaseOUT  and 5µM DTT (all from Life Technologies) in 1x first-strand 
buffer. The cDNA synthesis reaction was as follows: 5 min at 25°C, 45 min at 50°C followed 
by enzyme inactivation at 70°C for 15 min. cDNA generated from this reaction was diluted 
1:25 with nuclease-free water.  
Real time PCR  
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For gene expression analysis, 5µl of the cDNA (10ng of equivalent RNA) was 
amplified in each PCR amplification reaction using 500nM forward and reverse primers and 
SYBR Green Master mix (Roche Diagnostics, Indianapolis, IN, USA), according to the 
manufacturer’s instructions. Primer sequences used are listed in Table 3. Reactions were 
performed on the Roche LightCycler® 480 II. PCR cycles consisted of an initial denaturation 
step at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, 60°C for 30 sec and 72°C 
for 1 min. Each sample was subjected to melting curve analysis to confirm amplification 
specificity. Samples were run in triplicate and included three water controls for each gene 
analyzed. Samples were normalized to TATA box binding protein (TBP) and expressed as 
relative fold change using the ∆∆Ct method of relative quantification. 
For absolute quantification of VEGF isoforms a standard curve was constructed for 
each of the three isoforms by amplifying serial dilutions (103 - 109ng DNA/reaction) of a 
plasmid coding for a single isoform using primers specific for each isoform. The level of 
individual isoforms in each experimental sample was calculated relative to the standard 
curve. Each sample and dilution was run in triplicate, as described above. Results were 
expressed as the mean + SEM.   
Semi-quantitative PCR analysis 
Total mRNA and cDNA were prepared as described above. One microliter of cDNA 
was used as a template in a 25μl amplification mixture containing 200mM dNTPs, 1U Taq 
DNA polymerase (Roche Diagnostics) and 0.2μM of the primer pairs indicated in Table 4. 
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Samples were amplified for 35 cycles, and amplification products were separated by 
agarose gel electrophoresis, stained with ethidium bromide, and visualized by UV light.   
Administration of β3 agonist CL 316,243  
Adult male C57Bl/6J mice were injected intraperitoneally with ~100 – 120µL CL 
316,243 or saline (control) at a final dose of 1 mg/kg body weight, which is the most 
commonly used dose for CL 316,243-mediated adrenergic stimulation in mice in vivo, from a 
0.25mg/ml stock solution. Five mice were used for each time point. Mice were euthanized 
and tissue was harvested two, six and 24-hours post injection. Tissue for RNA isolation was 
directly placed in TRIzol® (Life Technologies) and stored in -80   C. 
Proliferation assay 
Cells were plated at a density of 10,000 cells per well of a 24-well plate in regular 
growth media and allowed to attach overnight. Growth medium was removed and cells 
were washed once with serum free DMEM and re-fed with DMEM containing 1% FBS with 
or without 10ng/ml VEGF. Cells were counted at 24 hour intervals for five consecutive days 
using a Coulter Counter (Beckman Coulter, Brea, CA, USA).  Each time point was set up in 
triplicate. 
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Table 3 – Primers for qPCR mouse genes 
Target gene Forward Primer Reverse Primer 
aP2 (FABP4) ATGAAATCACCGCAGACGACAGGA TGTGGTCGACTTTCCATCCCACTT 
PGC1α AGCCGTGACCACTGACAACGAG GCTGCATGGTTCTGAGTGCTAAG 
PPARγ GACATCCAAGACAACCTGCTG GCAATCAATAGAAGGAACACG 
VEGF GCACATAGAGAGAATGAGCTTCC CTCCGCTCTGAACAAGGCT 
VEGF  188 GCCAGCACATAGAGAGAATGAGC AACAAGGCTCACAGTGAACGCT 
VEGF 164 GCCAGCACATAGAGAGAATGAGC CAAGGCTCACAGTGATTTTCTGG 
VEGF 120 GCCAGCACATAGAGAGAATGAGC CGGCTTGTCACATTTTTCTGG 
TBP ACCCTTCACCAATGACTCCTATG TGACTGCAGCAAATCGCTTGG 
UCP1 GGCATTCAGAGGCAAATCAGCT CAATGAACACTGCCACACCTC 
 
Table 4 – Primers for RT-PCR for mouse genes 
Target gene Forward Primer Reverse Primer Amplicon Size 
aP2 CTGGAAGACAGCTCCTCCTCGAAG TAATCAACATAACCATATCCAAT 585 
GAPDH GTGGCAAAGTGGAGATTGTTGCC GATGATGACCCGTTTGGCTCC 291 
Nrp1 TCAGGACCATACAGGAGATGG TGACATCCCATTGTGCCAAC 619 
UCP1 TATCATCACCTTCCCGCTG GTCATATGTTACCAGCTCTG 505 
VEGF CCTCCGAAACCATGAACTTTCTGCTC CAGCCTGGCTCACCGCCTTGGCTT 665, 593, 461 
VEGFR1 GAGAGCATCTATAAGGCAGCGGATT CACGTTTACAATGAGAGTGGCAGTG 456 
VEGFR2 TACACAATTCAGAGCGATGTGTGGT CTGGTTCCTCCAATGGGATATCTTC 499 
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Apoptosis assay 
Apoptosis was induced in brown preadipocytes through nutrient deprivation. 
Preadipocytes were plated and grown to confluence in regular growth medium. Cells were 
rinsed twice for five min in serum free DMEM. Cells were then placed in serum free 
medium.  VEGF (25ng/ml) and/or DC101, a neutralizing antisera against mouse VEGFR2 
(15µg/ml) for 12 hours. Cells were rinsed twice in PBS (which was collected), trypsinized, 
pooled with medium and PBS and centrifuged. Whole cell lysates were prepared and 
analyzed for presence of the pro-apoptotic protein marker cleaved caspase 3 and other 
proteins by Western blotting as described. 
 Apoptosis was induced in fully differentiated brown adipocytes by treatment with 
10nM TNFα (Genway Biotech, San Diego, CA, USA) and 10µg/ml CHX for 6 hours in the 
presence or absence of DC101 as above. Cell survival was analyzed after the treatment.  Cell 
number was counted using a Coulter Counter as described above. For detection of cleaved 
caspase positive cells, cells were incubated with Alexa Fluor®488-conjugated cleaved 
caspase 3 antibody (Cell Signaling Technologies, cat # 9669) and FACS analysis was 
conducted using Cytofix/Cytoperm Fixation Permeabilization kit (BD Biosciences, San Jose, 
California, USA; cat # 554714), following the manufacturer’s instructions. Briefly, cells were 
rinsed in PBS, trypsinized and collected as above. The cells were then washed once in 
staining buffer (Opti-MEM (Life Technologies) with 1% BSA)  xed in 4% paraformaldehyde 
(PFA) for 15 min at 4   C, permeabilized in BD Perm/Wash buffer (BD Biosciences, Cat # 
554714) for 15 min , incubated in 50µl of the primary antibody (1:100) for 30 min in the 
dark, washed once in BD Perm/Wash buffer and resuspended in 350µl staining buffer for 
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FACS analysis. The cells were protected from light at all times following antibody incubation. 
Percentage of cleaved caspase 3-positive cells was analyzed using a Fluorescence Activated 
Cell Sorter (FACS) (BD LSR II, BD Biosciences).   
TUNEL assay 
Apoptotic cells in BAT were detected in paraffin sections by the TUNEL assay using 
the In Situ Cell Death Detection TMR Red kit (Roche Diagnostics), following the 
manufacturer’s instructions, with some modifications. Briefly, paraffin sections were 
rehydrated, deparaffinized, boiled in citrate buffer, pH 6.0 for 20 min and permeabilized for 
5 min in cold PBS containing 0.2% Tween-20.  Sections were then incubated at 37 °C 
covered from light in TUNEL reaction mix containing biotinylated nucleotides and terminal 
deoxynucleotidyl transferase (TdT) enzyme for 1 hour, washed three times in PBS and 
mounted. DNase treatment was performed as a positive control, and incubation without 
TdT enzyme was conducted as a negative control. 4’,6’-diamino-2-phenylindole (DAPI) 
labeling was used to identify cell nuclei. When immunofluorescence was combined with 
TUNEL assay to identify cell type, immunostaining was conducted first; the cells were then 
fixed for 10 min in 4% PFA, followed by TUNEL assay as described. For quantification, three 
sections from each BAT sample were scanned entirely and images were taken of all TUNEL 
positive cells with an Axioscope microscope (Carl Zeiss Microscopy LLC, Thornwood, NY, 
USA). The number of TUNEL positive cells was represented as the average number of 
apoptotic cells per section, for five mice expressing sFlt1and three control mice. 
 
145 
 
Adenovirus mediated sFlt1 expression 
Mice were anesthetized using ketamine/xylazine and injected with ~7.5 x 10^10 pfu 
of sFlt virus in 100µl volume via the tail vein. Adenoviruses administered intravenously are 
delivered primarily to the liver, targeting the hepatocytes and non-parenchymal (Kupffer 
and endothelial) cells. Production of the gene of interest is mediated by infection of these 
cells, which secrete the protein into systemic circulation (Reviewed in Sakurai et al., 2008). 
Five days post injection, serum was collected by submandibular bleeding and circulating 
sFlt1 levels were determined by ELISA (R&D Biosystems, Minneapolis, MN,USA; Cat # 
MVR100). Animals with circulating levels of sFlt1 of 200ng/ml or higher were included in the 
study.  Ad-null-infected mice showed no detectable sFlt1. Eight mice were used in each 
group. Mice were euthanized seven days post injection and tissues dissected. Three mice 
from each group were perfused for electron microscopy as described. For the remaining 
animals, total body weight as well as the weights of BAT and major WAT depots were noted. 
For histology, the tissues were placed directly in 4% PFA and fixed for 48 hours.  Tissue for 
protein/triglyceride analyses was flash frozen immediately in liquid nitrogen and stored in -
80   C. 
One possible issue concern regarding the use of adenoviral vectors is the innate 
immune response that can be triggered by systemic administration (reviewed in Sakurai et 
al. 2008). However, we have used this model of adenoviral-mediated expression extensively 
(Maharaj et al. 2008; Ford et al. 2011; Saint-Geniez et al. 2008).  Measurement of circulating 
levels of TNF-α in Ad-null and Ad-sFlt1 animals revealed no increase in TNF-α, whereas 
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positive controls such as culture media from LPS-stimulated macrophages contained more 
than 1500pg/ml of TNF-α (Walshe et al. 2009).  
Western blot analysis 
To prepare whole cell lysates, cells were homogenized in RIPA lysis buffer containing 
0.1% SDS (Sigma-Aldrich) over three freeze-thaw cycles, sonicated for ~ 5 sec, centrifuged at 
12,000xg for 10 min at 4   C and supernatant collected and stored at -80   C. Protein 
concentration was measured using a BCA assay (Bio-Rad Laboratories, Hercules, CA, USA). 
Equivalent amounts of proteins from 30 to 60µg, depending on the sensitivity of the 
antibody to be used, were separated by SDS-PAGE under reducing conditions, and 
transferred to an Immobilon-P membrane (Millipore, Billerica, MA, USA).  The membrane 
was incubated in blocking buffer (5% non-fat milk in PBS with 0.1% Tween) for 30-60 min 
and immunoblotted with the appropriate primary and secondary  antibodies diluted in 0.5 – 
3% non-fat milk in PBS with 0.1% Tween. Membranes were washed in PBS with 0.1% 
Tween. Proteins were visualized with SuperSignal West Pico, Dura or Femto extended 
duration substrates (Pierce Biotechnologies, Rockford, IL, USA). For reprobing, membranes 
were stripped by incubation for 30 min in 6.25 mM Tris-HCl, pH 6.8, 2% SDS and 100 mM β-
mercaptoethanol at 50 °C, blocked and reprobed.  
Immunohistochemistry and immunofluorescence 
Embryos (E15.5) and BAT were fixed overnight in 4% PFA in PBS and embedded in 
paraffin, sectioned (5µM) and stained with hematoxylin & eosin for routine histology and 
Masson’s Trichrome to stain connective tissue.  For immunohistochemistry, sections were 
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deparaffinized, rehydrated, boiled in citrate buffer (pH 6.0) for antigen retrieval, incubated 
with 1% hydrogen peroxide in methanol for 10 min to block endogenous peroxidase 
activity, and permeabilized with PBS containing 0.2% Tween for 5 min.  For 
immunohistochemistry with the an -LC3B an body, sec ons were permeabilized in 100% 
methanol for 20 min at -20  C.  Blocking of non-specific binding was accomplished by 
incubation in buffer made of serum from the host species of the secondary antibody (3%) in 
PBS with 0.2% Tween for 1 hour at room temperature before incubation with appropriate 
primary antibodies in blocking buffer overnight at 4°C in a humidified chamber. After 
washing three times in PBS, sections were incubated with biotinylated anti-rat or anti-rabbit  
antibodies in blocking buffer for 1 hour at room temperature, followed by three additional 
washes.  The primary antibody was visualized using avidin-biotin-horseradish peroxidase 
and DAB substrate (Vector ABC kit; Vector Laboratories); tissues were counterstained with 
hematoxylin for labeling cell nuclei. Isotope-matched IgGs served as negative controls for 
each experiment.  For immunofluorescence on paraffin sections, a procedure similar to that 
for immunohistochemistry was followed except antigen retrieval in citrate buffer was 
followed by incubation of sections in PBS with 0.2% sodium borohydride for 10 min to 
quench autofluorescence and incubation with hydrogen peroxide was not performed.  
For immunofluorescence of differentiated adipocytes, cells were grown on sterilized 
coverslips in 12-well plates until fully differentiated. Cells were fixed in 4% PFA for 10 min, 
washed, incubated in blocking buffer, followed by overnight incubation with appropriate 
primary antibodies. Samples were washed three times in PBS, followed by incubation with 
fluorophore conjugated anti-rat or anti-rabbit secondary antibodies for 1 hour at room 
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temperature, washed in PBS and counterstained with DAPI for identification of cell nuclei. 
Cells on coverslips were mounted on slides using mounting media (1:1 PBS and glycerol).  
To visualize mitochondria in differentiated brown adipocytes, live unfixed cells were 
incubated in 100nM CMTM-Rosamine (MitoTracker Orange, Invitrogen) for 30 min at 37   C, 
fixed in 4% formalin for 15 min, washed three times in PBS. If immunofluorescence was to 
be performed on the same samples, the cells were also permeabilized in ice cold acetone 
for 5 minutes followed by blocking and incubation with primary antibody.  
Electron microscopy 
Seven days following adenovirus injections, mice express ad-sFlt1 and the control 
ad-null mice were deeply anesthetized with ketamine (73 mg/kg) and xylazine (1.8 mg/kg) 
and perfused via the aorta with 10ml sodium cacodylate buffer 0.1 M, pH 7.4, for 2 min 
followed by 10ml fixative of PFA/ glutaraldehyde, 2.5% each in 0.1M sodium cacodylate 
buffer, pH 7.4 (Electron Microscopy Sciences; Hatfield, PA, USA).  Perfusion was 
accomplished with a 21-gauge cannula inserted into the aorta via the left ventricle. Fluid 
drained through the right atrium, and animals’ death from exsanguination was immediate 
upon perfusion. The BAT was dissected and fixed in the same fixative for 72 hours at 4  C.  A 
secondary  xa on was performed overnight at 4  C in 1% osmium tetroxide and 1.5% 
potassium ferrocyanide.  Osmium is the main fixative for lipids, which are not extracted 
during processing, allowing the adipocytes to maintain their morphology. This was followed 
by dehydration and embedding in propyleneoxide resin. Ultrathin sections were treated 
with 1% uranyl acetate followed by 0.2% lead citrate for visualization of cell ultrastructure 
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and examined by transmission electron microscopy using a Tecnai TM G2 Spirit BioTWIN 
transmission electron microscope (Oregon, USA).   
Statistical analysis  
Values are expressed as mean + SEM unless specified. Statistical analysis was 
performed using an unpaired Student t-test for comparison between two groups and one 
way Anova for comparison between multiple groups (***, P < 0.001; **, P <  0.01; *, P < 
0.05; ns, P < 0.05, ns: P>0.05). 
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Appendix 
RhoB Controls Adult Angiogenesis and Lymphangiogenesis through VEZF1 
Damien Gerald1, Irit Adini2, Sharon Shechter1, Carole Perruzzi1, Joseph Varnau1, 
Benjamin Hopkins1, Shiva Kazerounian1, Peter Kurschat2, Stephanie Blachon3, 
Mandrita Datta1, David Sherris4, Michael Klagsbrun2, Heidi Stuhlmann5, Alan C. 
Rigby6, Janice A. Nagy1,# and Laura E. Benjamin1,# 
 
 
 
This represents work done in Mandrita’s former thesis laboratory. She performed 
groundwork of demonstrating that RhoB regulates the transcription of Prox1, master 
regulator of lymphatic differentiation, and that VEZF1 does not mediate Prox1 expression 
directly, through techniques such as cloning of the Prox1 promoter fragments, luciferase 
assay etc.  She also optimized short hairpin RNA mediated silencing of RhoB and VEZF1 in 
primary lymphatic and blood vascular endothelial cells.  
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RhoB, a stress-induced small GTPase, modulates cellular 
responses to growth factors, genotoxic stress and neoplastic 
transformation. Here, we show that RhoB loss converts  
retinopathy-associated, pathological angiogenesis to a more 
physiological phenotype. RhoB loss also reduces 
angiogenesis, while enhancing lymphangiogenesis, during 
skin wound healing in adult mice, which reveals unique and 
opposing roles of RhoB in blood versus lymphatic 
vasculatures. By comparing primary human blood and 
lymphatic endothelial cells, we link these biological 
responses to the differential regulation of sprouting  and  
proliferation  by  RhoB.  Mechanistically  we  demonstrate  that  
nuclear RhoB-GTP  controls  expression  of  different  gene  
sets  in  both  endothelial  lineages through  VEZF1-mediated  
transcription,  thus  establishing  the  first  intra-endothelial  
molecular  mechanism  responsible  for  the  characteristic  
phased  response  of  early angiogenesis and delayed 
lymphangiogenesis following injury. Finally, we identify a  
small molecule inhibitor of VEZF1-DNA interaction that 
recapitulates RhoB loss in ischemic retinopathy, providing 
proof-of-concept for the therapeutic value of targeting  
transcription factors.  
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Large organisms exhibit two different vascular networks essential for life. The circulatory blood vascular  
network, arising during embryonic development by both vasculogenesis and angiogenesis, provides  
oxygen, nutrients, hormones and cells to tissues, and collects carbon dioxide and other metabolic waste  
products1. The blind-ended lymphatic vascular network that subsequently originates from the embryonic  
cardinal vein by budding and differentiation of a subpopulation of blood endothelial cells, regulates tissue  
fluid homeostasis, immune cell trafficking and absorption of dietary fats 2. Similarly in adults, numerous  
studies have shown that angiogenesis precedes lymphangiogenesis in damaged tissues3-9. However, the  
underlying mechanisms that timely coordinate these processes are still elusive. Considering the close  
identity between blood and lymphatic endothelial cells, a central question still unresolved is how blood  
vessels quickly engage in the revascularization of damaged tissues, while the growth of lymphatics is  
delayed in response to the same pathological stimulus? RhoB is an immediate early response gene rapidly  
inducible by many stimuli including genotoxic stress, cytokines and growth factors10-13. In contrast to its  
related members of the Rho/Rac/Cdc42 family of small GTPases, RhoB is primarily localized on  
endosomes and in the nucleus, and has been shown to regulate vesicle and growth factor receptor  
trafficking 14-17. RhoB null mice are viable, indicating that RhoB is dispensable for normal development  
18, however, RhoB deletion in mice can increase tumor formation19. Furthermore, studies in RhoB  
knockout mice indicate that RhoB is a critical modifier of apoptosis triggered by genotoxic stress. In  
transformed fibroblasts, RhoB promotes apoptosis in response to DNA damage18. In contrast, RhoB  
protects transformed keratinocytes from UVB-induced apoptosis, suggesting that RhoB’s functions are  
dependent upon the nature of stress and the cell context13. Our previous studies revealed for the first time  
the contribution of this small GTPase to the blood vasculature in the developing retina, which is  
associated with defective endothelial tip cell sprouting in RhoB null mice20. We found that RhoB is an  
important determinant of Akt stability and trafficking to the nucleus, and that this function plays a stage- 
specific role in the survival of sprouting blood vessel endothelial cells (BVECs) that contribute to new  
blood vessel assembly during post-natal retinal development. Given its critical role in the stress response,  
we hypothesized that RhoB might be relevant in adult pathological scenarios involving endothelial cell  
challenge, such as wound healing, inflammation, or reperfusion injury. Here, we show that RhoB null  
 155 
 
 
 
mice exhibit decreased angiogenesis leading to normalization of pathological angiogenesis associated  
with ischemic retinopathy, but earlier, increased and abnormal lymphangiogenesis following dermal  
injury or inflammation. Using human primary BVECS versus LVECs, we demonstrate that RhoB serves  
opposing roles in regulating proliferation and sprouting capability of these two endothelial populations.  
To further understand these exclusive functions of RhoB, we focused on a recently identified zinc finger  
transcription factor VEZF1, involved in embryonic angiogenesis and lymphangiogenesis21. For the first  
time, we confirmed the interaction of RhoB and VEZF1 in cells. And we explored the function of the  
RhoB-VEZF1 complex in both adult endothelia in vivo. Our transcriptome analysis of BVECS and  
LVECs uncovers relevant and new genes targeted by VEZF1 and co-regulated by RhoB-GTP. Lastly, we  
identified a small molecule specifically selected to interfere with VEZF1 binding to DNA, which  
recapitulates the ability of RhoB loss to normalize the pathological angiogenesis in the ischemic retina.  
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RESULTS  
RhoB loss normalizes blood vasculature in oxygen-induced retinopathy and 
reduces angiogenesis accompanying wound healing  
To analyze the impact of RhoB on postnatal angiogenesis, we first employed the mouse model of  
oxygen-induced retinopathy (OIR)22 to create a pathological angiogenic environment in neo-natal RhoB-/- 
mice.  After 5 days at 70% oxygen (P7-P12), analysis of the retinal vasculature indicates profound vessel  
regression, particularly in the central portion of the retina near the optic disc (OD), and confirms that the  
initial vascular response to high oxygen is not altered in the absence of RhoB (Fig. 1a). Subsequently,  
after 5 days of room air (P12-P17), wt pups mounted a robust pathological neovascularization in the retina  
typified by abnormalities in vascular structure (formation of glomeruloid bodies or “vascular tufts”  
(arrowheads), large avascular areas (star), and endothelial cell invasion through the inner limiting  
membrane (ILM) into the vitreous (arrows). High invasion rate into the wt vitreous was quantified by  
counting EC nuclei anterior to the ILM in H&E histological sections. In contrast, RhoB-/- mice showed a  
dramatic reduction of glomeruloid bodies, and 100-fold reduced intra-vitreous invasion rate. Thus, RhoB  
loss during ischemic retinal neovascularization was accompanied by reduced blood vessel growth and the  
conversion of the resultant neovascular network from a pathological to a more physiological phenotype.  
To evaluate the impact of RhoB deletion in another tissue, we subjected the mouse ear skin to a  
full thickness wound using a 2 mm biopsy punch. New blood vessels were induced in the granulation  
tissue of wt mice by 7 days after wounding (Fig. 1b). In contrast, RhoB-/-  mice exhibited poor  
neovascularization within the granulation tissue with a 2-fold decreased vascular density compared to wt.  
Interestingly in RhoB-/- mice, immunostaining for CD31 revealed not only the presence of positively  
stained blood vessels, but additional structures with a different morphology and weak staining intensity  
(arrowheads). CD31 is a protein also known to be expressed by lymphatic endothelial cells23. To validate  
the lymphatic identity of these additional vascular structures, we used an antibody against podoplanin, a  
protein that is specifically expressed in the lymphatic endothelium (Fig. 1c). Co-localization of CD31 and  
podoplanin confirmed the identity of these structures as lymphatic vessels infiltrating and surrounding the  
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granulation tissue in RhoB-/- mice (arrowheads). Taken together, these results indicate that RhoB plays a 
positive role in the formation of new blood vessels in different vascular beds responding to stress, and 
prompted us to further explore the lymphatic vasculature of RhoB-/- mice.  
 
RhoB   enhances   lymphangionenesis   associated   with   wound   healing   and 
inflammation  
To directly determine the participation of RhoB in the response of the mature lymphatic network to a  
pathological challenge, we assessed the effect of RhoB loss on lymphangiogenesis associated with  
cutaneous wound healing using the mouse ear model. By day 7 post-wounding, in vivo injection of  
high-molecular-weight FITC-dextran tracer directly into the dermal lymphatic vessels in wt mice did not  
reveal any obvious formation of new lymphatics associated with the granulation tissue, in agreement with  
previous studies6,9,24 (Fig. 2a and Movie S1). On the other hand, RhoB-/- mice exhibited a profound  
lymphangiogenic response as judged by the rapid increase in the filling of a distinct lymphatic network  
with the FITC-dextran tracer beginning between 2-10 seconds after tracer injection and progressively  
increasing by 30 seconds (2-fold increase) (Movie S2). These results indicate more numerous lymphatic  
vessels as well as an elevated interconnectivity in the lymphatic vessel network adjacent to the RhoB-/- 
wound. Thereafter, between 30 and 60 seconds, the appearance and accumulation of FITC-dextran in the  
tissue immediately surrounding the filled lymphatics (arrowheads), far from the tracer injection site,  
suggests an abnormal structure of these new lymphatics leading to the enhanced leakage of fluid and  
macromolecules. Confocal analysis following whole mount staining of lymphatics with anti-podoplanin  
on tracer-injected ears confirmed the abnormal structure of the lymphatic vessels in the RhoB-/- 
granulation  tissue,  i.e.,  lymphatic  lumen  enlargement  and  impaired  barrier  integrity  leading  to  
accumulation of FITC-dextran in the surrounding tissue (respectively, arrowhead and star, Fig. 2b).  
To demonstrate that the abnormal lymphatic structure in RhoB-/- stressed skin leads to defective  
draining function, we induced a delayed-type hypersensitivity (DTH) reaction using oxalozone as a  
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sensitizing agent25. The level of edema accompanying chronic inflammation in the ears was assessed by  
measurement of ear thickness (Fig. 2c). The maximum extent of edema, reached by 2 days after  
oxalozone application, was significantly higher in RhoB-/- ears as compared to wt. Thereafter, ear swelling  
declined more slowly and remained significantly higher in RhoB-/- compared to wt mice even after 11  
days, indicating that resolution of fluids that accumulated during the inflammatory phase is impaired in  
the RhoB-/- mice. Visualization of the lymphatic network at 7 days post-challenge by intralymphatic  
injection of high-molecular-weight FITC-dextran tracer revealed a massive lymphangiogenic response in  
RhoB-/- mice characterized by more numerous lymphatic vessels, enhanced lymphatic interconnectivity,  
and dramatic FITC-dextran leakage into the surrounding tissue (Fig. 2d and Movie S4) as compared to wt  
(Movie S3). These data indicate that the absence of RhoB permits the formation of an early, excessive and  
dysfunctional lymphangiogenic response, which disrupts the normal pattern of edema resolution.  
 
 
 
RhoB differentially affects BVEC and LVEC proliferation and sprouting  
To comparatively assess the function of RhoB in blood versus lymphatic endothelia, we used pure  
populations of human primary blood (BVECs) and lymphatic (LVECs) endothelial cells isolated from  
foreskin (Fig. S2). First, we determined the relative amounts of RhoB protein found in BVECs versus  
LVECs during resting conditions (cells at 100% confluence for 48h without media renewal), or during  
proliferative conditions (cells collected 24h and 48h after challenge initiated by trypsinization of  
confluent cultures followed by re-plating at 50% density) (Fig. 3a). RhoB was constitutively expressed in  
both resting and proliferating BVECs. In contrast, RhoB protein was barely detectable in LVECs at rest  
and at 48h after challenge. Interestingly, the level of RhoB protein increased in both BVECs and LVECs  
24h after proliferative challenge, suggesting that RhoB plays a critical role in both BVECs and LVECs in  
their immediate response to stress. To further analyze the function of RhoB in BVECs and LVECs, we  
either silenced or overexpressed RhoB, by siRNA nucleofection or adenovirus infection, respectively, and  
then subjected confluent cultures of the modified cells to proliferative stress (Fig. 3b). Immunostaining of  
pre-confluent cells 24h following proliferative stress, with an antibody against the proliferation marker  
  
 159 
 
 
 
Ki67, showed that RhoB silencing decreased the percent of proliferating BVECs two-fold, but nearly  
doubled the percent of proliferating of LVECs (Fig. 3c). In direct contrast, RhoB overexpression  
significantly promoted the proliferaton of BVECs, but repressed LVECs proliferation. Using a 3D 
sprouting assay, we also observed a differential response of BVECs and LVECs to alterations in RhoB 
expression (Fig. 3d). Indeed, RhoB silencing reduced the sprouting of BVECs induced by VEGF-A and led 
to increase sprouting of LVECs stimulated by VEGF-C.  In contrast, RhoB overexpression had the reverse 
effect, i.e., higher number of BVECs sprouting in response to VEGF-A, and repressed LVECs sprouting in 
response to VEGF-C. These results demonstrate that RhoB serves cell autonomous, yet opposing, roles in 
two essential features of blood and lymphatic endothelial cell biology, i.e., proliferation and sprouting, thus 
corroborating our in vivo observations.  
 
RhoB   collaborates   with   VEZF1   during   stress-induced   angiogenesis   and 
lymphangiogenesis  
To decipher the molecular mechanisms responsible for the differential effect of RhoB in blood and  
lymphatic vascular beds, we investigated the possibility that RhoB is functionally linked to the zinc finger  
transcription factor VEZF1, previously shown to regulate embryonic angiogenesis and lymphangiogenesis  
and a RhoB-interacting protein in vitro14,21. We crossed mice from the RhoB and VEZF1 knockout strains  
and generated an allelic series of mice, i.e., RhoB+/-, VEZF1+/- and RhoB+/-VEZF1+/-. Using the OIR assay  
as our read-out of pathological angiogenesis, we observed that loss of only one RhoB allele did not alter  
the pathological angiogenic response in the retina of RhoB+/- mice as compared to wt (Fig. 4a compared to  
Fig. 1a). However, VEZF1+/- mice exhibited a reduced pathological angiogenic response (2-fold decrease  
in the number of nuclei interior to inner limiting membrane) (Fig. 4a), which is further reprogrammed to  
more physiological angiogenesis in RhoB+/-VEZF1+/- mice, similarly to RhoB-/- mice (Fig. 4a compared to  
Fig. 1a). In parallel, we assessed the lymphangiogenic response to challenge using the ear wound model.  
By day 7 post-wounding, in dramatic contrast to what we observed in the RhoB-/- mice (Fig. 2a), injection  
of high-molecular-weight FITC-dextran tracer did not reveal new lymphatics in the region immediately  
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surrounding the site of the wound in RhoB+/- mice (Fig. 4b and Movie S5). In contrast, in RhoB+/- 
VEZF1+/- mice, the lymphangiogenic response was comparable to that observed in the RhoB-/- mice (Fig.  
4b and Movie S7 compared to Fig. 2a). Interestingly, VEZF1+/- mice exhibit an intermediate lymphatic  
phenotype with the emergence of several leaky lymphatics around the granulation tissue (arrowhead, Fig.  
4b and Movie S6).  
To address the interaction of RhoB with VEZF1 at the molecular level in BVECs and LVECs, we  
investigated the subcellular localization of these two proteins. Importantly, although RhoB was detected  
predominantly in the cytoplasm of both BECs and LECs, we also observed this small GTPase in the  
nucleus of both cell types, where VEZF1 proteins were exclusively detected (Fig. 4c). Moreover, RhoB  
and VEZF1 could be co-immunoprecipitated indicating the presence of a protein complex containing this  
small GTPase and this zinc-finger transcription factor (Fig. 4d). Taken together, these studies strongly  
argue that RhoB genetically interacts with VEZF1 in the regulation of the altered blood vascular response  
to ischemia as well as in the temporal repression of lymphangiogenesis during wound healing, and  
indicate that RhoB belongs to a nuclear transcriptional complex containing VEZF1.  
 
RhoB and VEZF1 share relevant target genes for BVEC and LVEC proliferation 
and sprouting  
To uncover how the collaboration between RhoB and VEZF1 affects BVEC and LVEC biology, we set  
about to identify the cohort of target genes whose expression is influenced by these two proteins. To  
accomplish this aim, we performed Affymetrix microarray analysis after silencing either RhoB or VEZF1  
in both endothelial cell types (Fig. S3). Interestingly, a significant number of the deregulated probe sets in  
RhoB silenced BVECs matched the deregulated probe sets in VEZF1 silenced BVECs (214 down- 
regulated and 243 up-regulated probe sets). Similarly, 1413 down-regulated probe and 1280 up-regulated  
probe sets in RhoB silenced LVECs compared favorably to the deregulated probe sets in VEZF1-silenced  
LVECs, suggesting that these deregulated probe sets could correspond to the specific genes targeted by  
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VEZF1 and co-regulated by RhoB. Using Gene Ontology (GO) classification to query the function of the  
target genes shared by RhoB and VEZF1, we identified ontology categories important for different  
aspects of endothelial cell biology including their proliferation and sprouting (Table S1). Among the  
subsets of shared target genes (Table S2), we confirmed the role of RhoB and VEZF1 in the regulation of  
expression of a finite number of particularly relevant genes by QRT-PCR (Fig. 5a). For example, the  
VEGF-A receptor, VEGF-R2, and its co-receptor, Neuropilin1 (NRP1), were both down-regulated in  
BVECs after silencing of either RhoB or VEZF1 (2-fold decrease in silenced cells compared to control).  
Although these two genes were also detected in the LVECs microarrays, QRT-PCRs revealed a lower  
basal level of expression and an insignificant decrease after silencing of either RhoB or VEZF1 in these  
cells, suggesting a predominant effect of RhoB-VEZF1 on VEGF-R2 and NRP1 expression in BVECs  
compared to LVECs. By contrast, the metallopeptidase inhibitor, TIMP3, was more highly expressed in  
LVECs, suggesting that down-regulation of this protein, triggered by both RhoB and VEZF1 knockdown,  
has a particularly potent impact in LVECs compared to BVECs. We also validated relevant genes  
deregulated by RhoB-VEZF1 that have previously been shown to be involved in BVEC proliferation and  
sprouting (e.g., PHD2, Endothelin1) or LVEC proliferation and sprouting (e.g., MMP2, CyclinE2).  
Moreover we identified new genes not previously recognized as being involved in lymphatic vessel  
biology (TIMP3, Vasohibin1). Interestingly, these genes exhibit different relative patterns of mRNA  
expression that most likely highlight specific promoter configurations.  
To further identify the direct target genes of VEZF1, and more importantly, those that are also  
co-regulated by RhoB, we analyzed the binding of these two proteins to a number of selected promoters  
by chromatin immunoprecipitation (Fig. 5b). Interestingly we discovered sequences containing potential  
VEZF1 DNA binding sites in the promoter regions of VEGF-R2 and NRP1. These regions exhibit 3-fold  
and 2-fold  enrichment,  respectively,  after  VEZF1  or  RhoB-Flag  chromatin  immunoprecipitation,  
specifically in BVECs. In contrast, the chromatin of the TIMP3 and Vasohibin1 promoter regions, which  
also contains putative VEZF1 DNA binding sites, is enriched 4-fold after VEZF1 or RhoB-Flag  
immunoprecipitation, specifically in LVECs. Analysis of the Endothelin1 promoter, known to be a direct  
target of VEZF1, confirms chromatin enrichment after VEZF1 or RhoB-Flag immunoprecipitation in  
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BVECs. Taken together, these data suggest that RhoB works in conjunction with VEZF1 on specific 
promoters to regulate the expression of essential direct target genes involved in the proliferation and 
sprouting of endothelial cells (BVECS and LVECs). Of critical importance, these sets of direct targets 
appear to be different in BVECs versus LVECs.  
 
 
 
RhoB-GTP specifically controls BVEC and LVEC proliferation  
A crucial feature of any small GTPase is the ability to toggle its intrinsic GTPase activity between “on”  
and “off” states, as determined by the ratio of the GTP-bound to the GDP-bound forms of the enzyme 26.  
To assess the importance of these two states in the regulatory function of RhoB in endothelial cells, we  
prepared adenoviral vectors encoding mutants of RhoB and used them to elicit overexpression of three  
different forms of the RhoB GTPase (wild type (adRhoB); the RhoB dominant negative form  
corresponding  to  the  GDP-bound  state  (adRhoB-DN);  and  the  RhoB  constitutively  active  form  
corresponding to the GTP-bound state (adRhoB-CA). Overexpression of wild type (wt) or mutant RhoB  
was performed in BVECs and LVECs undergoing proliferative challenge and the corresponding GTP  
levels were measured by GTP pulldown assay (Fig. 6a). As expected, neither BVECs nor LVECs infected  
with adRhoB-DN exhibited any detectable amount of GTP-bound RhoB, while both cell types infected  
with adRhoB-CA showed high levels of expression of the GTP-bound form of RhoB. Interestingly,  
following wt RhoB overexpression, a substantial amount of RhoB in the GTP-bound state could be  
detected in both BVECs and LVECs, indicating that both cell types maintain RhoB in a predominantly  
active form under proliferating conditions. To evaluate the possibility that the state of RhoB determines  
its localization within the cell, we analyzed the subcellular pattern of our mutants RhoB (Fig. 6b). Wt  
RhoB and all mutants of RhoB, including the dominant negative RhoB, were detected in the cytoplasm as  
well as in the nucleus of BVECs and LVECs, indicating that both the GTP- and the GDP-bound states of  
RhoB can be found within the nucleus.  
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To determine the biological effect of the GTP-bound versus the GDP-bound form of RhoB on  
endothelial cell proliferation, we measured the proliferative index of BVECs and LVECs overexpressing  
either wt or mutant RhoB (Fig. 6c). As previously observed, wt RhoB promotes and represses the  
proliferation of BVECs versus LVECs, respectively. Interestingly, whereas RhoB-DN did not affect the  
proliferation rate of either type of endothelial cell, RhoB-CA influenced the proliferation of BVECs and  
LVECs similarly to wt RhoB. This lack of effect on proliferation by the RhoB-DN correlates with its  
inability to regulate genes previously identified as RhoB-VEZF1 targets such as VEGF-R2, NRP1 and  
TIMP3 (Fig. 6d). Altogether, these results suggest that both forms of RhoB may exist as part of the  
nuclear RhoB-VEZF1 transcriptional complex. However, only RhoB-GTP has the ability to regulate the  
expression of genes that are specific targets of VEZF1 and modulate the proliferation rate of blood and  
lymphatic vessel endothelial cells.  
 
A  small  molecule  targeting  VEZF1-DNA  interaction  normalizes  angiogenesis 
accompanying OIR.  
Data already presented suggest that RhoB promotes pathological angiogenesis accompanying OIR  
(Fig.1a), in collaboration with VEZF1 (Fig. 4a). Therefore, we hypothesized that by interfering with the  
RhoB-VEZF1 pathway we might restore physiological revascularization in this setting. To target the  
RhoB-VEZF1 complex we focused on the DNA binding domain of VEZF1 that is composed of a zinc  
finger domain designed to recognize a specific DNA promoter sequence27. C2H2 zinc fingers occur in  
tandem arrays with many transcription factors composed of three or more fingers working in concert to  
target the transcription factor to its appropriate promoter28,29. An in silico approach was adopted to  
identify a small molecule that could inhibit the interaction of VEZF1 with DNA (VasculoMedics, private  
communication). This work discovered the small molecule VEZF1-compound 6 (VEC6) that significantly  
repressed  NRP1  promoter-dependent  luciferase  activity  in  the  presence  of  RhoB  and  VEZF1  
overexpression (Fig. 7a). To further validate the efficacy of this compound, the expression pattern of  
several target genes downstream of RhoB and VEZF1 was evaluated in BVECs and LVECs undergoing  
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proliferative stress in the absence or presence of VEC6 (Fig. 7b). VEC6 repressed the expression of  
VEGF-R2, NRP1 and TIMP3 as determined by RTPCR. Interestingly, VEC6 phenocopies the opposing  
effects of RhoB-VEZF1; i.e., this small molecule is able to repress the proliferation of BVECs, and  
promote the proliferation of LVECs (Fig. 7c). Importantly, these data provide additional support that  
VEC6 is working “on target” to effectively modulate the RhoB-VEZF1 complex. To evaluate the efficacy  
of this compound in vivo, RhoB+/- mice were subjected to the OIR assay in the presence of VEC6 or  
DMSO (vehicle), which were administered daily by intraperitoneal injection during the pathological  
phase (P12 to P17) (Fig. 7d). The mice treated with DMSO did not exhibit any modification in the  
pathological angiogenic response as compared to previous studies (Compare Fig. 7d to Fig. 1a and Fig.  
4a). However, VEC6 treatment increased the emergence of blood vessels with a normal morphology  
(arrowheads), and reduced both the avascular areas and pathological glomeruloid bodies (>2-fold  
decrease in the number of nuclei interior to inner limiting membrane). In conclusion, these data indicate that 
VEC6, identified by in silico approach, modulates the activity of the RhoB-VEZF1 complex by 
disrupting the VEZF1-DNA interaction interface, and they validate its efficacy in vivo.  
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DISCUSSION  
Typically, the response of the blood vasculature to inflammation, ischemia, and wounding precedes that  
of the lymphatic network3,4,24. However, the mechanisms governing the coordinated response of these two  
major vascular networks to pathological challenge are still poorly understood. By studying RhoB null  
mice, we observed that loss of RhoB decreased the extent of pathological angiogenesis in the ischemic  
retina. We confirmed this regulatory role of RhoB in the dermal vasculature, i.e., loss of RhoB led to a  
reduction in angiogenesis in response to wounding. In addition, we noted that lymphangiogenesis,  
following both dermal wounding and inflammatory challenge, was enhanced in RhoB null mice. Upon  
further investigation, we learned that, although RhoB is induced in both blood and lymphatic endothelial  
cells subjected to proliferative stress, RhoB promotes proliferation and sprouting in BVECs, but represses  
these functions in LVECs. To our knowledge, this is the first demonstration of a single protein (i.e.,  
RhoB), which serves intra-cellular and opposing regulatory roles in two closely related endothelial cell  
types (Fig. 8a).  
To understand the underlying molecular mechanism(s) responsible for these intriguing and  
differential functions of RhoB, we investigated the interaction of RhoB with the transcription factor  
VEZF1. For the first time, we uncover the importance of a direct interaction between RhoB and VEZF1  
in both blood and lymphatic endothelial cells, and document that it is the GTP-bound form of RhoB that  
exclusively regulates VEZF1-mediated transcription in both endothelial cell types. Notably, there have  
been very few reports that directly involve GTPases in regulating gene transcription. RhoA and Rac1  
have been observed in the nucleus and are reported to directly contribute to transcriptional complexes  
involving the transcription factors Glucocorticoid Receptors and TCF4, respectively30,31. Our results  
provide further evidence for a requirement of an associated GTPase activity to bring about efficient gene  
transcription by certain transcription factors. Recently, it has been shown that the p68RacGAP interacts  
with VEZF1 and facilitates the hydrolysis of the GTP form of Rac1 in endothelial cells32. This finding  
suggests that future studies will be needed to identify the different regulatory partners, e.g., the GAPs and  
GEFs, participating in the RhoB regulation of VEZF1 mediated transcription.  
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Next, we identified direct and indirect downstream target genes that are co-regulated by RhoB  
and VEZF1. Importantly, we determined that the sets of direct target genes of the RhoB-VEZF1 complex  
differ in BVECs versus LVECs. We propose that this differential regulation is responsible, at least in part,  
for the well-documented phenomenon of delayed lymphangiogenesis observed in pathological settings  
reported in vivo 3,4,24. Among the direct target genes that we identified in BVECS, VEGF-R2, NRP1 and  
Endothelin1 are known to support angiogenesis. Downregulation of another gene, i.e., PHD2, is involved  
in normalization of tumor vascular network33. Of the set of target genes that we identified in LVECs,  
MMP2 has already been linked with lymphatic sprouting34, but two other genes, i.e., TIMP3 and  
Vasohibin1, have not previously been implicated in LVEC biology. Thus, our study contributes important  
new information to the growing list of genes specific to the blood versus lymphatic vasculature.  
Finally, using an in silico approach we were able to successfully design a small molecule 
inhibitor, i.e., VEC6, targeting the VEZF1/DNA binding interface, that was able to recapitulate the effects of 
the loss of RhoB in the ischemic retina. This finding suggests that the RhoB-VEZF1 complex 
represents an interesting new target for developing novel therapies against numerous pathologies with a 
vascular component, e.g., diabetic retinopathy. However, VEC6 is also able to induce LVEC proliferation in 
vitro similar to silencing of RhoB, suggesting the possibility of a pro-lymphangiogenic effect in vivo. 
Further work using a second generation of inhibitory molecules more suited for in vivo studies in adult 
mice will be needed to address the question of lymphatic sensitivity and responsiveness. Notably, this 
question emphasizes the broader worth of considering more generally the lymphatic vascular network as a 
potential side target of any pro- or anti-angiogenic therapy.  
Overall our work highlights the importance of the RhoB-VEZF1 pathway in the temporal  
regulation of angiogenesis and lymphangiogenesis during wound healing. Tissue damage (e.g. skin  
wounds)   triggers   a   healing   response   precisely   coordinated   through   different   phases,   i.e.,  
hemostasis/Inflammation, proliferation, and remodeling/repair (Fig. 8b). The early angiogenic response  
participates in the initial inflammatory phase by facilitating recruitment of inflammatory cells into the  
wound bed (Movie S8). Thereafter, the formation of local edema enhances the migration of inflammatory  
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cells, endothelial cells, and myofibroblasts through the loose fibrin-rich provisional matrix of the 
granulation tissue to begin wound repair. Subsequently, the formation of new lymphatics aids in the 
drainage of excess fluid, cells and debris, to allow the remodeling phase to proceed, ultimately resulting in 
wound closure. Thus, RhoB actively participates in ensuring the delay in lymphangiogenesis that 
appears to be crucial to the success of the overall wound-healing program.  
Although we were unable to evaluate the impact of the RhoB-VEZF1 pathway on wound closure  
in the ear model, our parallel study of dorsal skin excisional wound healing revealed that healthy RhoB-/- 
mice did not exhibit any significant difference in the time required for complete wound closure as  
compared  to  wt  mice35.  This  result  correlates  with  previous  work  on  the  effects  of  VEGF-A  
overexpression on wound healing. Indeed, earlier and increased lymphangiogenesis elicited by VEGF-A  
did not affect the time required for wound closure in healthy animals6. In contrast, VEGF-C over- 
expression accelerated wound closure by inducing angiogenesis, lymphangiogenesis and recruitment of  
inflammatory cells in diabetic animals9. We recently observed a similar phenomenon in RhoB-/- diabetic  
mice suggesting that the impact of deregulation of angiogenesis and/or lymphangiogenesis could be  
exacerbated in pathological conditions such as those occurring in diabetic animals. Future studies will  
address the effects of RhoB loss on pathological angiogenesis and lymphangiogenesis associated with  
tumour growth and metastasis.  
In conclusion, we propose that the immediate early response gene RhoB, in its GTP-form, 
interacts with the transcription factor VEZF1, to regulate, at least in part, the distinct blood and lymphatic 
endothelial responses to different pathological stimuli. Additional analysis of this small GTPase will 
further our understanding of its differential angiogenic and lymphangiogenic regulatory mechanisms and 
identify new therapeutic strategies for appropriate intervention.  
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METHODS  
Mice. RhoB-/- mice, a gift from George Prendergast 18, were maintained in both SV129 and FVB  
backgrounds. VEZF1+/- mice, a gift from Heidi Stuhlmann 21 were maintained in the SV129 background.  
In order to study the functional cooperation between RhoB and VEZF1 in vivo, RhoB-/- mice in the SV129  
background were crossed with VEZF1+/- mice in the SV129 background. Resulting double heterozygotes  
were crossed to obtain all required genotypes in one litter (RhoB+/-, VEZF1+/-, RhoB+/-VEZF1+/-). All  
studies were conducted in compliance with the Beth Israel Deaconess Medical Center IACUC guidelines.  
Retinopathy of Prematurity. Mice were exposed to 75% oxygen beginning on postnatal day P7. A  
minimum of 8 groups were used; depending on the litter, each group contained from 5-8 pups. Mice were  
then returned to room air on day P12. Retinas were harvested on day P17, fixed in formalin (10%  
formaldehyde) for 1 hour, and incubated with FITC-Lectin BS-1 (Sigma) in PBS containing 0.2% Triton- 
X100 and 10% Goat serum O/N at 4OC. The retinas were washed (4-5 times for 1 hr) in PBS.  
Approximately 4 incisions at the edges were made to flatten the retinal cup onto a glass slide for  
fluorescent microscopy and digital photography using a Leica MZFIII microscope and a Leica DC200  
digital camera. Pups used for studies involving treatment with VEZF1 inhibitors were injected into I.P.  
with 30mg/kg/day of test compound from P12 to P17 and then retinas were processed and imaged as  
above.  
Ear Acute Injury and Chronic Inflammation. Full-thickness wounds were created in the center of the  
ears of adult (6-8 weeks) mice using a 2 mm biopsy punch. At 7 days post injury ears were examined by  
whole   mount   staining   and/or   by   intravital   microscopy   to   assess   both   angiogenesis   and  
lymphangiogenesis. Chronic inflammation was induced by delayed-type hypersensitivity (DTH) in the ear  
skin of RhoB null and WT mice as described previously in25. Briefly, adult mice (6-8 weeks) were  
sensitized by topical application of a 2% oxazolone (4-ethoxymethylene-2 phenyl-2-oxazoline-5-one;  
Sigma, St Louis, MO) solution in acetone/olive oil (4:1 vol/vol) to the shaved abdomen (50 µl) and to  
each paw (5 µl). Five days later, ears were challenged by topical application of 1% oxalozone solution (20  
µl). Ear swelling was assessed by ear thickness measurement using a Mitutoyo caliper each day for 11  
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days following challenge. Lymphangiogenesis was assessed by intravital microscopy.  
Ear Whole Mount Staining. Whole mounts of ears were prepared for confocal microscopy using the  
protocol of 8. Mouse ears were dissected and placed in 4% PFA. Dorsal and ventral aspects of each ear  
were separated by first cutting along the entire edge of the ear and then peeling the two halves apart. After  
3 hr fixation, tissues were blocked overnight in PBS containing 5% goat serum and 0.3% Triton-X100. 
Tissues were then incubated successively overnight in primary antibodies (CD31 [MEC13.3, 553370, BD 
Pharmigen], and Podoplanin [ab11936, Abcam]) and secondary antibodies (Jackson) each diluted 1/200 in 
blocking solution. Samples were mounted on glass slides and observed with a confocal microscope (Zeiss 
LSM 510 Meta). Confocal 3D projections were processed by Zeiss LSM Image software. Each 3D projection 
image corresponds to a tissue thickness of 100 µm. CD31 signal of 3D projections was quantified by 
using the measure function (% Area) from NIH ImageJ software, after selection of the wound angiogenic 
area (white lines).  
Ear Intravital Microlymphangiography. These experiments were performed as described36. Briefly,  
mice were anesthetized with Avertin and placed in a transparent acrylic resin mold. Ears were mounted  
flat on the resin support and held in place by silicone vacuum grease and viewed in a Leica MZFLIII  
fluorescent microscope. High molecular weight FITC-dextran (2000 kDa lysine-fixable, Invitrogen at 20  
µg/µl in saline) was injected into the lymphatics through a 10 µm pre-pulled borosilicate glass  
micropipette (World Precision Instruments, Sarasota, FL) attached to a 500 µl Hamilton syringe fitted with 
a threaded plunger. Using a micromanipulator (WPI), the micropipette was injected into the dorsal surface of 
the periphery of the ear in order to engage a lymphatic lumen. Additional tracer (5-20 µl) was then slowly 
injected under the control of a threaded plunger. The progress of the fluorescent tracer through the 
lymphatic network was followed in real time by digital image capture (60 frames/minute) using a Leica 
DC350 FX digital camera in conjunction with Image-Pro Plus 6.2 Software. The resultant image stack was 
then combined to produce a movie of tracer transport. Isolated frames, corresponding to specific times 
following tracer injection, were used to quantify the FITC-dextran tracer signal in each image using the 
measure function (% Area) from NIH ImageJ software.  
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Human Dermal Microvascular Endohelial Cell Isolation and Culture. Primary dermal human  
microvascular  endothelial  cells (HMVECs)  from  human  foreskins (from  at  least  four  separated  
individuals) were isolated as previously described by using immunomagnetic beads37. Both BVECs and 
LVECs were isolated with magnetic Dynabeads pre-associated with CD31 (Invitrogen). Subsequently, 
LVECs were separated from BVECs by using goat anti-mouse Dynabeads associated with Podoplanin 
antibody (Angiobio). A total of six different cell isolation lots were used at passage 4-5 for all in vitro 
experiments. Each experiment was performed on at least two different cell isolation lots. HMVECs were 
grown in pre-coated plates with collagen I in MCDB131 medium (CellGro) supplemented with L-Alanyl- 
L-Glutamine (CellGro, 2mM) and MVGS supplement (Cascade Biologics).  
Transfection. siRNA transfection in HMVECs was performed using HMVEC-L Nucleofector kit  
(Lonza). Briefly, cells at 100% confluence were harvested with trypsin-EDTA and washed in PBS. 100 µl  
of nucleofection solution was used for 1x106 cells. Program S-005 was used for transfection. The cells  
were then removed from the cuvette and plated into a pre-coated 6 well cell culture plate. Final siRNA  
concentration was 50 µM in plate. RhoB and VEZF1 were silenced by using pre-designed siRNAs from  
Ambion (RhoB: siRNA ID# 42060, 41981, 41889, and VEZF1: siRNA ID# S15222, S15223, S15224).  
Silencer Select Negative Control #1 siRNA was used as control. Transfection of Hela cells was performed  
using  TransIT-HelaMONSTER  transfection  kit (Mirus).  VEZF1  overexpression  was  obtained  by  
transfection of human VEZF1 expression vector from Origene. Luciferase assays were performed using the 
Dual-Luciferase Reporter Assay System (Promega).  
Adenovirus and Mutagenesis. RhoB-Flag adenoviruses were generated using AdEasy Adenoviral  
system (Promega). Briefly, human RhoB coding sequence was amplified from human primary endothelial  
cell cDNA and inserted in pShuttle-IRES-hrGFP-1. Site-directed mutagenesis of RhoB was induced by  
PCR using Phusion High-Fidelity DNA polymerase (Fynnzymes) and Dpn I digestion. Mutagenic primers  
were used to prepare mutants for Constitutive Active (G14V) and Dominant Negative (T19N) forms of  
RhoB. All wild type and mutant sequences were checked by DNA sequencing. AdEasy recombinants  
were generated by electroporation of BJ5183 cells containing pAdEasy-1 vector, with Pme I linearized  
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shuttle vector. Adenoviruses were expanded in 293FT cells. All viruses were purified with the two-step  
CsCl centrifugation procedure. Purified adenoviruses were stored in Viral Preservation Media (Tris HCl  
20 mM pH8, MgCl2 2mM, sucrose 5%) at -80°C. Cells were infected at a MOI of 50 pfu/cell.  
Cell Immunostaining. Human dermal endothelial cells were grown in complete medium on coverslips  
pre-coated with collagen. Cells were collected after 24 h in order to assess the proliferation rate with Ki67  
antibody (18-0191Z, ZYMED) or at confluence for Prox-1 (20R-PR039, Fitzgerald) and CD31 (555444,  
BD Pharmingen) immunostaining to confirm BVECs versus LVECs population identity. Cells were fixed  
with 4% paraformaldehyde for 5 min, followed by permeabilization and blocking with PBS containing,  
5% goat serum, 0.1% Triton X-100 for 1h at room temperature. Primary antibodies were diluted 1/200 in  
blocking solution without Triton X-100 and then incubated with cells at 4oC for O/N. Cells were then  
incubated with appropriate secondary antibody (Jackson). Coverslips were washed and mounted in Dako  
Fluorescent Mounting Medium containing DAPI (3µg/ml). Quantification of the proliferation rate with  
Ki67 antibody was determined by the analysis of three independent experiments and the consideration of  
ten random fields for each experiment.  
Sprouting assay. Spheroid production was performed as described in38. Briefly, in 96 well plates, 400  
endothelial cells per well were seeded in 100 µl/well of MVGS media containing 20% Methylcellulose  
(Sigma). After 24h, cell aggregates, named spheroids, were collected and centrifuged. Then, three- 
dimensional cultures of spheroids were prepared by using the overlay method as previously described39.  
In brief, spheroids were resuspended in media containing 2% Growth factor-reduced Matrigel (BD  
Biosciences), and seeded on top of the underlay containing a 50:50 mixture Matrigel and Bovine collagen  
I (PureCol, 3mg/ml, Inamed Biomaterials). Before mixing, collagen I was neutralized as described  
(citation of Seton-Rogers et al, 2005, PNAS, #5, p1257). Stimulatory cytokine, (human VEGF-A (25  
ng/ml) or human VEGF-C (100 ng/ml) (RD Systems), respectively for BVECs and LVECs) was added to  
the Matrigel/collagen I underlay mixture. After 24h of stimulation, phase-contrast pictures were taken  
using a microscope (Nikon eclipse TE300) equipped with a camera (Leica, DFC 350 FX). Fluorescent  
images of GFP positive cells were obtained by confocal microscopy (Zeiss LSM 510 Meta). For  
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quantification, the cumulative sprout length of 15 randomly selected spheroids from three independent 
experiments was reported per data point.  
Cell Extracts and Immunoblot analysis. Cytoplasm extracts were obtained by using a cytoplasmic lysis  
buffer (Triton X-100 0.25%, Tris-HCl 10 mM pH8, EDTA 5mM, EGTA 0.5 mM and proteases inhibitors  
(SIGMA-P8340)). After centrifugation, the nuclei pellet was resuspended in Urea lysis buffer (Urea 8M,  
Tris HCl 50 mM pH8, EDTA 5mM and proteases inhibitors). Total extracts were performed by direct cell  
digestion in Urea lysis buffer. Western blot analysis was performed as in40, using antibodies recognizing  
human  RhoB (CellSignaling-2098),  RhoA (Bethyl-lab-929),  VEZF1 (Abcam-ab50970),  Tubulin  
(Calbiochem-CP06), DNA polymerase β (Abcam-26343), LYVE-1 (UpState-07-538), Prox1 (Fitzgerald20R-
PR039), CD31 (BDPharmingen-555444), Podoplanin (Angiobio-11-003), VEGFR3 (SantaCruz-sc- 
321), and Flag tag (Abcam-ab1162).  
Co-Immunoprecipitation (Co-IP) and Chromatin-Immunoprecipitation (ChIP). Co-IPs and ChIPs  
were performed using 0.5 x 106 cells per IP. Prior to Co-IPs, proteins were cross-linked with 1.5mM EGS  
agent 41. For ChIPs, proteins were first cross-linked with 1.5 mM EGS, and proteins were then cross- 
linked to DNA with 1% Formaldehyde. After cytoplasmic fractionation, nuclei were digested in Complete  
Digestion Buffer from Nuclear complex Co-IP kit (Active motif). DNA was sheared by sonication. IP  
protocol was followed as described by supplier. Each IP was performed using 6 µg of antibodies against  
human VEZF1 (Abcam-ab85414), Flag tag (Sigma-F1804) and human Polymerase II (Covance-MMS- 
126R) and compared to IgG controls. Cross-linked proteins from Co-IPs were separated by treatment with  
1M Hydroxylamine-HCl solution pH 8.5 (1:1 vol/vol), and analyzed by Western blotting. For ChIPs,  
DNA was purified as described in42. DNA enrichment was analyzed by Real Time PCR.  
GTP pulldown assay. RhoB activity was assessed by measuring the amount of GTP-bound form of  
RhoB using the small GTPase activation assay (STA-403) from Cell Biolabs. 5 x 106 cells were used for  
each pulldown reaction performed with Rhoketin RBD Agarose beads, as described by manufacturer. The  
proteins were revealed by immunoblot analysis using antibodies recognizing human RhoB and Flag tag.  
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Analysis of Gene Expression. Total RNAs from two independent cell isolation lots, each from at least  
four separate individuals, were isolated using RNeasy Kit and treated by DNase I during extraction steps  
(Qiagen). cDNAs were prepared from 0.5 µg total RNA using random hexaprimers as templates and  
SuperScript III (Invitrogen). Quantitative real-time RT-PCR was carried out on an AbiPrism 7500 system  
using SYBR Green. The primer sequences are available upon request. For Affymetrix GeneChip probe  
array, 1 µg total RNA of one cell isolation lot from at least four separate individuals was synthetize as  
cRNA, which was hybridized to Affymetrix HT Human U133A GeneChips. Fold change of gene  
expression and Gene Ontology (GO) analysis were established using the dChip software43 . Present probe  
sets with a differential expression ≥ 1.5 fold and p < 0.05 were taken into account.  
Statistical Analysis. Results were presented as mean±SEM. Statistical significance of all data were 
analyzed using the unpaired two-tail Student’s t test in the Microsoft Office Excel 2003 software. p values < 
0.05 were considered to be statistically significant.  
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FIGURE LEGENDS  
Figure 1 RhoB deletion blocks oxygen-induced pathological angiogenesis in the retina and  
decreases vessel density in skin wound-induced granulation tissue. (a) Whole mount staining of  
blood vessels (BS-I lectin) in the retina of wt and RhoB-/- pups subjected to hyperoxia from P7 to  
P12, and then returned back to normoxia from P12 to P17 (OD = Optic Disc). Histological (H&E)  
analysis of wt and RhoB-/-  retinas at P17. Quantification of nuclei number interior to Inner  
Limiting Membrane (ILM) (n = 10 mice per genotype, mean±SEM). (b) Confocal analysis  
following whole mount staining of CD31 expression in the granulation tissue present 7 days  
after ear wounding (with 2 mm biopsy punch) in adult wt and RhoB-/- mice (6-8 weeks old).  
Quantification  of  CD31  positive  staining  in  the  neovasculature  of  the  granulation  tissue  
(delineate with white lines) (n = 6 mice per genotype, mean±SEM). (c) Confocal analysis  
following whole mount staining of CD31 and podoplanin expression in the granulation tissue  
present 7 days after wounding. Arrowheads highlight lymphatic vessels and denote areas of co- 
localization of CD31 and podoplanin in the merged image thus confirming the identity of the  
lymphatic vessels. Scale bars: Whole mount staining = 100 µm, H&E sections = 50 µm (a), 200  
µm (d-c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 175 
 
 
 
 
 
 
Figure 2 RhoB loss leads to enhanced and abnormal lymphangiogenesis in response to stress.  
(a) Intravital microlymphangiography by in vivo injection of FITC-Dextran (MW 2000 kDa) into  
lymphatics of ear skin 7 days after ear wounding (2 mm biopsy punch) in adult wt and RhoB-/- 
mice. Dextran positive areas in isolated frames taken from the movies at early (2-10 seconds  
(s), middle (30s) and late (60s) times following tracer injection were quantified in (g) (n = 7 mice  
per genotype, mean±SEM). (b) Confocal analysis following in vivo FITC-dextran injection in  
lymphatics and whole mount staining of podoplanin expression in the granulation tissue present  
7 days after ear wounding in adult wt and RhoB-/- mice. Arrowhead and star respectively 
highlight dextran leakage from an abnormal lymphatic vessel and tracer accumulation in the 
adjacent tissue of RhoB-/- mice in the merged image. (c) Induction of DTH reactions in the ear skin 
of adult wt and RhoB-/- mice using oxalozone. Ear swelling is expressed as the increase (Δ) over the 
original ear thickness in µm. Ear thickness was measured daily for 11 days following challenge 
using a Mitotoyu caliper (n = 12 mice per genotype, mean±SEM). (d) Intravital 
microlymphangiography by in vivo injection of FITC-Dextran (MW 2000 kDa) into lymphatics of ear 
skin 7 days after inflammation induced by oxalozone in adult wt and RhoB-/- mice. FITCdextran 
positive areas in isolated frames taken from movies at early (2-10 seconds (s)), middle (30s) and 
late (60s) times following tracer injection were quantified (n = 6 mice per genotype, mean±SEM). 
Scale bars: 1mm (a-d) and 100 µm (b).  
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Figure 3 Differential regulation of BVECs and LVECs proliferation and sprouting by RhoB. (a)  
Representative Western blot showing the endogenous level of RhoB protein in BVECs and  
LVECs in the resting state (100% confluence for 48 h without media renewal) versus the  
proliferative state (24h and 48h after challenge initiated by cell plating at low, i.e., 50%, density).  
Western blotting for a related GTPase, RhoA, did not indicate any variation in RhoA expression  
levels in BVECs or LVECs under resting or proliferative conditions and thus confirmed the  
specificity of the RhoB antibody and the unique regulation of RhoB in these cells. Tubulin was  
used as loading control. (b) Representative Western blot showing the efficiency of RhoB  
silencing by siRNA nucleofection, and the level of RhoB overexpression following adenovirus  
infection, in BVECs and LVECs 24h after proliferative challenge. The RhoB-Flag protein was  
detected using antibodies directed against the RhoB protein and by antibodies against the Flag  
tag. (c) Proliferation index of BVECs and LVECs after RhoB silencing and RhoB overexpression  
at 24h after proliferative challenge, determined as the ratio of the number of Ki67 positive cells  
to the total number of cells (expressed as %, mean±SEM). (d) Sprouting from BVECs and  
LVECs spheroids in 3D Matrigel-collagen I matrix, induced for 24h by VEGF-A or VEGF-C,  
respectively,   after   RhoB   silencing (phase-contrast   pictures)   or   RhoB   overexpression  
(fluorescent confocal projections). GFP expression, resulting from infection with the RhoB  
adenoviral  vector  containing  an  IRES-GFP,  was  used  as  an  internal  control  for  the  
overexpression  experiments.  Individual  sprouts  in  RhoB-silenced  cells  are  noted  by  red  
(BVECs)  or  green (LVECs)  arrowheads,  and  in  RhoB-overexpressing  cells  by  white  
arrowheads. Quantitative analysis of endothelial cell sprouting was performed by measuring the 
cumulative length of all of the sprouts originating from one spheroid (described in 38), using NIH 
ImageJ software (mean±SEM). Scale bars: 50 µm (d).  
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Figure 4 Functional interaction between RhoB and VEZF1 during oxygen-induced pathological  
angiogenesis and lymphangiogenesis associated with wound healing. (a) Whole mount staining  
of blood vessels (BS-I lectin) in the retina of RhoB+/-, VEZF1+/- and RhoB+/-VEZF1+/- pups (P17)  
subjected to OIR assay (OD = Optic Disc). Histological H&E analysis of RhoB+/-, VEZF1+/- and  
RhoB+/-VEZF1+/- retinas at P17. Quantification of nuclei number interior to Inner Limiting  
Membrane (ILM) (n = 6 per genotype, mean±SEM). (b) Intravital microlymphangiography by in  
vivo injection of FITC-Dextran (MW 2000 kDa) into lymphatics of ear skin 7 days after ear  
wounding (2 mm biopsy punch) in adult RhoB+/-, VEZF1+/- and RhoB+/-VEZF1+/- mice, shown at  
60 seconds post tracer injection. Dextran positive areas in isolated frames taken from the  
movies at early (2-10 seconds (s), middle (30s) and late (60s) times following tracer injection  
were quantified (n = 6 mice per genotype, mean±SEM). (c) Representative Western blot of  
nuclear and cytoplasmic extracts showing the dual localization of RhoB in both nuclei and  
cytoplasm of BVECs and LVECs, whereas another RhoGTPase, RhoA, was detected only in  
the cytoplasm. In contrast, VEZF1 was exclusively detected in nuclei. DNA Polβ and Tubulin  
proteins were used as internal controls for nuclear and cytoplasmic extracts, respectively. (d)  
Representative Western blot following immunoprecipitation of overexpressed Myc-RhoB in Hela  
cells using an antibody against Myc tag. Overexpressed VEZF1 proteins were only co- 
immunoprecipitated in presence of Myc-RhoB. Scale bars: Whole mount staining = 100 µm,  
H&E sections = 50 µm (a), 1mm (b).  
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Figure 5 Target Genes shared by RhoB and VEZF1 in BVECs and LVECs. (a) Relative mRNA  
levels of VEGF-R2, NRP1, PHD2, Endothelin1, TIMP3, MMP2, CyclinE2 Vasohibin1 in BVECs  
and  LVECs  following  silencing  of  either  RhoB  or  VEZF1  as  determined  by  QRT-PCR  
(performed in triplicate on two different cell isolation lots, mean±SEM). (b) In vivo binding of  
VEZF1  and  RhoB-Flag  to  the  promoter  region  of  target  genes,  i.e.,  VEGF-R2,  NRP1,  
Endothelin1, TIMP3, Vashohibin1, MMP2 containing predicted in silico VEZF1 DNA binding  
sites (red triangle in schematic drawing of promoters) assessed by ChIP experiments. The start  
site of transcription is referred as +1. Position of primers used for QPCR experiments is  
represented by blue arrows. The enrichment for each DNA fragment upon immunoprecipitation of 
VEZF1 and RhoB-Flag is illustrated as histograms based on % of input (QPCR performed in 
triplicate on two different cell isolation lots, mean±SEM).  
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Figure 6 BVEC and LVEC proliferation is specifically regulated by GTP-bound state of RhoB.  
(a) Representative Western blot for detection of RhoB protein activation by GTP pulldown assay  
after adenoviral-mediated overexpression of wt RhoB-Flag (adRhoB) and RhoB mutants, i.e.,  
adRhoB-DN for Dominant Negative (GDP-bound state), adRhoB-CA for Constitutive Active  
(GTP-bound state). adGFP was used as the control. Anti-RhoB and anti-Flag antibodies  
successfully detected all RhoB-Flag proteins in input samples. Anti-RhoB antibody exhibits a  
non-specific cross-reactivity with rhotekin proteins used for GTP-bound Rho GTPase trapping  
(star). (b) Proliferation index of BVECs and LVECs after overexpression of wt RhoB-Flag and its  
mutants at 24h after proliferation challenge, determined as the ratio of the number of Ki67  
positive cells to the total number of cells (expressed as %, mean±SEM). adGFP was used as  
the control. (c) Relative levels of VEGF-R2 and NRP1 in BVECs, and TIMP3 in LVECs after  
overexpression of wt RhoB-Flag and its dominant negative mutant adRhoB-DN at 24h after  
proliferation challenge as determined by QRT-PCR (mean±SEM).  
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Figure 7 Normalization of pathological angiogenesis during OIR by small molecules targeting  
VEZF1 binding to DNA. (a) Schematic drawings of the human NRP1 promoter containing  
predicted in silico VEZF1 DNA binding sites (red triangles) depicting VEZF1 (red oval) binding to  
DNA, and RhoB (green circle) binding to VEZF1. The start site of transcription is referred as +1.  
The small molecule NSC 11435 named compound VEC6 docking to this VEZF1 zinc finger  
pocket (indicated by blue crosses) was screened for its ability to interfere with the interaction  
between VEZF1 and its DNA binding site leading to decreased promoter transactivation by the  
RhoB-VEZF1 complex. Activity of the human NRP1 promoter in Hela cells (control) and Hela  
cells overexpressing RhoB and VEZF1 (RhoB/VEZF1) in presence of solvent (DMSO) or VEC6  
(20nM for 24h) (3 independent experiments, each containing duplicates, mean±SEM). (b)  
Relative levels of VEGF-R2, NRP1, TIMP3 in BVECs and LVECs following treatment with  
compound VEC6 (20 nM for 24h) as determined by QRT-PCR (mean±SEM). (c) Proliferation  
index of BVECs and LVECs treated with compound VEC6 at 24h after proliferative challenge,  
determined as the ratio of the number of Ki67 positive cells to the total number of cells  
(expressed as %, mean±SEM). (d) Whole mount staining of blood vessels (BS-I lectin) in the  
retina of RhoB+/- pups subjected to OIR and treated with vehicle (DMSO) or compound VEC6 by  
daily intraperitoneal injection between P12 and P17 (OD = Optic Disc). Histological analysis  
(H&E staining) of RhoB+/- retinas at P17 following treatment with DMSO or VEC6. Quantification  
of the number of nuclei interior to Inner Limiting Membrane (ILM) (8 animals per group,  
mean±SEM). Scale bars: Whole mount staining = 100 µm, H&E sections = 50 µm.  
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Figure  8 Model for RhoB-mediated coordination of the angiogenic and lymphangiogenic  
responses to pathological challenge initiated by dermal wounding. (a) After tissue challenge  
initiated by dermal wounding and in response to numerous extracellular signals that remain to  
be explored in vivo, the immediate early response gene RhoB is induced and its protein  
accumulates in both blood and lymphatic vascular endothelial cells. The GTP-bound form of  
RhoB (red star) partially localizes in the nucleus of these cells, where its physical interaction  
with the transcription factor VEZF1 regulates the differential expression of specific direct target  
genes in BVECs and LVECs leading to an increase in BVEC proliferation and sprouting and a  
simultaneous decrease in LVEC proliferation and sprouting. Accordingly, RhoB null mice exhibit  
reduced angiogenesis versus earlier, augmented and abnormal lymphangiogenesis in this and  
other pathological scenarios. (b) We propose that the opposing roles served by RhoB in these  
two endothelial cell types contribute to the coordination of an early angiogenic response versus  
a delayed lymphangiogenic response previously observed in wound healing. In this setting, the  
early  angiogenic  response  participates  in  the  initial  inflammatory  phase  by  facilitating  
recruitment of inflammatory cells into the wound bed (day 5-7). The delayed lymphangiogenesis  
allows these cells time to initiate tissue repair. Thereafter, the new lymphatics support the  
resolution of the local edema (small black arrows) by draining fluid excess, cells and debris (big  
black arrow) (day 9-14).  
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